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Cancer is a major cause of disease burden and mortality worldwide, while incidence is 
rising (1,2). Classical treatments aimed at eradicating cancer comprise surgery to remove 
affected tissues, as well as chemotherapy and radiation therapy to invoke DNA damage 
and affect tumor cell division. Unfortunately, many patients still succumb to metastatic 
disease, which is largely caused due to treatment resistance. Insight in characteristics, 
on which cancers rely for growth and metastasis, resulted in identification of targetable 
‘hallmarks of cancer’ and distinct molecular cancer subtypes. Examples of cancer 
hallmarks are sustainment of proliferative signaling, evading growth suppressors, 
resisting cell death, inducing angiogenesis, replicative immortality, as well as activation 
of invasion and metastasis. More recently identified cancer hallmarks comprise of 
genome instability and mutation, deregulation of cellular energetics, evading growth 
suppressors, tumor promoting inflammation and avoidance of immune destruction (3,4).
Sustainment of proliferative signaling can be caused by dysregulation of growth factor 
receptors or their respective ligands. Among growth factor receptors often found 
aberrant is the human epidermal growth factor receptor (HER) family, consisting of 
members epidermal growth factor receptor (EGFR), HER2, HER3 and HER4. Through 
ligand binding, followed by homo or heterodimerization, HERs can be activated and 
consequent activation of downstream signaling pathways results in cancer cell survival, 
proliferation, metastasis and invasion (5). Among non-HER family tyrosine kinases, c-MET 
is found causative for many solid cancers through mutation, protein overexpression, 
gene amplification and through auto/paracrine upregulation of its ligand hepatocyte 
growth factor (HGF). Abnormal activation of the c-MET/HGF-axis leads to increased 
tumor proliferation, invasiveness and angiogenesis (6). Another characteristic commonly 
found overexpressed in many forms of human cancers is transmembrane glycoprotein 
epithelial cell adhesion molecule (EpCAM), which was shown to have a functional role in 
tumor proliferation, invasion and migration. Because of its abundant tumor expression, 
EpCAM can be utilized as docking station, to home antibody constructs like bispecific 
t-cell engaging antibodies (BiTEs) towards cancer cells. These BiTEs can in turn attract 
cytotoxic T-cells and thereby overcome the avoidance of immune destruction cancer 
hallmark (7). 
Growth factor receptors, such as EGFR, HER3 and c-MET form intricate and interlinked 
pathways through shared downstream intermediaries. Targeted treatment directed 
against one of these receptors can therefore result in treatment resistance via 
compensatory upregulation, amplification or mutation of another, to take over the 
proliferative drive. In light of this, treating HER2-driven breast cancer with HER-targeting 




expression, signaling activity and relocalization of HER3 to the plasma membrane, which 
may attenuate the response to lapatinib (8). Resistance against EGFR-targeted TKIs 
in non-small lung cancer (NSCLC) on the other hand, can be mediated through clonal 
selection or de novo c-MET overexpression or gene amplification (9,10). c-MET-mediated 
EGFR TKI resistance can be effectively mitigated by HSP90 inhibitors in NSCLC, while 
resulting in potent downregulation of c-MET (11).
Molecular imaging allows for non-invasive in vivo measurement of molecular 
characteristics, either through radionuclide-based single photon emission computed 
tomography (SPECT) and positron emission tomography (PET), nuclear magnetic 
resonance for magnetic resonance imaging (MRI) or by employing fluorescent dyes and 
endogenous molecules for optical imaging. Using therapeutic biomolecules as tracers, 
via modification with dyes or radioactive isotopes, organ distribution, pharmacokinetics, 
pharmacodynamics and tumor targeting can be studied. In contrast to invasive static 
techniques, such as biopsies, with an inherent narrow field of view, PET provides the 
ability for three-dimensional scans of multiple lesions over time. Repetitive PET scans 
can therefore provide information regarding tumor marker plasticity in response to 
therapy (12). In order to label highly tumor marker specific antibodies for use as PET 
tracer, the radioisotope Zirconium-89 (89Zr) can be employed (13). Among PET isotopes, 
89Zr is particularly well suited for studying large biomolecules, as it has a physical half-life 
of 3.27 days, fitting the biological half-life of antibodies. 
Fluorescently labeled antibodies and antibody fragments, can be employed for optical 
techniques, such as fluorescence imaging. Advantages of these techniques consist of 
real time high spatial resolution imaging capabilities for organ level imaging without 
radiation burden, off-the-shelf tracers and less costly infrastructure. Fluorescent tracers 
furthermore allow for study of drug intra-organ distribution from the macroscopic, down 
to the microscopic scale. Drawbacks of conventional fluorescence imaging comprise of 
limited signal penetration, lack of whole body imaging capabilities and three-dimensional 
information. Novel optoacoustic imaging techniques negate part of these drawbacks, as 
signal contains spatial information and signal penetration is greatly enhanced compared 
to standard fluorescence techniques, allowing to study fluorescent tracer biodistribution 
in more detail. 
The aim of this thesis is to develop new 89Zr and IRDye 800CW-labeled antibodies and 
antibody fragments for PET and optical imaging techniques to evaluate drug tumor 




Chapter 2 comprises of a literature search, which focusses on how molecular imaging 
techniques could potentially facilitate optimal implementation of molecular targeted 
agents in cancer, using the human HER family as a model. Among the topics discussed are 
how molecular imaging could be employed to characterize target expression in lesions, 
monitor drug effectiveness and detect emergence of treatment resistance. Furthermore, 
an integrative omics discovery platform is described for ‘effect sensors’, molecular 
imaging targets which are critical informative markers for treatment effectiveness or 
resistance. 
The preclinical imaging studies presented in this thesis are performed using Zirconium-89 
(89Zr) and IRDye 800CW labeled antibodies and antibody-based fragments for PET and 
near-infrared fluorescence imaging respectively. 89Zr-labeled antibodies are applied 
to assess target expression, tissue distribution, as well as response and resistance to 
targeted therapies in vivo in chapters 3, 4, 5 and 6. A near-infrared dye IRDye 800CW 
labeled antibody fragment is employed to study in vivo fluorescence imaging for in vivo 
tumor targeting and ex vivo macro- and microscopic Intratumoral drug distribution in 
chapter 6, while in chapters 7, an IRDye 800CW-labeled fluorescent antibody probe is 
used in novel microscopic methods. 
Preclinical EGFR imaging using radiolabeled monoclonal antibodies (mAbs) have 
revealed a mismatch between in vivo EGFR expression and tumor tracer uptake (14). 
Shedding of extracellular domain can influence the biodistribution of antibody-based 
tracers. Soluble EGFR extracellular domain (sEGFR) is found in the blood of cancer 
patients and healthy volunteers (15), and could potentially influence kinetics of an EGFR 
antibody tracer. In chapter 3 we inquire whether sEGFR could influence the kinetics 
and tumor targeting of EGFR antibody-based PET tracer 89Zr-imgatuzumab. To assess 
the effect of circulating sEGFR on tracer kinetics, protein dose of 89Zr-imgatuzumab 
is escalated in mice bearing three different EGFR-expressing human xenograft tumor 
models. Xenografted mice received 10, 25 or 160 μg 89Zr-imgatuzumab, co-injected with 
equal doses 111In-IgG control. Tumor uptake by PET and ex vivo biodistribution for the 
89Zr-imgatuzumab protein doses tested is then compared with EGFR tumor expression 
by immunohistochemistry and ELISA, as well as the amount of circulating plasma sEGFR 
from ex vivo samples. 
Treating HER2-driven breast cancer with HER-targeting TKI lapatinib can lead to a rapid 
compensatory increase in expression, signaling activity and relocalization of HER3 to 
the plasma membrane (16, 17). Immunohistochemistry (IHC) showed increased HER3 
expression in newly diagnosed HER2-overexpressing breast cancer patients, 2 weeks 
after lapatinib treatment initiation, which might attenuate its antitumor action (8). 




using PET, instead of with invasive techniques such as repeated biopsies. In chapter 4 
treatment effects of lapatinib on in vivo HER3 expression are studied using HER3 PET 
tracer 89Zr-mAb3481. Lapatinib effects on HER3 expression and internalization rate are 
studied in vitro using flow cytometry in a panel of HER2-amplified human cancer cell 
lines. Tumor accumulation of 89Zr-mAb3481 and HER3 expression is studied in HER2-
amplified xenograft bearing mice, receiving either vehicle or lapatinib treatment. 
PET and biodistribution data are compared to ex vivo HER3 expression analysis by 
immunohistochemistry and Western blot. 
Dynamic changes in c-MET expression of non-small cell lung cancer (NSCLC) tumors 
occur and changes in levels could indicate drug efficacy, or emergence of resistance 
towards EGFR TKIs (9). Non-invasive visualization  of c-MET dynamics could therefore 
potentially guide therapy. In Chapter 5a we aimed to investigate the suitability of c-MET 
one-armed antibody PET tracer 89Zr-onartuzumab to detect c-MET dynamics in response 
to EGFR TKI resistance and HSP90 inhibition by NVP-AUY-922 in human EGFR mutant 
NSCLC xenografts. In vitro, effects of EGFR TKI erlotinib and NVP-AUY-922 on proliferation 
and EGFR and c-MET membrane expression is measured by proliferation assay and flow 
cytometry in NSCLC cell line HCC827 and EGFR TKI erlotinib resistant c-MET upregulated 
HCC827 sub clone HCC827ErlRes. 89Zr-onartuzumab tumor uptake is assessed in mice 
xenografted with HCC827 and HCC827ErlRes on opposite flanks. Expression of c-MET 
is also assessed by 89Zr-onartuzumab PET in HCC827 xenografted mice prior and after 
treatment with NVP-AUY-922 or vehicle. Ex vivo, PET and biodistribution findings are 
compared with c-MET immunohistochemistry. Chapter 5b discusses the potential clinical 
applications and developments of c-MET-targeted PET and optical imaging tracers in 
oncology. 
Recently, understanding of mechanisms used by cancers to escape immune responses 
has led to multiple new immune-based cancer treatment strategies. One of such 
strategies is the BiTE antibody construct platform. BiTe constructs consist of a variable 
arm recognizing a tumor-specific marker, and another binding CD3 on cytotoxic T-cells, to 
elicit polyclonal T-cell responses to target-expressing tumor cells (7). Chapter 6 describes 
a study towards tumor targeting and tissue distribution of 89Zr and IRDye 800CW labeled 
BiTe AMG110, targeted against EpCAM and CD3. 89Zr- and IRDye 800CW-AMG110 in 
mice bearing high EpCAM-expressing HT-29 colorectal cancer xenografts is studied up 
to 6 days post injection. Specificity of 89Zr-AMG 110 uptake is further assessed in head 
and neck squamous cell cancer FaDu (intermediate EpCAM) and promyelocytic leukemia 
HL60 (EpCAM-negative) xenografts. Fluorescent IRDye 800CW-AMG 110, and unspecific 
BiTe IRDYe 680RD-MEC14  are injected in HT-29 tumors to visualize the intratumoral 
distribution on the macroscopic level with Odyssey fluorescence scans and compared 
with EpCAM expression and tumor viability by immunohistochemistry. Microscopic 
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distribution of IRDye 800CW-AMG110 is furthermore studied using fluorescence 
microscopy.
In chapter 7 we report the applications of label-free nonresonant four-wave mixing 
(NR-FWM) microscopy, in combination with fluorescence imaging of HER2 and EGFR 
targeting tracer IRDye 800CW-cetuximab and IRDye 800CW-pertuzumab respectively, 
in vitro on human cancer cells and in ex vivo xenograft tumor tissues. In this chapter a 
comparison is made between vibrationally nonresonant FWM imaging and vibrational 
resonant coherent anti-Stokes Raman scattering signal. Furthermore, suitability of NR-
FWM tumor tissue imaging in combination with fluorescence imaging of IRDye 800CW-
labeled tracers is explored. 
Chapter 8 summarizes the results of this thesis and contains a general discussion and 
future perspectives. 
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Cancer is a growing problem worldwide. The cause of death in cancer patients is often due 
to treatment-resistant metastatic disease. Many molecularly targeted anticancer drugs 
have been developed against ‘oncogenic driver’ pathways. However, these treatments 
are usually only effective in properly selected patients. Resistance to molecularly targeted 
drugs through selective pressure on acquired mutations or molecular rewiring can 
hinder their effectiveness. This review summarizes how molecular imaging techniques 
can potentially facilitate the optimal implementation of targeted agents. Using the 
human epidermal growth factor receptor (HER) family as a model in (pre)clinical studies, 
we illustrate how molecular imaging may be employed to characterize whole body 
target expression as well as monitor drug effectiveness and the emergence of tumor 
resistance. We further discuss how an integrative omics discovery platform could guide 
the selection of ‘effect sensors’ - new molecular imaging targets - which are dynamic 
markers that indicate treatment effectiveness or resistance.
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1. Introduction
Cancer is the third leading cause of death in the world and mortality is expected to 
rise (1,2). Despite current state-of-the-art treatment options, many cancer patients 
will ultimately die due to metastatic disease. In the last few decades, new insights in 
biological processes underlying cancer led to a flood of rationally designed targeted drug 
candidates (3). However, these targeted agents have not reached their full potential 
due to inadequate patient selection, which may partly be solved by enrichment of 
patient populations using specific biomarkers (3). Underlying reason for these patient 
sub-populations is inter-tumor heterogeneity caused by genotypic and phenotypic 
differences between tumors of similar histopathological subtype (4). Similarly, within 
and between tumor lesions of a single patient (intra-tumor heterogeneity), drug target 
and biomarker expressions are neither homogeneous nor static (4). Thus, high degrees 
of intra-tumor heterogeneity in acquired mutations and target expression levels can 
lead to clonal heterogeneity, an outgrowth of treatment-resistant cells, and ultimately, 
treatment failure (5, 6). Furthermore, pathway rewiring can lead to acquired resistance. 
Combined, these factors prevent or circumvent efficacy of targeted drugs (7), requiring 
advanced detection tools to determine tumor heterogeneity, biomarker expression 
dynamics for improving patient selection, and monitor treatment efficacy. In this review, 
we will discuss how molecular imaging may complement molecular testing to facilitate 
patient selection and monitor drug efficacy. We will also review discovery platforms 
for novel imaging markers that signify response or resistance to molecularly targeted 
treatments.
Molecular imaging is well-suited for visualization and clinical assessment of biological 
processes, as it can non-invasively and quantitatively monitor whole-body marker 
expression (8,9). By comparing the uptake of imaging tracers across all lesions and 
between patients, the tumor heterogeneity, drug delivery, and biological responses 
to drug treatment can be assessed before clinical progression becomes apparent 
by conventional techniques, e.g. biopsies and anatomical imaging (8). Furthermore, 
molecular imaging has the potential to monitor ‘effect sensors’, early response 
biomarkers providing insight into the functional changes at the cellular level that reflect 
the effectiveness of treatment or emergence of resistance mechanisms.
We will also explore various techniques and platforms that can be utilized for 
identification, selection and molecular imaging of drug targets and effect sensors. The 
role of the human epidermal growth factor receptor (HER) family in human cancers has 
been extensively studied. Consequently, multiple HER-targeted agents are in clinical 
use and many HER-targeted imaging strategies and resistance mechanisms have been 
reported (10). Therefore, we will use the known crosstalk, resistance mechanisms and 




Public data base searches were performed on PubMed, ClinicalTrials.gov and Google 
Scholar for combinations of the following search terms: EGFR, HER2, HER3, HER4, 
c-MET, VEGF-A, Src, ImmunoPET, PET, SPECT, molecular imaging, fluorescence imaging, 
near-infrared, nuclear imaging, optoacoustic imaging, resistance, breast cancer, lung 
cancer, gastric cancer, colorectal cancer, systems biology, integrative omics, genomics, 
transcriptomics, proteomics, mass spec, biomarker, and treatment response.
Important abbreviations
Protein-related; EGFR: epidermal growth factor receptor; HER: human EGFR family; 
HER2-4: human EGFR 2-4; RTK: receptor tyrosine kinase; c-MET: cellular-mesenchymal to 
epithelial transition factor; HSP90: heat shock protein-90; Src: Rous sarcoma oncogene 
cellular homolog
Cancer-related; CRC: colorectal cancer; NSCLC: non-small cell lung cancer; HNSCC: head 
and neck squamous cell carcinoma; TKI: tyrosine kinase inhibitor; mAb: monoclonal 
antibody
Imaging; SPECT: Single photon emission computed tomography; PET: positron emission 
tomography; CT: computed tomography; Zr: zirconium; In: indium; Ga: Gallium; Cu: 
Copper; Tc: technetium; I: iodine; F: fluorine; C: carbon; NIRF: near-infrared fluorescence; 
800CW: IRDye 800CW
Omics; CNAs: copy number aberrations; PTMs: post-translational modifications; MS: 
mass spectrometry; TCGA: The Cancer Genome Atlas consortium 
2. HER family pathways and resistance in cancer
2.1 HER family signaling 
To understand how HER-targeted imaging strategies could potentially benefit patients, it 
is important to identify the HER-mediated signal transductions, which are the underlying 
processes determining treatment efficacy. The HER family consists of four receptor 
tyrosine kinases (RTKs); epidermal growth factor receptor (EGFR), HER2, HER3 and HER4 
(also ERBB1-ERBB4). HER members function through homo- or heterodimerization to 
stimulate proliferation, cell survival, and metastasis (Figure 1A) (11). Like most RTKs, 
HER proteins comprise an extracellular ligand-binding domain and an intracellular 
ATP-dependent tyrosine kinase (TK) domain. Ligand-induced conformational changes 
in HER family proteins allow for dimerization, which promotes transphosphorylation of 
tyrosine residues in TK domains of dimerization partners leading to downstream protein 
kinase B (AKT) and extracellular signal-regulated kinase (ERK) pathway activation (12,13). 
Various ligands non-exclusively bind to EGFR, HER3 and HER4, as listed in Figure 1C (11). 
In contrast, no ligand is known to bind HER2. Rather, HER2 conformation allows 
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constitutive dimerization making it the preferred dimerization partner for other HER 
family members (14). HER3 only has weak intrinsic kinase activity and thus mainly 
depends on heterodimerization for phosphorylation of six unique tyrosine residues in 
the C-terminal tail, initiating potent downstream signaling (15–17). 
Figure 1. Involvement of HER family in cancer treatment and resistance
A) Ligand binding to HER family members induces homo- or hetero-dimerization. Transphosphorylation of 
kinase domains then induces a downstream phosphorylation cascade including PI3K/AKT/mTOR and RAS/RAF/
MEK/ERK pathways. B) Cancers that dependent on HER family activity can be treated using mAbs or TKIs. 
Binding of mAbs can inhibit receptor function by preventing dimerization or ligand binding, or by inducing 
internalization and degradation. Small molecule TKIs inhibit transphosphorylation by blocking the ATP binding 
pockets, either of the receptors or downstream signaling nodes. C) Multiple mechanisms of resistance to HER 
family-directed therapy have been discovered. Expression of truncated variant HER2-p65 or EGFRvIII prevent 
antibody binding, while gatekeeper mutations in EGFR limit binding of erlotinib or gefitinib to TK domain of 
EGFR (left panel). Inhibition of HER signaling can be restored by interactions with non-HER family members, 
namely c-MET, IGF1R or Src (middle panel). Lastly, compensatory feedback mechanism exist within the HER 













































































































































































































































































2.2 HER family receptors in cancer and treatment resistance
HER ligands are aberrantly expressed in various cancers and HER family members, 
especially EGFR and HER2, are oncogenic drivers upon mutation or amplification 
(Figure 1) (10). Therefore, several HER-directed therapeutics have been developed 
including small molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies 
(mAbs) (Figure 1B) (10). The HER2 mAb trastuzumab increases overall survival of 
patients with metastatic disease and of patients with HER2-positive breast cancers in the 
adjuvant setting (18). Nevertheless, resistance to HER-directed treatments frequently 
occurs (Figure 1C). Resistance can develop from selective pressure on existing or de 
novo mutations, which circumvent drug action (19). Alternatively, treatment resistance 
can develop through rewiring of parallel signaling pathways often involving other RTKs 
taking over the proliferative drive (19–24). Although not all mechanisms of treatment 
resistance are understood, multiple mechanisms that drive resistance to HER-directed 
agents have been elucidated underscoring the need for preventive and alternative 
treatment strategies.
Treatment with EGFR-directed mAbs cetuximab or panitumumab shows anti-tumor 
efficacy in a subset of colorectal cancer (CRC) patients harboring KRAS wild-type (wt) 
tumors while EGFR TKIs gefitinib or erlotinib are not effective due to the absence of 
mutations in EGFR (10). In CRC patients with EGFR-wt tumors, resistance to EGFR-
directed therapeutics can emerge through selection or de novo acquisition of oncogenic 
KRAS mutations (25). In contrast to CRC, treatment with EGFR-mAbs in non-small cell 
lung cancer (NSCLC) hardly improves clinical outcomes. Yet, treatment with gefitinib and 
erlotinib has an anti-tumor effect in NSCLC patients harboring activating mutations in 
the EGFR TK domain (26). Invariably, these patients develop resistance, which in ~60% 
of the patients, is due to the EGFR-T790M ‘’gatekeeper’’ mutation that renders EGFR 
insensitive to both gefitinib and erlotinib (Figure 1C) (26). To counter this mechanism, 
second and third generation EGFR TKIs with increased affinity for EGFR-T790M are in 
development. The TKI afatinib, approved for EGFR-exon 19 deletions or exon 21 L858R 
substitutions in NSCLC, is also being evaluated in combination with cetuximab in NSCLC 
patients harboring T790M mutations. (27,28). The EGFRvIII mutation, which lacks the 
ligand-binding domain encoded by exons 2–7 leading to constitutive kinase activity, 
is mainly found in glioblastoma multiforme. The lack of a ligand-binding domain and 
absence of kinase mutations make that EGFRvIII mutant cancers respond poorly to TKIs 
and EGFR mAbs regardless of mAb ability to bind to the receptor (29). 
In breast cancer, HER2 is an oncogenic driver with 20-25% of breast cancers harboring 
HER2 amplification and are classified as HER2-positive. Compared to amplifications, HER2 
mutations are rare. Nevertheless, these mutations are found in ~2% of NSCLCs and may 
render tumors amenable to HER2-directed therapy (30). Multiple underlying mechanisms 
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have been described for HER2-directed trastuzumab treatment resistance. For instance, 
expression of a truncated p95-HER2 isoform hampers binding of trastuzumab to HER2 
and results in clinical trastuzumab resistance (31,32). Alternatively, resistance can 
develop through increased signaling from other RTKs, including EGFR, HER3, insulin-like 
growth factor receptor (IGF1R), and cellular-mesenchymal to epithelial transition factor 
(c-MET) (33). Since trastuzumab does not prevent interaction between HER2 and other 
RTKs, the HER2-directed mAb pertuzumab was developed to prevent dimerization by 
blocking the HER2-dimerization domain (34). In light of this, the addition of pertuzumab 
to trastuzumab and docetaxel as first-line treatment resulted in a longer overall survival 
of patients with metastatic breast cancer (35). Furthermore, a trastuzumab-based 
antibody-drug conjugate (ADC), ado-trastuzumab emtansine (T-DM1), was developed
to deliver a potent maytansinoid toxin payload to HER2-positive cells. Treatment 
with T-DM1 showed an overall survival benefit in patients with HER2-positive breast 
cancers and tumor responses were seen in patients who had developed trastuzumab 
resistance (36). Thus, novel treatment and combination strategies, such as the addition 
of pertuzumab or using ADCs, can limit or circumvent resistance to trastuzumab. 
Although overlooked for a long time, HER3 received interest as a drug target when 
somatic mutations were discovered in breast and gastric cancers, and when a role 
for HER3 signaling as a resistance mechanism to HER-directed therapeutics was 
revealed (37). Specifically, when HER family members are targeted by TKIs, HER3 can 
re-activate downstream signaling, ultimately shifting signaling towards increased 
phosphoinositide-3 kinase (PI3K) /AKT activity and increased HER3 expression (20,21). 
Indeed, resistance to the EGFR/HER2-directed TKI lapatinib in HER2-positive breast 
cancer cell lines was the result of increased EGFR-HER3 signaling complexes induced 
by autocrine secretion of HER3 ligand NRG1 (Figure 1C). Notably, NRG1 expression 
was a negative predictor of lapatinib treatment, suggesting binding of NRG1 to EGFR-
HER3 complexes as a potential cause of resistance (22). As the TK domain of HER3 is 
virtually inactive, drug design for HER3-targeted therapies mainly focuses on preventing 
dimerization using mAbs, which are currently being clinically evaluated (37). Additionally, 
changes in HER3 expression or activation might serve as an early readout of resistance 
to EGFR or HER2 therapy. 
2.3 Resistance mechanisms through non-HER family receptors and downstream 
signaling nodes.
HER family members also interact with non-HER family members (23,38). The crosstalk 
between RTKs and downstream signaling nodes compose of feedback activation loops 
leading to intriguingly complex signaling networks. This diversity also underlies many 
resistance mechanisms to drugs that target single components of this signaling network 
and could be potential imaging targets to monitor treatment efficacy.
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One dimerization partner that can drive resistance to HER-targeting drugs is c-MET, a 
RTK that promotes growth, metastasis, and angiogenesis (39). Binding of the ligand 
hepatocyte growth factor/scatter factor (HGF/SF) to c-MET leads to homodimerization, 
autophosphorylation, and downstream signaling through PI3K and AKT (40) making 
c-MET a prime suspect for alternative signaling after EGFR blockade (23,40). Indeed, 
resistance to cetuximab or gefitinib in head and neck squamous cell carcinoma (HNSCC) 
and NSCLC cell lines involved MET amplification and subsequent heterodimerization of 
HER3 with c-MET (Figure 1C) (23,24). Furthermore, in preclinical studies, HGF-induced 
c-MET signaling resulted in resistance to gefitinib in NSCLC and lapatinib in breast 
cancer cell lines (19,41). These reports signify that dual targeting of c-MET and EGFR 
might be necessary to prevent the emergence of resistance. Preliminary in vitro results 
have indeed shown synergistic effects of combined inactivation of EGFR and c-MET in 
HNSCC and NSCLC cell lines (23,42,43). Several c-MET targeting agents ranging from 
TKIs, antibodies against c-MET, as well as antibodies against the c-MET ligand HGF are 
currently in phase III clinical trials (44). 
Another player in HER family signal transduction is Rous sarcoma oncogene cellular 
homolog (Src), a non-receptor TK that regulates cell growth, migration, and survival 
signaling pathways. Src interacts with EGFR and HER2 as well as with c-MET, IGF1R, 
platelet-derived growth factor receptor (PDGFR) and fibroblast growth factor receptor 
(FGFR) (45). Binding of Src to HER2 conferred resistance to trastuzumab in human tumor 
cell line models harboring a HER2-exon 16 deletion (Figure 1C) (46). In another study, 
Src activation conferred resistance to erlotinib in vitro and in vivo by inducing c-MET 
expression in HNSCC models, which could be rescued by genetic or pharmacological 
inactivation of c-MET (47) indicating that Src, at least in the selected in vitro models, is a 
key regulator of c-MET-mediated resistance to HER-targeted agents.
Compensatory signaling upon EGFR inhibition can also be mediated by IGF1R. 
Considerable overlap has been observed in the functions of IGF1R and the HER family 
and upregulation of the IGF1R signaling axis has been observed to compensate for the 
loss of HER signaling (48). In a retrospective study of 155 patients with HER2-positive 
breast cancers treated with trastuzumab as an adjuvant, increased expression of EGFR 
and IGF1R and dysregulation of the AKT pathway were observed following the failure 
of neoadjuvant or conventional therapy and were associated with worse treatment 
outcome (49). In line with these results, IGF1R activation and dimerization with HER2 
was observed in a trastuzumab-resistant clone of the human breast cancer cell line 
SKBR3 but not its parental trastuzumab-sensitive cell line (38). Furthermore, resistance 
to irreversible EGFR TKIs was mediated through activation of the IGF1R pathway in PC9 
NSCLC cells (48). Also, epigenetic alterations were shown to drive IGF1R engagement 
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in a human cancer cell lines panel, causing transient resistance to gefitinib, erlotinib, 
cisplatin and BRAF inhibitor treatment (50).
Taken together, a theme emerges in which inactivation of key HER family members 
results in strong positive feedback on various other RTKs, including c-MET, IGF1R, and 
Src. Ultimately, this rewiring restores proliferation and survival signaling and results in 
treatment-resistant clones. How this positive feedback is wired at the molecular level is 
unclear, although it seems to converge at reinstating AKT or ERK signaling. 
Also, when downstream signaling components of the HER pathway are targeted, rapid 
rewiring and activation of parallel pathways were observed. Inhibition of PI3K in HER2-
positive cell lines resulted in activation of FOXO transcription factors and upregulation 
of HER3 (48), which was similar to HER2 inhibition (20). Also, PI3K inhibition in HER2-
overexpressing human breast cancer xenografts resulted in acquired dependency on 
ERK signaling (51). Further, inhibition of AKT, the critical downstream target of PI3K, 
induced HER3 expression and activation of HER3, IGF1R, and the insulin receptor (IR) 
in human breast cancer, prostate cancer, and NSCLC cell lines (52). Likewise, treatment 
of breast cancer cell lines with the mechanistic target of rapamycin (mTOR) inhibitor 
AZD8055 resulted in induction of HER proteins and activation of HER3 specifically (53). 
The aforementioned resistance mechanisms underscore the plasticity of the HER family 
and parallel signaling networks and warrants the development of non-invasive diagnostic 
tools that can be applied serially to identify not only which tumors respond to anti-HER 
drugs but also when resistance to these agents develops. 
3. Molecular imaging strategies
Here, we will discuss how molecular imaging strategies might be employed to improve 
HER family-directed treatment with a focus on marker-selective imaging agents. 
Besides imaging generic cancer processes such as glucose metabolism with 18F-FDG 
or proliferation by 18F-FLT, marker-selective imaging agents can capture a broad range 
of cancer hallmarks (54), which might be informative for the efficacy of HER-directed 
treatment.
Molecular imaging can be performed by various modalities, e.g. radionuclide, optical, 
optoacoustic and magnetic resonance imaging, with each modality having unique 
advantages as well as limitations (8). Molecular imaging with radionuclides is the most 
widely used technique. The main attractive features of radionuclide-based imaging 
are high signal sensitivity and the ability to non-invasively acquire quantitative three-
dimensional information of whole body tracer distribution. For single photon emission 
computed tomography (SPECT) imaging, a three-dimensional image is computed from 
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multiple two-dimensional images taken at different angles of a gamma ray-emitting 
radioisotope. On the other hand, when multiple detectors are used, positron emission 
tomography (PET) imaging can be inherently three dimensional, based on the origin of 
the two near-perpendicular 511 keV gamma rays emitted after positron annihilation. 
In contrast to SPECT, physical collimators are not necessary for PET resulting in higher 
sensitivity, spatial resolution, and corresponding shorter acquisition time for scans 
allowing more temporal resolution to study dynamic features (55). 
Accurate quantification of cellular receptor levels using molecular imaging agents can 
be affected by - but not limited to - a variety of factors such as blood flow, vascular 
permeability, vascularization, lymphatic drainage, cellular internalization rate, non-
specific binding, blood and interstitial pressure, metabolites, number of binding-sites, 
the enhanced permeability and retention effect, as well as tracer pharmacokinetics 
(56,57). Additional complications in quantification, can come from external sources 
such as respiration movements of the subject as well as differences between scanners, 
settings, and reconstruction algorithms. The partial volume effect, image blurring due 
to the finite resolution of the scanner, and target heterogeneity within the tissues 
contained in the smallest resolution unit (i.e. pixels, voxels) can also affect the accuracy 
of quantification (57). To resolve these issues, efforts have been directed towards more 
accurate quantification of molecular imaging data, a subject that has been expertly 
reviewed by others (56,57).
Radioisotopes for SPECT and PET imaging can be incorporated in targeting molecules 
in various ways, e.g. through covalent binding or chelation. Selection of the most 
appropriate radioisotope is based on the physical half-life of the radionuclide, which 
should match the biological half-life of the imaging agent to balance optimal time for 
tracer accumulation in lesions with sufficient signal strength, while minimizing radiation 
burden. For instance, carbon-11 (11C, t
1/2 
= 20 min, PET) and fluorine-18 (18F, t
1/2 
= 110 
min, PET) are often used to label small molecules, with little or no alteration of their 
kinetic parameters. In contrast, high molecular weight biomolecules, such as antibodies, 
need relatively long-lived radiometals for optimal contrast, such as zirconium-89 (89Zr, 
t
1/2 
= 78.4 h, PET), indium-111 (111In, t
1/2
 = 67.3h, SPECT) or radiohalogen iodine-124 (124I, 
t
1/2 
= 100.3 h, PET). Fluorine-18, as well as radiometals copper-64 (64Cu. t
1/2 
= 12.7 h, PET), 
technetium-99m (99mTc, t
1/2 
= 6.0 h, SPECT) and galium-68 (68Ga, t1/2 = 68 min, PET) are 
well-suited for imaging biomolecules with short biological half-lives.
Besides radionuclide-based imaging, optical methods such as near-infrared fluorescence 
(NIRF) and optoacoustic imaging have received increasing attention. These techniques 
combine high resolution with real-time signal acquisition in the field of view. Advantages 
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of optical methods compared to radionuclide-based imaging are the lack of radiation 
burden to patients, ‘’off the shelf’’ availability of tracer molecules, and relatively low 
costs. Limitations of optical imaging include the difficulty of signal quantitation, limited 
penetration depth, and a restricted field of view. Optical methods, therefore, appear 
most suited for localized organ-level imaging, such as intra-operative or endoscopic 
imaging. 
Molecular imaging capabilities are rapidly expanding and many known processes and 
pathways that comprise the hallmarks of cancer can be visualized using PET or SPECT 
tracers (54). In this context, molecular imaging can be used to non-invasively determine 
lesion biomarker status to facilitate proper patient selection. Labeled drugs or analogs 
thereof can be used to assess drug accumulation across lesions. Many HER family 
targeting tracers have been described in the literature. The tracers mentioned in this 
review highlight the most important findings within each imaging strategy, and are 
listed in Table 2. For a systematic overview of HER-targeted tracers, we refer to excellent 
reviews by others (58,59).
3.1 Target expression imaging
Molecular imaging may be used in the clinical setting to measure HER family expression 
status in multiple tumor lesions simultaneously and to visualize the inter-tumor 
heterogeneity. Measuring multiple lesions at once might be relevant as single biopsies 
or small tumor fractions are not an adequate representation of all lesions (60). Whether 
molecular imaging can be used to better predict response to EGFR-targeted agents 
is unresolved. However, several animal studies showed a correlation between EGFR 
expression of human cancer xenografts and uptake of 64Cu-cetuximab, 111In-cetuximab 
and 111In-f(ab’)2-cetuximab (61–63). Other preclinical studies, however, found discordance 
between xenograft EGFR expression and 89Zr-cetuximab or 64Cu-cetuximab accumulation. 
In these studies, EGFR overexpression did not necessarily result in corresponding high 
tumor tracer accumulation, suggesting that factors other than EGFR expression, such 
as perfusion and vascular permeability might influence cetuximab-based tracer tumor 
uptake (64, 65). For instance, in a preclinical study circulating shed EGFR ectodomain 
(sEGFR) influenced the kinetics and tumor targeting of the EGFR antibody tracer 89Zr-
imgatuzumab (66). In a patient study, six out of 10 metastatic CRC patients showed 
89Zr-cetuximab tumor uptake when administered with a therapeutic dose of cetuximab. 
Four of these six patients had clinical benefit of cetuximab therapy, while a progressive 
disease was observed in three out of four patients without 89Zr-cetuximab uptake (67). 
Although promising, larger cohorts should be screened to establish the value of 89Zr-




The EGFR TKIs erlotinib and gefitinib display higher affinity for oncogenic EGFR mutants. 
This feature can be exploited to selectively image mutant EGFR variants and provides an 
attractive tool for assessing heterogeneity in EGFR mutation status. In several preclinical 
studies, there was a higher accumulation of 11C-erlotinib in NSCLC and glioma xenografts 
containing activating EGFR mutations in exon 19 and 21 when compared to xenografts 
of erlotinib-resistant EGFR-T790M, EGFR-wt, or EGFR with activating mutations in its 
extracellular domain (68–70). The 11C-erlotinib volume of distribution was higher in 
patients with NSCLC lesions with EGFR activating exon 19 deletion than in lesions from 
patients without activating mutations (Figure 2D,E) (71). In another series of 13 NSCLC 
patients, three out of four patients with 11C-erlotinib PET positive lesions responded to 
erlotinib treatment while the best response seen in in two out of nine patients with 
11C-erlotinib PET negative lesions was a stable disease (72). A case report showed high 
11C-erlotinib uptake in brain metastases of a NSCLC patient with an exon 19 mutation in 
the primary tumor with response to erlotinib in both primary tumor and brain metastases, 
underscoring the potential value of mutant-specific imaging of EGFR status (73). Imaging 
with the pan-HER TKI afatinib can also be used to visualize receptor mutation status. 
Analysis of 18F-afatinib showed higher accumulation in A549 EGFR-wt and HCC827 EGFR-
exon 19 deletion compared to H1975 EGFR-T790M human NSCLC cell line xenografts. 
This reflects the affinity of afatinib to EGFR with activating mutations (74).
Analogously, several preclinical imaging studies have been performed to visualize 
EGFRvIII status. Specifically, IRDye 800CW (800CW)-panitumumab and an 800CW-EGFR 
affibody bound to EGFR-wt and EGFRvIII with similar affinity in a rat glioma model. In 
contrast, 800CW-labeled EGFR ligand EGF identified EGFR-wt but not EGFRvIII-expressing 
lesions, reflecting the compromised EGFRvIII ligand-binding pocket (75). In another 
study, the 124I-IMP-R4−labeled EGFRvIII-specific antibody ch806 was tested in human 
glioblastoma EGFRvIII-transfected U87MG xenografts expressing EGFRvIII; no preferential 
imaging of EGFRvIII could be established since only EGFRvIII cell lines were used (76). 
Another EGFRvIII-specific antibody, 99mTc-labeled 3C10, displayed over ten-fold higher 
accumulation in EGFRvIII-transfected U87MG human glioblastoma xenografts compared 
with the parental U87MG (77). Furthermore, the IRDye 680RD-labeled EGFRvIII antibody 
biotin-4G1 accumulated more in EGFRvIII-expressing F98npEGFRvIII than in EGFR-wt 
F98npEGFR rat glioblastoma xenografts (78). Overall, evidence exists that EGFRvIII might 
be distinguished from EGFR-wt using EGFRvIII tracers. However, more rigorous preclinical 
and clinical data and relevance are required to move this field forward. 
Research on fluorescently labeled proteins recognizing EGFR mainly focused on their 
use as an add-on ‘red flag’ technique for intraoperative and endoscopic procedures. 
Both 800CW-cetuximab and 800CW-panitumumab were tested for detection of breast 
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cancer xenograft lesions (79). Also, EGFR nanobody 800CW-7D12 could detect EGFR-
overexpressing A431 human squamous cell carcinoma xenografts (80). In a preclinical 
intraoperative study, 800CW-7D12 could visualize orthotopic primary tongue tumor 
xenografts and resulting cervical lymph node metastases which were otherwise not 
detectable with the naked eye (81). Also, 800CW-cetuximab was successfully used to 
detect EGFR-positive lesions in a preclinical simulated colonoscopy of a resected human 
colon with human EGFR-expressing colon cancer HCT116luc xenografts stitched into the 
colon wall (82). 800CW-cetuximab was likewise tested in HNSCC patients during surgery 
using wide-field NIR imaging. In these patients, tumor-to-background ratios of 4.3 and 
5.2 were observed at 3 to 4 days after infusion of 25 and 62.5 mg/m2 doses of 800CW-
cetuximab respectively (83). There was a correlation between the fluorescent signal 
of 800CW-cetuximab and EGFR density in excised HNSCC tumors as determined by 
IHC (84). To establish the clinical value of EGFR-targeted tracers, multiple clinical studies 
with 800CW-cetuximab and 800CW-panitumumab for intraoperative procedures and 
89Zr-cetuximab, 11C-erlotinib, and 89Zr-panitumumab for EGFR PET imaging are currently 
pursued (Table 1). 
HER2 overexpression in breast cancer is associated with worse prognosis, if not treated 
with HER2-directed therapy (85). HER2 has therefore been extensively studied as an 
imaging target to select patients for HER2-directed therapy (Figure 2A). 89Zr-trastuzumab 
as well as 89Zr-pertuzumab showed specific uptake in HER2-positive xenografts in 
mice (86–88) while 111In- and 89Zr-trastuzumab, 111In- and 68Ga-labeled HER2 affibodies 
and a 68Ga-HER2-nanobody have been applied in patients diagnosed with HER2-positive 
breast cancer (89–94). 64Cu- and 89Zr-trastuzumab and 68Ga-ABY-025 PET are currently 
being tested for their value in identifying HER2-positive lesions and heterogeneity in 
breast and gastric cancer patients (Table 1). 
As discussed above, HER3 has been implicated in many escape mechanisms from HER 
family-targeted therapies. Therefore, early identification of changes in HER3 expression 
might serve to identify patients at risk of HER3-mediated treatment resistance and 
possibly for selection of patients eligible for HER3-targeted treatment. HER3 expression 
levels have been successfully imaged in vivo with the antibody 89Zr-lumretuzumab (95) 
and 64Cu-DOTA-HER3 F(ab’)2 (96), as well as 99mTc-, 111In- and 68Ga-labeled HEHEHE-Z08698 
and HEHEHE-Z08699 affibodies (97–99) while bispecific HER2/HER3 tracer 111In-DTPA-
Fab-PEG24-HRG, based upon heregulin and a trastuzumab Fab, showed HER3 and HER2-
mediated uptake in SK-OV-3, MDA-MB-468 and BT474 xenografts (100). HER3 imaging 
has been studied clinically with 64Cu-patritumab, revealing tumor uptake in cancer 
patients, as well as high liver uptake which could be saturated with pre-administration 
of 9 mg/kg cold patritumab (101). In imaging studies of patients, 89Zr-lumretuzumab 
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HER3 showed a decrease in tracer tumor uptake after administration of 400, 800 and 
1600 mg flat doses of unlabeled lumretuzumab when compared to a pre-dosing 89Zr-
lumretuzumab scan with a 100 mg protein dose (102). Another HER3 antibody tracer, 
89Zr-GSK2849330, is currently being studied in the clinic (Table 1). 
3.2 Imaging of drug accumulation in tumors
Several imaging probes do internalize after binding to their targets. Radiometals 64Cu, 
68Ga, 89Zr, and 111In have residualizing properties, because these highly charged isotopes 
will remain trapped in cells after tracer internalization and subsequent catabolization 
resulting in accumulation of signal over time in antigen-expressing tissues. Radiohalogens 
such as 18F and iodine isotopes, and fluorescent dyes, on the other hand, are released 
from the cell after catabolization of the imaging probe. Residualizing probes will therefore 
roughly reflect the cumulative tracer exposure, while tracers using non-internalizing or 
non-residualizing isotopes approximate antigen density and binding capacity of the 
tracer over time. 
An example of a non-residualizing approach is the antibody-photosensitizer conjugate 
IRDye 700DX (700DX)-cetuximab, which was effective in inhibiting tumor growth and 
could simultaneously image human triple negative breast cancer xenografts (103). 
700DX-cetuximab is currently being evaluated as dual imaging and treatment 
(theranostic) modality in patients with recurrent head and neck cancer (Table 1). Use of 
a fluorescent approach to study drug accumulation might be feasible for lesions within 
the penetration depth of signal as well as during surgery or in endoscopic procedures. 
Accumulation of residualizing radioactive tracers in lesions, on the other hand, could 
be used as a proxy for antigen-specific delivery of the toxic payloads of ADCs and radio-
immunotherapeutic agents. 89Zr-cetuximab was able to predict the accumulation of 
EGFR-directed radio-immunotherapeutics 88Y- and 177Lu-labeled cetuximab in A431 
xenografts (104). Furthermore, a 64Cu-labeled variant of MM-302, a HER2-targeting 
liposome containing doxorubicin, was successfully used to predict deposition, kinetics, 
and efficacy of the parental liposome in xenografts (105, 106). An ongoing clinical trial 
assesses whether deposition of 64Cu-MM-302 can predict the outcome of the doxorubicin-
loaded parent liposome therapy in advanced breast cancer patients (Table 1). A similar 
approach was already used in 56 breast cancer patients receiving 89Zr-trastuzumab PET 
scans prior to T-DM1 therapy to determine intra/interpatient HER2 heterogeneity and 
to identify non-responding patients. In this study, 28 out of 39 89Zr-trastuzumab PET-
positive patients responded to T-DM1 therapy, while 14 out of 16 of 89Zr-trastuzumab 
PET-negative patients had a stable or progressive disease (107). These results indicated 
that 89Zr-trastuzumab might be used to identify patients who benefit from T-DM1 
therapy. In another study, 89Zr-labeled MMOT0530A, the naked antibody component 
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Figure 2. Molecular imaging strategies of HER family proteins
A-C) Expression of cell membrane bound HER2 can be imaged by specific binding of 89Zr-trastuzumab to 
HER2, leading to residualizing of 89Zr in tumor cells due to internalization and subsequent degradation of the 
antibody-receptor complex. HSP90 inhibition by NVP-AUY922 leads to destabilization and degradation of HER 
family proteins at the plasma membrane, leading to lower antigen availability and reduced tracer uptake. 
B) PET images of mice scanned with 89Zr-trastuzumab before (Top) and after (Bottom) treatment with NVP-
AUY922, quantified for 144 hours (122). C) 89Zr-trastuzumab PET imaging of a metastatic breast cancer patient 
before (Top) and after 3 weeks of NVP-AUY922 treatment (Middle), with CT-scan prior to treatment shown in 
Bottom panel. Quantification of all lesions shows a heterogeneous response with a total average decrease in 
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of the mesothelin-ADC DMOT4039A, accumulated preferentially in human pancreatic 
cancer xenografts (108). 89Zr-MMOT0530A was further tested in 11 patients with ovarian 
or pancreatic cancer, revealing a large degree of heterogeneity of lesion tracer uptake, 
while PET uptake 4 days post injection correlated with IHC staining for mesothelin on a 
per patient basis. However, the small patient sample precluded analyses of correlation 
between lesion 89Zr-MMOT0530A uptake and clinical response to the corresponding 
ADC DMOT4039A (109). 
Important in this context, residualization of tracers can be modulated by therapeutic 
interventions. For instance, multiple antibodies targeting the same antigen could 
lead to enhanced residualization, as was shown for 89Zr-pertuzumab and concurrent 
trastuzumab administration in HER2-positive xenografted mice (110). Decreased steric 
hindrance of HER2 after administration of mucolytic agent N-acetylcysteine increased 
the uptake of 89Zr-trastuzumab in MUC4-expressing JIMT1 human breast cancer 
model (111). Interestingly, treatment with anti-angiogenic agents could affect uptake 
and accumulation of tracer through modulation of vascularization and permeability 
for macromolecular therapeutics such as antibodies (112,113). Specifically, uptake of 
either 89Zr-labeled trastuzumab, bevacizumab, or IgG control antibody in xenografts 
was decreased in animals treated with the vascular endothelial growth factor A 
(VEGF-A) antibody bevacizumab due to vascular normalization (112,113). We envision 
that molecular imaging strategies could be employed for rationally designing drug 
combinations to increase deposition of drugs in tumors and possibly increase efficacy, 
for instance of ADCs. Importantly, such strategies can also instruct which treatment 
combinations should be avoided. 
3.3 Imaging treatment effects 
As therapies often elicit changes in expression, membrane localization and dynamics of 
proteins, such changes could potentially be used as ‘effect sensors’ to monitor treatment 
response (Figure 2F). Assessment of functional treatment effects has been performed 
by measuring cell membrane proteins and ligands for which expression is known to 
be modulated upon successful target engagement. As an example, the VEGF receptor 
(VEGFR) ligand VEGF-A was potently down-regulated after heat shock protein-90 (HSP90) 
Figure 2. Molecular imaging strategies of HER family proteins (continued)
89Zr-trastuzumab uptake after 3 weeks of NYP-AUY922 treatment (125). D,E) Higher accumulation of 11C-erlotinib 
occurs in tumors with specific activating mutations in EGFR due to its higher affinity to the mutated TK compared 
to EGFR-wt. NSCLC tumors with exon-19 deletion (series A) showed higher uptake compared to EGFR-wt tumors 
(series B). A1-B1: CT fused-parametric 11C-erlotinib Vt; A2-B: CT; A3-B3: 18F-FDG (71) F,G) Imaging of HER3 levels 
using 64Cu-DOTA-F(ab’)
2
 can be utilized as effect sensor of AKT inhibitors, as GDC-0068 specifically induces 
expression of HER3, but not EGFR, as feedback mechanism of AKT inhibition in mouse xenografts after 72h 
of treatment (119). H,I) Imaging of intracellular processes can be facilitated by TAT-modified antibodies. 111In-
DTPA-anti-yH2AX-Tat antibodies visualized the formation of DNA damage foci marked by γ-H2AX treatment 
upon treatment with irradiation of DNA damaging agent bleomycin in mouse xenografts (129).
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Table 1. Overview of ongoing clinical trials with molecular imaging of HER 
family members and related targets 
TARGET EXPRESSION IMAGING
EGFR ClinicalTrials.gov identifiers





89Zr-trastuzumab NCT01420146, NCT02286843, NCT01832051, 





















inhibition and consequently led to a decreased uptake of 89Zr-bevacizumab in breast 
and ovarian cancer xenografts (114,115). Downregulation of VEGF-A can also be the 
result of mTOR inhibition by mTOR inhibitors such as everolimus and could be visualized 
using 89Zr-bevacizumab in mice and humans (116,117). Also, treatment with VEGFR1-3-
targeting TKI, sunitinib, a TKI targeting VEGFR1-3 led to changes in VEGF-A tumor levels 
that could be effectively assessed by bevacizumab F(ab')2-fragment 
89Zr-ranibizumab in 
ovarian and colon cancer xenografts (118). 
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Besides measuring ligands, analysis of RTK expression has been used as an effect 
sensor for successful target engagement. For instance, PI3K inhibitor GDC-0941 and 
AKT inhibitor GDC-0068 led to upregulation of EGFR in HCC70 human breast cancer 
xenograft which could be visualized with a 64Cu-DOTA EGFR F(ab’)2 fragment derived 
from cetuximab (119). Afatinib treatment, on the other hand, lowered HER2 expression 
in a human gastric cancer N87 xenograft model in mice, which was visualized using 89Zr-
trastuzumab (120). Lapatinib, on the other hand, interfered with receptor dynamics by 
upregulating and stabilizing HER2 at the plasma membrane, ultimately leading to lower 
89Zr-trastuzumab-F(ab’)2 tracer uptake in a breast cancer model (121). HSP90 inhibition 
also downregulated RTKs such as IGF1R and HER2, which was effectively discriminated 
by 89Zr-mAb391 and 89Zr-trastuzumab by PET, respectively, as well as by AlexaFluor680-
Z
Her2:342
 affibodies for HER2 with near-infrared fluorescence in breast cancer xenografts 
(Figure 2B) (115,121–124). This latter approach was clinically validated using HER2 as an 
effect sensor for treatment with HSP90 inhibitor NVP-AUY922 in HER2-positive breast 
cancer patients using 89Zr-trastuzumab PET and correlated with a response by computed 
tomography (CT) (Figure 2C) (125). Also, inhibition of AKT by GDC-0068 led to an 
upregulation of HER3 in patient-derived triple negative breast cancer xenografts, which in 
turn increased dual EGFR/HER3 antibody 89Zr-MEHD7945A tumor uptake (126). Selective 
imaging of HER3 upregulation after GDC-0068 treatment in MDA-MB-468 human breast 
cancer xenografts was demonstrated using 64Cu-DOTA-HER3 F(ab’)2 (Figure 2F,G) (119).
These are examples of HER family therapy effects that can be visualized and might be 
applied to adjust therapy in a timely fashion. However, only a few effects sensors are 
currently available to image treatment effects. This is partly because the effect sensor 
has to be excreted or expressed extracellularly to have accessibility to the target. This is 
due to the difficulty of high molecular weight imaging probes like antibodies, to cross the 
plasma membrane, and if required, the nuclear membrane. 
3.4 Imaging Intracellular processes in vivo
Visualization of intracellular targets has been largely restricted to small molecule-
based imaging tracers. In general, intracellular processes for which imaging is currently 
feasible are generic processes such as tumor glucose metabolism by 18F-FDG and cellular 
proliferation using 18F-FLT and 11C-thymidine incorporation. One strategy to overcome 
the hurdle posed by the inability of antibodies to cross membranes, is modifying them 
with the HIV1-derived cell-penetrating transactivator of transcription (TAT) peptide, to 
ensure nuclear deposition (Figure 2H) (127). Using this technique, 111In-anti-p27kip1-TAT 
antibody SPECT imaging was able to visualize upregulation of the nuclear localized cyclin-
dependent kinase inhibitor p27kip1 after trastuzumab treatment of mice bearing human 
breast cancer xenografts (128). More recently, this approach has also been applied for 
detection of DNA damage using a phospho-specific ɣH2AX antibody in human breast 
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cancer xenografts and during tumorigenesis in a transgenic BALB-neuT murine breast 
cancer model, 111In- and 89Zr-labeled TAT-modified phospho-ɣH2AX antibody detected 
DNA breaks induced by chemo and radiotherapy (Figure 2H,I) (129–131). 
Many targeted therapies aim to inactivate intracellular proteins, which currently are not 
accessible for high molecular weight imaging probes. Approaches similar to imaging with 
the TAT-modified phospho-ɣH2AX antibody could be envisioned, where changes in the 
activity of intracellular signaling pathways, including altered activation states of AKT or 
MAPK, could be visualized. Imaging these targets might reveal whether the intended 
therapeutic inactivation of a specific intracellular target is achieved and sustained or 
whether signaling is reactivated or rewired. If the plasma membrane no longer posed 
a barrier in such strategies, the number of possible targets for high molecular weight 
probes would greatly increase. In such a scenario, imaging studies of prognostic or 
predictive markers could focus on the most relevant targets, and would no longer be 
restricted to proxies at the plasma membrane.
3.5 Radiomics
The emerging field of radiomics combines imaging data with ’omics’ methodology. In 
radiomic analyses, quantitative features are mined from large data sets of (mainly routine) 
medical tomographic imaging data such as PET, CT and MRI scans using bioinformatics. 
Examples of features comprise, amongst others, descriptors for shape, size, volume and 
texture in space and over time, which in turn might reflect underlying pathophysiology. 
These features are combined with clinical outcome data and other patient characteristics 
to develop predictive models for genetic and molecular characteristics, prognosis, as 
well as treatment response (132,133). 
Tentative retrospective radiomics studies for prediction of HER tumor status have yielded 
encouraging results. A set of 11 radiomic features extracted from CT images of patients 
with lung adenocarcinoma was predictive for EGFR mutation status, with an area under 
the curve (AUC) of the receiver operating characteristic curve (ROC) of 0.667 for radiomic 
data alone, and 0.709 when combined with clinical parameters (134). In another study, 
a decision tree based upon several CT textural features could differentiate KRAS mutants 
from EGFR-wt NSCLC patients with sensitivity, specificity, and accuracy of 96.3%, 81.0% 
and 89.6%, respectively (135). Radiomic features extracted from 18F-FDG PET in NSCLC 
patients could discriminate mutant EGFR from EGFR-wt as well as mutant EGFR from 
KRAS mutants but could make no distinction between KRAS mutant and EGFR-wt (136). 
To our knowledge, no radiomics studies with HER-targeted molecular imaging probes 
have been reported. However, future radiomic analysis of large databases of PET data 
from HER-targeted tracers, combined with clinical data, might help identify features for 
prediction of underlying patient phenotype and outcome. 
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Table 2. Overview of preclinical and clinical tracers
TARGET EXPRESSION
Tracer Modality Scaffold Study 
type
Target Remarks Ref
64Cu-cetuximab PET mAb Preclinical EGFR Correlation with EGFR 
expression xenografts
62





SPECT f(ab’)2 Preclinical EGFR Correlation with EGFR 
expression xenografts
61
89Zr-cetuximab PET mAb Preclinical EGFR No correlation with EGFR 
expression xenografts
64
64Cu-cetuximab PET mAb Preclinical EGFR No correlation with EGFR 
expression xenografts
65










NIRF mAb Preclinical EGFR Detection of implanted EGFR-
positive lesions in





NIRF mAb Clinical EGFR Intraoperative tumor detection 




NIRF mAb Clinical EGFR Correlation between ex vivo 
fluorescent signal and EGFR 





PET mAb Preclinical EGFR Influence of circulating shed 














Preclinical EGFR Intraoperative visualization 
of orthotopic primary tongue 










NIRF mAb Preclinical EGFR-wt/ 
EGFRvIII





NIRF affibody Preclinical EGFR-wt/ 
EGFRvIII





NIRF ligand Preclinical EGFR-wt/ 
EGFRvIII
Accumulated in EGFR-wt, 
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TARGET EXPRESSION (CONTINUED)
Tracer Modality Scaffold Study 
type
Target Remarks Ref
99mTc-3C10 SPECT mAb Preclinical EGFR-wt/ 
EGFRvIII
Accumulated more in EGFRvIII 




NIRF mAb Preclinical EGFR-wt/ 
EGFRvIII
Accumulated more in EGFRvIII 




PET mAb Preclinical EGFRvIII Accumulated in EGFRvIII-
transfected U87MG xenografts
68
11C-erlotinib PET TKI Preclinical EGFR-wt/ 
mutEGFR
Accumulation more in exon 
19 and 21 mutated than in 




11C-erlotinib PET TKI Clinical mutEGFR Volume of distribution higher 
in NSCLC patients with EGFR 
exon 19 deletion than in 
lesions of patients without 
activating mutations 
71
11C-erlotinib PET TKI Clinical mutEGFR 3 out of 4 patients with 11C-
erlotinib PET positive lesions 
responded to erlotinib, while 
best response in 11C-erlotinib 
PET negative lesions was stable 
disease in 2 out of 9 patients 
72
11C-erlotinib PET TKI Clinical mutEGFR Case report of high 
11C-erlotinib uptake in brain 
metastases of EGFR exon 19 
mutated NSCLC patient which 
responded to erlotinib
73
18F-afatinib PET TKI Preclinical EGFR/
HER2
Higher accumulation in 
EGFR-wt and EGFR-exon 19 
deletion, compared to 
EGFR-T790M xenografts
74




89Zr-trastuzumab PET mAb Clinical HER2 Detection of lesions in 





SPECT mAb Clinical HER2 Detection of lesions in 
HER2-positive breast cancer 
patients
93
89Zr-pertuzumab PET mAb Preclinical HER2 Specific uptake in HER2-
positive xenografts 
79
111In-ABY-002 SPECT affibody Clinical HER2 Detection of lesions in 
HER2-positive breast cancer 
patients
90
68Ga-ABY-002 PET affibody Clinical HER2 Detection of lesions in 











Clinical HER2 Detection of lesions in 










HER3 and HER2-mediated 









PET mAb Clinical HER3 Tumor uptake in patients with 
solid tumors, as well as tumor 








































NIRF mAb Preclinical EGFR Photoimmunotherapy and 
detection of lesions
103
89Zr-cetuximab PET mAb Preclinical EGFR Prediction of accumulation 





Preclinical HER2 Predict deposition, kinetics 
and efficacy of the parental 
doxorubicin-loaded liposome in 
xenografted mice and primates
105, 
106 
89Zr-trastuzumab PET mAb Clinical HER2 89Zr-trastuzumab scans to 
determine intra/interpatient 
HER2 heterogeneity and (non-)
responders to T-DM1 therapy
107
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ACCUMULATION (CONTINUED)
Tracer Modality Scaffold Type 
study
Target Remarks Ref
89Zr-trastuzumab PET mAb Preclinical HER2 Increased uptake of 
89Zr-trastuzumab after 
N-acetylcysteine treatment of 
MUC4-expressing xenografts
111
89Zr-pertuzumab PET mAb Preclinical HER2 Enhanced residualization of 
89Zr-pertuzumab with 
concurrent trastuzumab 



















SPECT mAb Preclinical HER2/ 
generic
Anti-angiogenic agent B20-4.1 
decreased general antibody 




PET mAb Preclinical meso-
thelin
Tumor accumulation of naked 





PET mAb Clinical meso-
thelin
89Zr-MMOT0530A uptake as 
predictor for clinical response 




Tracer Modality Scaffold Study 
type




PET f(ab’)2 Preclinical EGFR EGFR upregulation after PI3K 
inhibitor GDC-0941 and AKT 
inhibitor GDC-0068 treatment
119
89Zr-MEHD7945A PET mAb Preclinical EGFR/ 
HER3 
EGFR and HER3 upregulation 
after AKT inhibition by 
GDC-0068 
126
89Zr-trastuzumab PET mAb Preclinical HER2 Downregulation of HER2 
expression through afatinib 
treatment
120
89Zr-trastuzumab PET mAb Preclinical HER2 HER2 downregulation after 
HSP90 inhibition with 
NVP-AUY-922
122
89Zr-trastuzumab PET mAb Preclinical HER2 HER2 downregulation after 
HSP90 inhibition with PU-H71
124
89Zr-trastuzumab PET mAb Clinical HER2 HER2 downregulation after 
HSP90 inhibition with 






Tracer Modality Scaffold Study 
type
Target Effect studied Ref
89Zr-trastuzumab 
F(ab’)2 
PET f(ab’)2 Preclinical HER2 Upregulation and stabilization 
of HER2 at the plasma 





PET f(ab’)2 Preclinical HER2 HER2 downregulation after 





NIRF affibody Preclinical HER2 HER2 downregulation after 





PET f(ab’)2 Preclinical HER3 HER3 upregulation after AKT 
inhibition by GDC-0068 
119
89Zr-mAb391 PET mAb Preclinical IG1R IGF1R downregulation after 





PET mAb Preclinical VEGF VEGF-A downregulation after 











PET mAb Clinical VEGF Downregulation of VEGF-A 
through everolimus treatment
117
89Zr-ranibizumab PET f(ab’)2 Preclinical VEGF Sunitinib treatment-induced 
changes in VEGF-A tumor levels
118
INTRACELLULAR PROCESSES 
Tracer Modality Scaffold Study 
type
Target Effect studied Ref
111In-anti-
p27kip1-TAT 





SPECT mAb Preclinical phospho-
ɣH2AX
Detection of DNA breaks 





SPECT mAb Preclinical phospho- 
ɣH2AX
Detection of DNA breaks 
induced during tumorigenesis 





PET mAb Preclinical phospho- 
ɣH2AX
Detection of DNA breaks 
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4. Platform integration to guide selection of novel tracers
Both the arsenal of available tracers as well as the technology for molecular imaging are 
advancing rapidly. However, molecular imaging can benefit from other disciplines for the 
identification of novel discriminating factors. In this regard, large data sets of biological 
information can increasingly be utilized for the identification of the most interesting and 
informative targets for imaging. Clinical and pre-clinical studies progressively include 
‘omics’ methodologies encompassing genomic, transcriptomic, and proteomic analyses. 
Combined with clinical outcome metrics these data yield an ‘integrative omics’ approach. 
This offers great opportunities for extensive data mining to discover biomarkers which 
associate with tumor characteristics, treatment responses, and survival outcomes. These 
biomarker panels are not only useful to define new molecular-based tumor markers 
for molecular testing, but also provide a great resource to identify relevant molecular 
imaging targets, indicative of treatment effectiveness or resistance (137–139). 
4.1 Clinical classification using integrative omics
Integrative omics can be applied to uncover key pathways that are altered in cancer 
by utilizing information from the ‘cancer genome’ with an associated ‘cancer 
proteome’ (140). Often-used platforms include combinations of genomics (i.e. DNA 
sequencing for mutations, copy number aberrations (CNAs), and methylation of genes), 
transcriptomics (microarray RNA-based or RNAseq-based expression analysis), and 
proteomic analysis (proteins abundance and post-translational modifications (PTMs) 
using mass spectrometry (MS) or multiplexed reverse-phase protein arrays (RPPA)) 
(Figure 3) (141). Because integrative omics approaches use unbiased selection methods, 
they are of potential interest for classification of patient groups and identification of 
biomarkers. Large-scale initiatives have attempted to diversify on histological cancer 
subtypes by identifying common features within the high information density of multiple 
platforms. For example, in-depth genomic analysis of 2,000 breast cancers identified 10 
genetic classifications of breast cancer with distinct survival outcomes, although their 
clinical relevancy will need to be validated (142). Reassuringly, in a study of over 6,000 
breast cancer patients, expression profiling using a panel of 70 genes (MammaPrint) 
showed that adjuvant chemotherapy could be safely withheld in the group of patients 
with genetically low-risk hormonal breast cancers (143). Further in-depth analysis of 
gene expression showed how immune cell-specific gene patterns could be used to define 
the fraction of infiltrating immune cells within 7,270 breast cancer profiles. The data also 
identified associations between different tumor compositions and therapy response as 
well as the outcome for known breast cancer subtypes (144). Besides diversifying on 
single cancer types, integrative omics analysis can identify molecular patterns across 
cancer types. The Cancer Genome Atlas (TCGA) consortium, for instance, has compiled 
transcription and genomic profiling of more than 500 tumor samples each for 11 cancer 
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types (145). Meta-analysis on all combined TCGA-data sets uncovered new insights into 
shared features and common oncogenic drivers across tumor types and was used to 
classify tumors as being either largely driven by mutations or chromosomal aberrations 
(146). The potential of integrative omics to yield new imaging targets was indicated by 
an explorative study. Combined analyses of microarray database Oncomine and Gene 
Ontology identified not only known imaging targets (e.g. HER2 in breast cancer) but 
also potential imaging targets to differentiate between normal and cancer tissues in six 
different cancer types including MUC1 in ovarian cancer (138). The studies mentioned 
above confirmed previously established profiles, and more importantly, uncovered sub-
classifications with distinct biological features, disease characteristics, and prognosis. 
The studies above mainly used genomic and transcriptomic analyses, whereas 
technological advances have significantly improved the sensitivity and resolution of high-
throughput proteomics (147). Genomic and proteomic integration was recently applied in 
a large-scale analysis of TCGA colorectal cancer data (148). Five unique protein signatures 
were identified, which confirmed established genomic signatures and revealed clinically 
relevant cancer sub-populations (148). A similar approach was employed for the breast 
cancer TCGA cohort that also included phospho-proteomic analysis linking genetic 
alterations to changes in phosphorylated kinases (149). To a certain degree, protein 
expression is expected to resemble gene transcription levels, especially in the case of 
CNAs, resulting in gene amplifications or deletions (150). However, the proteogenomic 
analysis of TCGA data showed very often protein levels did not correlate well with mRNA 
levels or CNAs, underscoring the need for proteomic data to validate and further improve 
genetics-based classifications. This notion is particularly important for genomics-based 
selection of biomarkers intended for use in tissue samples or imaging. Taken together, 
omics studies have shown that (epi)genetic alterations give rise to a wide range of new 
molecular-based cancer classifications and large-scale genomic and proteomic analyses 
can support their identification.
Many biomarkers are used for patient stratification before treatment, however, they are 
not necessarily suitable for patient follow-up during and after treatment. In contrast to 
molecular imaging that allows for multiple, non-invasive whole body scans over time, 
genomic biomarkers are limited by the number of invasive re-biopsies for follow-up 
sampling and not necessarily informative for all lesions due to intra-tumor heterogeneity. 
This can potentially be improved by including molecular imaging in treatment decisions. 
For example, patients with 89Zr-trastuzumab PET HER2-positive pattern, showed more 
clinical benefit on T-DM1 therapy when compared to patients with a HER2 PET-negative 
pattern (107). It is also of note, that detection of circulating tumor DNA (ctDNA) in blood 
might partly alleviate the difficulty of repeated invasive biopsies and allow for patient 
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follow-up during treatment by retrospective analysis of serially obtained samples. For 
instance, a de novo EGFR mutation in exon 21 could be identified in circulating tumor 
DNA of a patient with recurrent ovarian cancer (151). Similarly, the emergence of EGFR-
T790M mutation was detected prior to progressive disease by serial measurement of 
ctDNA in plasma of NSCLC patients and was associated with worse overall survival (152). 
An alternative strategy to discover therapy response biomarkers would involve pre- and 
post-treatment analysis of the proteomic make-up of tumors from responders versus 
non-responders. Such an approach would define proteins that dynamically change 
depending upon the efficacy of treatment and as such might be used as effect sensor 
biomarkers. Pre-clinical imaging studies have shown the feasibility of monitoring 
drug-induced changes in protein expression with radionuclide imaging, such as the 
successful imaging of increased expression of EGFR and HER3 following treatment with 
PI3K/AKT TKIs using 64Cu-antibody F(ab’)2 fragments (119). Using this approach, potential 
effect sensors identified in omics studies could be validated with molecular imaging. 
However, large-scale proteome analysis of tumor samples about treatment is not widely 
performed, mainly due to the difficulty in obtaining post-treatment samples. Such 
analyses are certainly warranted to identify reliable markers for treatment response. 
Although molecular profiling studies have provided valuable insights in cancer subtypes, 
the question remains whether the profiles can be reliably measured with standard 
clinical techniques and if they truly improves the survival outcomes. Recent clinical trials 
have shown the feasibility of treatment based on selected biomarkers panels, whole 
genome, or proteome analysis. For example, the BATTLE trial assessed the feasibility of 
a selected set of genomic and proteomic biomarkers for erlotinib treatment, including 
EGFR mutations or CNA analysis, to guide treatment decision for NSCLC patients (153). 
At a larger scale, the WINTHER trial aims at full genomic analysis to stratify patients 
with so-called ‘actionable alterations’, mutations that can be targeted with approved 
or experimental treatments (154). Another example is the CPCT initiative in which 
next generation sequencing of tumor samples was performed to guide drug choice for 
patients with metastatic disease (155). It is conceivable that omics-based screening will 
identify more patients with actionable alterations, leading to incremental knowledge 
and increasingly predictive biomarker profiles. To this end, molecular imaging could 
play a role in biomarker-driven studies that focus on alterations that lead to changes 
in expressed proteins. To clinically test treatments based on molecular biomarkers, 
trial designs are adapted to enroll patients with rare mutations from multiple cancer 
types in so-called basket clinical trials. Using such a design, patients from 7 different 
cancer types harboring a BRAF-V600E mutation could be treated with the BRAF inhibitor 
vemurafenib (156). The recently launched TAPUR study (NCT02693535) encompasses 
15 basket trials for patients with rare mutations. Amongst these are trials for patients 
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with EGFR-mutated tumors to be treated with erlotinib, EGFR-wt tumors without any 
downstream RAS or RAF mutations with cetuximab, and treatment with trastuzumab 
and pertuzumab for patients with tumors harboring HER2 amplifications. These 
developments will give an indication of the added value of omics for trial designs 
and treatment guidance and offer a unique opportunity for molecular imaging to be 
incorporated in future profiling studies.
4.2 Platform integration to identify novel biomarkers 
Biomarkers are increasingly a part of clinical testing for classification of cancer and 
differentiation into relevant subgroups. Activating EGFR mutations are targeted for 
effective treatment with TKIs erlotinib or gefitinib in NSCLC while ALK mutations or ROS1 
translocations define a subgroup responding to crizotinib (157). Other prototypical 
examples of genomic biomarker-based guidance for treatment choice are BCR-ABL 
translocations in chronic myeloid leukemia treated with imatinib, BRCA1/2 mutations in 
ovarian cancer treated with PARP inhibitors, and BRAF-V600E mutations in melanoma 
treated with BRAF inhibitors (158–160). Besides these genomic biomarkers, many 
tumor-expressed protein biomarkers have been reported, including HER2, estrogen 
receptor (ER), and progesterone receptor (PR) in breast cancer, and c-KIT in gastro-
intestinal stromal tumors (161). Interestingly, these protein targets (except c-KIT) can be 
successfully monitored in the clinic using a diverse panel of molecular imaging techniques 
for HER2, ER, and PR (94, 162, 163). Despite the plethora of biomarkers reported in 
the literature, only a relatively small number has been approved for clinical use (161). 
However, a renewed focus in precision medicine to develop targeted drugs together 
with matched biomarkers should improve the utility and numbers of biomarkers in the 
clinic (157). We anticipate that by providing insight into whole body and temporal 
expression of biomarkers, molecular imaging approaches can be one of the platforms to 
validate and apply new and existing tumor markers.
Genomic changes do not translate to phenotypic changes per se due to, for instance, 
regulation of RNA translation or protein function affected by post-translational 
modifications (PTMs). PTMs, such as phosphorylation and ubiquitination, can greatly 
affect the activity, stability, and function of proteins and can be highly dynamic 
modifications. Proteogenomic analyses by the Clinical Proteome Tumor Analysis 
Consortium (CPTAC) on CRC and breast cancer TCGA tumor specimens showed that 
translational factors could be quantitatively analyzed by proteomics and integrated with 
genomics to validate and improve molecular profiling (148,149). Integration of multiple 
platforms allows for more depth of analysis and stringent selection, potentially leading 
to more successful biomarkers (164). The addition of proteomics to existing genomic 
platforms can determine whether genomic markers are functionally expressed, allows 
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for correlation of metabolic and enzymatic processes with genomic profiles, and can 
be used to follow-up on serum biomarkers and effect sensors in time. Ultimately, this 
could lead to robust molecular imaging candidates to visualize drug resistance or tumor 
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Figure 3. Omics-based strategies to facilitate discovery of novel molecular imaging targets
Tissue or serum samples collected from patients, or from other in vivo and in vitro sources, can be analyzed 
by genomic, transcriptomic, and proteomic discovery platforms. The resulting profiles can then combined by 
integrative omics approaches to develop molecular-based tumor classifications and discover potential infor-
mative biomarkers. From this integrative approach new protein targets or mutations could be discovered that 
distinguish tumor from benign tissue. Similarly, analyzing pre- and post-treatment profiles could potentially 
lead to discovery of effect sensors that signify response to treatment or emergence of resistance pathways.
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To find new molecular imaging targets, proteomics can be used for validation of selected 
genomic markers or identification of new markers based upon the integration of 
proteomic and genomic data. For validation or measurement of a selected number of 
biomarkers after the initial discovery, targeted MS techniques such as multiple reaction 
monitoring-MS (MRM-MS) or reverse phase protein array (RPPA) are most suitable, 
whereas new biomarkers are better identified with quantitative proteomics. Thus far, 
MRM-MS has been mostly employed for serum biomarkers such as prostate-specific 
antigen or changes in metabolism (165). Serum biomarkers are extensively explored 
using proteomics and employed as diagnostic tools. However, serum biomarkers 
mostly reflect tumor load and do not provide information on inter- and intra-tumor 
heterogeneity making them less suitable as molecular imaging targets. Nevertheless, 
serum analysis can be integrated with genomics to study treatment responses. For 
instance, by analyzing temporal changes in gene expression and serum metabolites in 
an EGFR-L828R-T790M-driven mouse tumor model, it was possible to identify changes 
in metabolic pathways, such as the glutathione pathway essential for tumor response 
to EGFR TKI afatinib alone or in combination with the mTOR inhibitor rapamycin (166). 
As glutamine is a precursor of the glutathione pathway, molecular imaging with 
18F-glutamine PET in NSCLC and breast cancer patients might facilitate monitoring 
drug-induced changes in this pathway (167). Thus, similar approaches can be used 
to measure changes in metabolic or enzymatic processes identified by genomics and 
confirmed by proteomic measurements. In addition to imaging of the prostate specific 
membrane antigen (PSMA) to visualize prostate cancer, the enzymatic activity of PSMA 
could be visualized with urea-based tracers, which are metabolized by PSMA (152, 153). 
Such studies point to cellular processes underlying biomarkers that might be used for 
molecular imaging. 
RPPA is a promising technique for analysis of cellular biomarker panels, as it allows 
multiplexed assessment of markers limited only by the availability of specific antibodies. 
The combination of transcriptomic, genomic, and drug sensitivity data by RPPA 
analysis of 71 proteins in 84 NSCLC cell lines showed that sensitivity to EGFR inhibition 
correlated better with activated EGFR levels than EGFR abundance (160). These data are 
in concordance with the correlation between activated EGFR and EGFR TKI sensitivity 
found in clinical studies. As another example, a pattern of high AXL expression and 
c-MET activation was identified using RPPA in breast cancer tissues supposedly driving 
proliferation (170). Gene expression analysis studies have further led to the identification 
of AXL as a driver of resistance to EGFR TKIs in HNSCC and NSCLC models (171, 172). 
Considering that AXL imaging has already been performed with 64Cu-labeled (173) and 
NIRF-dye Cy5.5-conjugated AXL antibodies (174) in AXL-positive A549 human NSCLC 
xenografts in mice, this proliferation pathway and resistance mechanism to EGFR TKIs 
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could potentially be monitored by non-invasive imaging. RPPA has been employed 
on a large scale targeting nearly 200 proteins and phosphorylated variants on 4,379 
tumor samples, largely from 11 TCGA cancer cohorts and 3 independent cohorts (175). 
Although these data, so far only used to uncover pan-cancer proteomic relations in the 
TCGA cohorts, still provide a unique opportunity to integrate genomic TCGA analyses 
with proteomic data across multiple tumor types (176).
Identification of novel prognostic biomarkers or protein-based early effect sensors 
should not depend on fixed, preselected, antibodies used in RPPA and is better studied 
with a quantitative MS-based proteome-wide analysis. This can be performed using 
either isotope or chemical labeling or by label-free quantitation. Proteogenomic 
analysis of the TCGA CRC cohort was performed with label-free analysis using spectral 
counting and expression levels of protein were quantified in relation to all measured 
samples (148). To accurately quantify protein expression changes or PTMs, knowledge 
of control or standardized expression levels is essential. To this end, protein-labeling 
techniques can be employed together with MS, which utilizes incorporation of stable 
isotopes in cell lines. For example, SILAC-MS quantifies ratios between proteins derived 
from stable isotope-labeled cell lines and their unlabeled counterparts from control cell 
cultures. This technique can thus be used to measure protein dynamics when a certain 
treatment is applied to one of the cell cultures (177). Alternatively, isotope labeling 
can be performed post-treatment on cells or patient tissues using standardized SILAC-
labeled reference samples or chemical labeling using isobaric tags for the relative and 
absolute quantitation (iTRAQ) method (178). Using SILAC-based proteomics, increased 
levels of EGFR, Clusterin-CLU, and HADHB were found as potential biomarkers in 
trastuzumab-resistant breast cancer cell lines compared to their parental controls (179). 
An early proteomic response to EGFR inhibition by gefitinib in human NSCLC cell line 
A431 was also investigated using SILAC-MS identifying a panel of 15 membrane proteins 
upregulated after gefitinib treatment (180). Although not clinically validated, these 
proteins identified in both studies were suggested as early markers of resistance to 
trastuzumab. Quantitative proteomics is, therefore, a promising discovery platform for 
new molecular imaging effect sensors by analyzing drug-induced changes in proteomes 
of cancer cells. 
A largely untouched area of biomarkers is PTMs of proteins, that can be identified using 
MS. SILAC- and iTRAQ-based MS strategies, which are highly effective in quantifying 
changes in multiple PTMs simultaneously, such as changes in phosphorylation, 
glycosylation, or ubiquitination (181). PTMs are particularly interesting molecular 
markers as they portray the underlying, highly dynamic, biologic processes in cancer. 
For example, the extensive phospho-proteome analysis was performed to map EGFR 
signaling in relation to the sensitivity to HER family inhibitors. This approach confirmed 
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alterations in established downstream signaling after EGFR TKI treatment, while 
feedback pathways involving HER2 and HER3, as well as changes in autophagy pathways 
were identified (166, 167). Furthermore, SILAC phospho-proteomic analysis detected 
high levels of phosphorylated EGFR in EGFR-wt pancreatic cancer cell lines sensitive to 
erlotinib, suggesting phosphorylated EGFR as a predictive marker for erlotinib treatment 
when EGFR mutations are absent (184). Using iTRAQ labeling of 105 TCGA breast cancer 
samples with corresponding genomic and clinical data, new correlations between 
genetic alterations (e.g. CNAs) and protein translation were found. For instance, loss of 
chromosome arm 5q containing SKP1 and CETN3 in basal breast cancers was shown as 
the potential cause of increased expression of EGFR and Src (149). Furthermore, CNAs 
could also be linked to changes in phosphorylation, as HER2 amplification induced over-
expression and activation of not only HER2 but also of the surrounding genes CDK12, 
MED1, and GRB7 (149). Assuming the availability of specific probes for detection of 
PTMs, molecular imaging, for example using TAT-modified antibody strategies, would 
allow for direct analysis of pathway activation status, and may be more informative than 
analysis of the plain abundance of pathway components. 
Developments in genomic and proteomic platforms will continue to improve biomarker 
discovery that will lead to implementation in clinical studies. With the existing and 
expanding data from these studies, molecular imaging targets can be identified that can 
potentially guide treatment decisions. 
5. Discussion
Development of targeted therapies and their implementation in clinical practice can be 
aided by molecular testing of tumor biopsies or blood-borne markers. Complementary 
to these diagnostic tools, we described how molecular imaging techniques could provide 
valuable information on whole body distribution of drug targets to aid the assessment of 
drug efficacy during treatment. Measuring target presence and dynamics across multiple 
tumor lesions could be highly relevant to assess drug uptake, especially regarding 
marker-dependent agents using toxic payloads such as ADCs. Besides radionuclide-based 
imaging strategies, advances in optical imaging might enable simultaneous visualization 
of multiple markers at organ-level resolution, removing the radiation burden and 
lowering production costs. To unveil many relevant intracellular processes, technical 
advances should be aimed at bringing high affinity, large molecular weight probes, such 
as antibodies and analogs past cellular membranes, allowing high-contrast visualization 
of intracellular processes in tumor cells. Whether molecular imaging of oncogenic 
growth factor receptor imaging is sufficient to assess treatment efficacy and resistance 
of HER family-driven cancers is currently being investigated in clinical trials. 
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Many imaging agents are directed to commonly used tumor markers or drug targets to 
acquire a better understanding of target distribution and behavior. However, this array 
of markers can be greatly expanded by making use of integrative omics approaches that 
link patient and tumor characteristics to genomic and proteomic analysis. From these 
efforts, molecular markers have been discovered that distinguish specific subsets of 
cancers that could be assessed by molecular imaging. Similarly, radiomics approaches 
combine patient and tumor characteristics, including mutation status, for computational 
analysis of molecular imaging data to discover prognostic or predictive features for 
treatment response and outcome. Key oncogenic tumor targets or distinguishing tumor 
markers identified by omics approaches are not often the ideal extracellular imaging 
targets. However, new technologies in intracellular localization of imaging tracers might 
enable monitoring the activation status of these relevant biological components. Lastly, 
there is an unmet opportunity for pre- and post-treatment imaging of effect sensors that 
can be discovered by omics analysis of serially obtained tumor samples.
In summary, an extensive arsenal of molecular probes is already available to image HER 
family members and related proteins. Coupled to omics-based discovery platforms, this 
can open up an arsenal of other novel tracers for monitoring treatment efficacy and drug 
resistance. 
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Preclinical positron emission tomography (PET) imaging revealed a mismatch between 
in vivo epidermal growth factor receptor (EGFR) expression and EGFR antibody tracer 
tumor uptake. Shed EGFR ectodomain (sEGFR), which is present in cancer patient sera, 
can potentially bind tracer and therefore influence tracer kinetics. To optimize EGFR-PET, 
we examined the influence of sEGFR levels on tracer kinetics and tumor uptake of EGFR 
monoclonal antibody 89Zr-imgatuzumab in varying xenograft models. 
Human cancer cell lines A431 (EGFR overexpressing, epidermoid), A549 and H441 
(both EGFR medium expressing, non-small cell lung cancer) were xenografted in mice. 
Xenografted mice received 10, 25 or 160 μg 89Zr-imgatuzumab, co-injected with equal 
doses 111In-IgG control. MicroPET scans were made 24, 72 and 144 h post injection, 
followed by biodistribution analysis. sEGFR levels in liver and plasma samples were 
determined by ELISA. 
89Zr-imgatuzumab uptake in A431 tumors was highest (29.8 ± 5.4 %ID/g) in the 160 μg
dose group. Contrary, highest uptake in A549 and H441 tumors was found at the 
lowest (10 μg) 89Zr-imgatuzumab dose. High 89Zr-imgatuzumab liver accumulation was 
found in A431 xenografted mice, which decreased with antibody dose increments.
 89Zr-imgatuzumab liver uptake in A549 and H441 xenografted mice was low at all doses. 
sEGFR levels in liver and plasma of A431 bearing mice were up to 1000-fold higher than 
levels found in A549, H441 and non-tumor xenografted mice. 
89Zr-imgatuzumab effectively visualizes EGFR-expressing tumors. High sEGFR levels can 
redirect 89Zr-imgatuzumab to the liver, in which case tumor visualization can be improved 
by increasing tracer antibody dose. 
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Overexpression and mutations of epidermal growth factor receptor (EGFR) are 
associated with tumor cell growth, differentiation, proliferation, apoptosis and cellular 
invasiveness (1). Clinical treatment options for KRAS wild-type EGFR in head and neck 
squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (mCRC), encompass 
monoclonal antibodies (mAbs) cetuximab and panitumumab. Mutant EGFR expressing 
tumors, including non-small cell lung cancer (NSCLC), are treated with the tyrosine 
kinase inhibitors erlotinib and gefitinib (2–4). 
EGFR-targeted therapy might be improved by optimizing antibody-dependent cell-
mediated cytoxicity (ADCC) responses. Imgatuzumab (GA201) is a novel humanized 
anti-EGFR IgG1 isotype mAb, glycoengineered for enhanced ADCC, as well as inhibiting 
ligand-dependent signaling of EGFR. Imgatuzumab recognizes human EGFR and is not 
cross-reactive with murine EGFR (5). It showed superior in vivo efficacy compared to 
cetuximab and non-glycoengineered imgatuzumab in both KRAS-mutant and KRAS-wild 
type tumor models. In phase 1 studies imgatuzumab demonstrated promising efficacy in 
heavily pretreated patients with advanced EGFR-positive solid tumors and KRAS mutant 
EGFR-positive advanced colorectal cancer (6, 7).
Whole body determination of EGFR expression in lesions using molecular imaging could 
support decision making during clinical development and clinical practice. Antibody 
biodistribution can be visualized by labeling mAbs with the PET isotope Zirconium-89 
(89Zr, t½ = 78.4 h). We previously developed and successfully tested 89Zr-labeled antibody-
based tracers targeting human epidermal growth factor receptor 2 (HER2), vascular 
endothelial growth factor (VEGF) and HER3 in the preclinical and clinical setting (8–12). 
89Zr-labeled antibodies have also been developed for preclinical EGFR imaging (13–15). 
Furthermore, clinical EGFR imaging has been performed with 89Zr-cetuximab in advanced 
colorectal cancer patient (16, 17). Additional clinical studies are currently ongoing for 
both 89Zr-cetuximab and 89Zr-panitumumab (ClinicalTrial.gov identifiers NCT01691391, 
NCT02117466 and NCT02192541). 
Unfortunately, preclinical EGFR antibody-based imaging studies revealed a mismatch 
between in vivo EGFR protein expression and tumor tracer uptake (13, 18). Many factors 
have been suggested for this mismatch, including perfusion rates, vascularity, vascular 
permeability, interstitial pressure and mAb plasma half-life (18). Circulating HER2 
extracellular domain (ECD) and trastuzumab are known to form complexes, which are 
swiftly cleared by the liver (18). Underscoring the possibility of shed ECD to significantly 
influence kinetics of antibodies, shed HER2 serum levels over 500 ng/mL extensively 
influenced trastuzumab kinetics in patients at weekly doses of 100 mg trastuzumab (19). 
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For EGFR and EGFR-targeting mAbs this relation is less clear. However, some studies show 
extensive levels of circulating soluble EGFR extracellular domain (sEGFR) in patients and 
healthy volunteers (20). sEGFR might therefore also influence kinetics and tumor uptake 
of tracer doses used for 89Zr-labeled EGFR targeting antibodies. 
In order to optimize EGFR imaging and visualize EGFR expression in vivo we developed 
the EGFR PET tracer 89Zr-imgatuzumab and examined the influence of sEGFR on 




Human cancer cell lines with varying levels of EGFR expression were used. The NSCLC cell 
lines H441 and A549 and the epidermoid carcinoma cell line A431 were obtained from 
the American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were quarantined 
until screening for microbial contamination and mycoplasm was performed and proven 
to be negative. Cells were tested and authenticated in April 2015 by Baseclear (Leiden, 
The Netherlands) using STR profiling. Cells were subcultured twice weekly, using Roswell 
Park Memorial Institute-1640 (RPMI-1640, Gibco, Paisley, UK) / 2 mM L-glutamine (Gibco) 
supplemented with 10% fetal calf serum (FCS, Bodinco, Alkmaar, The Netherlands) for 
H441, RPMI-1640, with 10% FCS for A549 and high glucose Dulbecco’s Modified Eagle’s 
Medium (DMEM, Gibco) with 10% FCS for A431. All cell lines were cultured in a fully 
humidified atmosphere at 37 °C and 5% pCO2. Flow cytometric analysis was performed 
on a BD Accuri™ C6 flow cytometer (BD Biosciences, Breda, The Netherlands) to assess 
EGFR protein expression status using imgatuzumab (25.3 mg/mL, Roche Glycart AG, 
Schlieren, Switzerland) as primary antibody and mouse anti-human Fc-specific FITC 
conjugated secondary antibody (clone HP-6017, Sigma-Aldrich, Zwijndrecht, The 
Netherlands).
89Zr-imgatuzumab tracer development and quality control
Imgatuzumab was incubated with a 5-fold molar excess of TFP-N-Suc-desferal-Fe 
(Df, ABX GmbH, Hamburg, Germany) and subsequent 89Zr-labeling was performed as 
described earlier (8), using clinical grade 89Zr (Perkin Elmer, Groningen, The Netherlands). 
Maximal attainable specific activity was determined using varying amounts of 89Zr per 
mg antibody between 50 and 1000 MBq/mg. Radiochemical purity (RCP) was assessed 
by trichloroacetic acid (TCA) precipitation test (22). Df-imgatuzumab conjugates were 
checked for aggregation and fragmentation by size exclusion high performance liquid 
chromatography (SE-HPLC). The Waters SE-HPLC system was equipped with a dual 
wavelength absorbance detector, in-line radioactivity detector and TSK-GEL G3000SWXL 
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column (JSB, Eindhoven, The Netherlands). Phosphate buffered saline (PBS; 140 mmol/l 
NaCl, 9 mmol/l Na2HPO4, 1.3 mmol/L NaH2PO4; pH = 7.4) was used as mobile phase. 
Stability of 89Zr-imgatuzumab was tested for 2 weeks in 0.9% NaCl at 4 °C, human serum 
at 37 °C and 0.5 M HEPES pH 7.2 buffer at 37 °C. 
Immunoreactive fraction of Df-imgatuzumab conjugates was assessed by competition 
assay. In short, NUNC BreakApart 96-well plates were coated overnight at 4 °C 
with 100 μL 100 ng/mL EGFR ECD (Roche Glycart AG) in 0.1 M Na2CO3 buffer pH 9.6. 
89Zr-imgatuzumab was diluted to 4000 ng/mL in assay diluent which consisted out of 
PBS, 0.5% bovine serum albumin Fraction V and 0.05% Tween 20. Plates were washed 
with washing buffer (PBS with 0.05% Tween 20) and blocked by 200 μL assay diluent 
for 1 h at room temperature (RT) and washed again. 0.004 to 156.25-fold molar excess 
unmodified imgatuzumab was pre-mixed 1:1 with diluted 89Zr-imgatuzumab solution 
and 100 μL of the mixtures were incubated in wells for 1 hour at RT. After washing, wells 
were broken apart and counted using a calibrated well-type LKB-1282-Compu-gamma 
system (LKB WALLAC). Counts were plotted against concentration competing unmodified 
imgatuzumab and the half maximal inhibitory concentration (IC50) was calculated using 
Graphpad 5.0 (GraphPad Software, Inc., La Jolla, CA, USA). The IC50-value was divided by 
the final tracer concentration (2000 ng/mL) to yield the immunoreactive fraction. 
Indium-111 labeling IgG control 
Human IgG (Nanogam®, Sanquin, Amsterdam, The Netherlands) was used as aspecific 
control. IgG was conjugated with p-SCN-Bn-DTPA (Macrocyclics, Dallas, TX, USA) as 
described earlier (23). Radiolabeling was performed using indium-111 (111In) chloride 
(Mallinckrodt, Prague, Czech Republic). Radiochemical purity of 111In-IgG labeling was 
checked by instant thin layer chromatography (ITLC) using 0.1 M citrate buffer pH 6.0 as 
eluent. 
Animal studies
Male nude mice (BALB/cOlaHsd-Foxn1nu, Harlan, Boxmeer, The Netherlands) were 
inoculated with A431, H441 (both 5*106 cells in 200 µL PBS) or A549 (3*106 in 300 µL 
1:1 PBS and high growth factor Matrigel (BD Biosciences, Breda, The Netherlands) 
subcutaneously (sc). Xenografts were allowed to grow to at least 100-200 mm3. For 
microPET imaging, A431, A549 and H441 xenograft-bearing mice (n=3-6 per group) were 
injected intravenously (iv) via the penile vein with ~10, 25 and 160 μg 89Zr-imgatuzumab 
(effective injected protein doses were 9.6 ± 0.08, 23.8 ± 0.11 and 151.2 ± 1.1 μg, labeled 
with 4.60 ± 0.06, 3.99 ± 0.13 and 5,64 ± 0.11 MBq 89Zr respectively for the 10, 25 and 
160 μg dose groups). MicroPET scans were made 1, 3 and 6 days post injection (pi) using 
a Focus 220 PET scanner (CTI Siemens), followed by ex vivo biodistribution analysis after 
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the final scan. Some A431 bearing mice received ~10, 25 or 100 μg 89Zr-imgatuzumab 
(effective injected protein doses were 9.5 ± 0.05, 23.3 ± 0.26 and 86.0 ± 4.0, labeled 
with 1.11 ± 0.03, 0.99 ± 0.06 and 0.91 ± 0.09 MBq 89Zr respectively for the 10, 25 and 
100 μg dose groups) only for ex vivo biodistribution analysis 6 days pi. Ex vivo results 
of biodistribution-only A431 tumor bearing mice were pooled with mice used for the 
microPET imaging study, A431 tumor bearing group size was therefore 6 to 12 animals. 
All mice received an equal amount of 111In-IgG control (1 MBq) as aspecific control. For 
all tracer injections 10 μg 89Zr-imgatuzumab and an equal amount of 111In-IgG was used, 
with cold imgatuzumab and IgG added to reach the total stated protein doses. 
Scans were reconstructed and in vivo quantification was performed using AMIDE (v1.0.4, 
Stanford University, Stanford, CA, USA) (24). MicroPET data are presented as mean 
standardized uptake value (SUVmean). Region of interests (ROI) were drawn for tumor based 
upon ex vivo weight, assuming 1 g/ml tissue density. For blood pool measurements, a 
fixed-sized sphere was drawn in the center of the heart, for liver and spleen a fixed-sized 
ellipsoid ROI was drawn in representative parts of the organs. After the final scan, mice 
were sacrificed and organs of interest collected for biodistribution studies. Organs and 
standards of the injected tracer were counted in a calibrated well type LKB-1282-Compu-
gamma system (LKB WALLAC) and weighed. After decay correction, ex vivo tissue activity 
was expressed as the percentage of injected dose per gram tissue (%ID/g). Xenograft 
tumors were partly formalin-fixed and paraffin embedded for immunohistochemistry 
(IHC) and partly frozen for subsequent sEGFR ELISA analysis. Plasma of xenograft and 
non-xenograft bearing (control) mice was used for sEGFR ELISA analysis, based upon 
shed c-MET analysis by Jagoda et al (25). Plasma was obtained by heart puncture 
and subsequent centrifugation of blood in lithium heparin blood collection tubes (BD 
Vacutainer, Plymouth, UK). All animal experiments were approved by the Institutional 
Animal Care and Use Committee of the University of Groningen.
sEGFR ELISA analysis
Near-confluent A431, A549 and H441 cell cultures were washed with PBS and incubated 
for 72 h in fetal calf serum free growth media, as well as serum-containing growth media, 
as described earlier (26), after which supernates were removed and centrifuged to 
remove cell debris. Cells of confluent cell cultures were washed with PBS and harvested 
using trypsin. Lysates of cells, xenograft tumors and liver tissue of A431, A549 and H441 
xenograft bearing mice were obtained by mechanical disruption in M-PER Mammalian 
Protein Extraction Reagent (Thermo Scientific, Bleiswijk, The Netherlands) supplemented 
with EDTA-free protease/phosphatase inhibitor cocktail (Thermo Scientific). Protein 
concentrations of cell, tumor and liver lysates were determined by Bradford assay (27). 
sEGFR was detected using a human extracellular domain EGFR ELISA (SEK10001, Sino 
Biological, Beijing, China), according to manufacturer’s instructions. 
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Formalin fixed, paraffin-embedded tissue slices were stained for EGFR with a rabbit 
mAb (clone D38B1 XP®, Cell Signaling Technology, Leiden, The Netherlands) and for 
microvessel density using a rat anti-murine CD31 mAb (clone SZ31, Dianova GmbH, 
Hamburg, Germany). Hematoxylin & eosin (H&E) staining was performed regularly 
to assess tissue viability and morphology. Digital scans of slides were acquired by a 
NanoZoomer 2.0-HT multi slide scanner (Hamamatsu) and analyzed with NanoZoomer 
Digital Pathology viewer software. A 0 – 300 histo-score EGFR staining was assessed as 
follows: no staining 0+, weak cytoplasmic staining 1+, strong cytoplasmic staining 2+ and 
strong membrane and cytoplasmic staining 3+, with H-score calculated using the formula 
1 × (% of 1 + cells) + 2 × (% of 2 + cells) + 3 × (% of 3 + cells). Microvessel density was 
scored in 3 areas, defined as hot spot areas with the maximum number of microvessels 
as described earlier (22).
Statistical analysis
Data are presented as mean ± SEM. Statistical analyses were performed using the Mann-
Whitney test (Graphpad 5.0) or One-way ANOVA with a Bonferroni post test for multiple 
comparisons. P-values ≤ 0.05 were considered significant.
Results
89Zr-imgatuzumab tracer development and quality control
Df-imgatuzumab conjugate bound up to 500 MBq 89Zr/mg Df-imgatuzumab at a 
radiochemical purity (RCP) ≥ 95% after radiolabeling, without further purification (Suppl. 
Fig. 1A). SE-HPLC revealed absence of aggregates and fragments in Df-imgatuzumab 
conjugates. The immunoreactive fraction of Df-imgatuzumab conjugate was assessed by 
competition assay at 68.9 ± 6.3% compared to unmodified imgatuzumab (Suppl. Fig. 1B). 
89Zr-imgatuzumab was stable in vitro, the maximum observed decrease in RCP was from 
99.4 ± 0.1% to 93.4 ± 0.8% in 0.5 M HEPES buffer pH 7.2 after 14 days at 37°C (Suppl. 
Fig. 1C).All batches of 89Zr-imgatuzumab used as tracer had a RCP ≥95% by TCA 
precipitation, while 111In-IgG batches had a RCP ≥90% by ITLC.
MicroPET imaging and biodistribution in different tumor models
MicroPET analysis showed preferential tumor uptake of 89Zr-imgatuzumab in A431, A549 
and H441 xenografts models (Fig. 1A). For A549 and H441, the highest 89Zr-imgatuzumab 
tumor uptake was observed for the 10 μg dose 6 days pi (Fig. 1B), while higher doses 
lowered tumor uptake. An opposite pattern was observed in A431 tumors, where 
89Zr-imgatuzumab tumor uptake increased with increasing tracer dose (Fig. 1B). Blood 
levels of 89Zr-imgatuzumab were highest for the 160 μg tracer dose at day 1 pi for all 
tested models and decreased gradually over time (Fig. 1B). 89Zr-imgatuzumab blood 
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levels were significantly lower in A431 tumor bearing mice compared to both A549 and 
H441 at 10 μg and 25 μg (P < 0.001) and at 160 μg (A549: P < 0.01, H441: P < 0.05). 
High liver accumulation was observed in A431 compared to both A549 and H441 tumor 
bearing mice at 10 μg (P < 0.001) and at 25 μg (P < 0.01), but not in the 160 μg tracer 
dose group (Fig. 1A, 1B).
Biodistribution studies showed that 89Zr-imgatuzumab uptake in A431 tumors was not 
different from 111In-IgG uptake in the 10 μg dose group (8.4 ± 1.0 vs. 7.7 ± 0.7 %ID/g, 
P = 0.50), but after increasing the dose to 25, 100 and 160 μg, significant tumor uptake 
was observed. Highest A431 tumor uptake was observed at 160 μg tracer dose, with 
29.8 ± 5.4 %ID/g for 89Zr-imgatuzumab, compared to 9.8 ± 1.1 %ID/g for 111In-IgG uptake 
(P < 0.05) (Fig. 2). Tumor-to-blood ratios of all tracer doses in A431 tumor bearing mice 
were consistently higher for 89Zr-imgatuzumab compared to 111In-IgG, revealing absolute 
tracer uptake in A431 tumors was limited by blood pool availability of 89Zr-imgatuzumab 
(Fig. 3). Tracer uptake in A549 in tumors was the highest for the 10 μg dose group at 
12.2 ± 2.1 %ID/g for 89Zr-imgatuzumab vs. 7.2 ± 1.5 %ID/g for 111In-IgG (P = 0.13), while 
tumor-to-blood values for 10 and 25 μg were significantly higher for 89Zr-imgatuzumab 

































































































































Figure 1. A), Representative maximal intensity projections of microPET scans 144 h after tracer injection for 10, 
25 and 160 μg doses of 89Zr-imgatuzumab in A431, A549 and H441 xenograft bearing mice. Livers are marked 
with L, while xenografts are marked with an arrow. B), MicroPET quantification for tumor, liver and blood pool 
at 24, 72 and 144 h after tracer injection for 10, 25 and 160 μg tracer dose in A431, A549 and H441 xenograft 
bearing mice. Data is expressed as SUVmean ± SEM.
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with 10 μg 89Zr-imgatuzumab (28.0 ± 1.6 %ID/g) compared to 111In-IgG (9.8 ± 1.6 %ID/g, 
P < 0.01), whereas at 160 μg 89Zr-imgatuzumab tumor uptake (14.2 ± 1.7 %ID/g) was 
similar to 111In-IgG (19.2 ± 5.0 %ID/g, Fig. 2). Both A549 and H441 tumors showed target 
saturation at the 160 μg dose (Fig. 2, 3). Tumor-to-blood ratios for both A549 and H441 
showed a similar pattern to absolute uptake data, denoting uptake of 89Zr-imgatuzumab 
in these tumors was not limited by blood pool availability (Fig. 3). 
High liver uptake of 20.9 ± 1.3 %ID/g was observed in mice bearing A431 tumors at 
10 μg 89Zr-imgatuzumab, this was higher than for A549 (6.5 ± 0.5 %ID/g, P < 0.0001) 
and H441 (8.5 ± 1.0 %ID/g, P < 0.001) bearing mice at equal dose. Liver uptake in A431 
bearing mice could be blocked by increasing the tracer antibody dose, as can be seen 
by the decreasing differences between 89Zr-imgatuzumab and 111In-IgG liver uptake 
(Fig. 2). Specific spleen uptake of 89Zr-imgatuzumab was observed in all tumor models, 
which was saturable at higher doses, as shown by decreasing differences between 
89Zr-imgatuzumab and 111In-IgG spleen uptake at higher tracer doses (Fig. 2). 
A431


















































Figure 2. Ex vivo uptake data for tumor, liver, spleen and blood, presented as % ID/g 89Zr-imgatuzumab and 
111In-IgG non-specific control, for 10, 25 and 160 μg doses in A431, A549 and H441 xenograft bearing mice.
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EGFR expression analysis and immunohistochemistry
EGFR cell surface expressions in vitro by flow cytometric analysis (Fig. 4B) and ex vivo 
by ELISA in tumor lysates (Fig. 4C) were concordant. Expression level of EGFR per gram 
protein based upon ELISA was highest in A431, followed in declining order by A549 and 
H441 xenografts. All xenograft tumors expressed EGFR as determined by IHC (Fig. 4A).
Highest EGFR H-score was found in A431, followed by H441 and the least amount 
of staining was found in A549 xenografts (Fig. 4A & D). A549 tumor cell density was 
markedly lower compared with A431 and H441 tumors (Fig. 4A). Microvascular density 
was found to be similar in all three xenograft models (Fig. 4E).
sEGFR analysis of plasma, liver and cell lysates
ELISA showed high sEGFR levels (831 ± 71 ng/mL) in plasma of A431 tumor bearing, 
which were three magnitudes higher than observed in A549, H441 and non-tumor 
bearing control mice (P < 0.01). A549 and H441 sEGFR plasma levels did not deviate 
from background measurement in plasma of non-tumor bearing control mice (Fig. 5A). 
sEGFR levels were also elevated at 790 ± 109 ng/g protein sEGFR in liver lysates of A431 
xenograft bearing mice (P < 0.01), but not in A549 and H441 when compared to non-
tumor bearing control mice (Fig. 5B). To confirm the shedding potential of A431 in vitro, 
confluent cell cultures serum-free supernates were tested for sEGFR. sEGFR levels in 
A431 supernates (999 ± 21 ng/ml) were approximately 1000-fold higher (P < 0.001) 
compared to A549 and H441 (0.06 ± 0.004, respectively 0.87 ± 0.03 ng/ml) (Fig. 5C). 
sEGFR in supernates from serum-containing media cultures showed a similar pattern 
and equal magnitude, indicating inhibition of proteolytical cleavage by serum did not 
influence the amount of sEGFR shedding in these cell lines (Fig. 5D). Serum-free and 
serum-containing media controls were negative for sEGFR.























Figure 3. Tumor-to-blood ratios of 89Zr-imgatuzumab and 111In-IgG for indicated doses in A431, A549 and H441 
xenograft bearing mice.
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Figure 4. A), Ex vivo tissue 
analysis. Mean vessel density 
(MVD), EGFR and hematoxylin
and eosin immunohisto-
chemical staining of A431, 
A549 and H441 tumors. 
B), In vitro flow cytometric 
analysis of EGFR membrane 
expression in A431, A549 and 
H441 cells. C), Ex vivo human 
EGFR extracellular domain 
levels in A431, A549 and 
H441 tumor tissue lysates. D), 
EGFR histo-score (H-score) for 
A431, A549 and H441 tumors. 
E, Mean vessel density score 





This is the first paper showing tumor uptake of an EGFR-targeted antibody tracer can 
be affected by EGFR shedding. High levels of sEGFR acted as antigen sink, redirecting 
89Zr-imgatuzumab to the liver, which reduced tumor uptake at lower tracer doses in 
A431 xenografts. Contrarily, in A549 and H441 xenografts models, lacking detectable 
EGFR shedding, low liver uptake was observed and tumor uptake could be saturated by
 89Zr-imgatuzumab dose increments.
A431 xenografts showed the highest tumor uptake at the highest tracer dose used. 
Specific liver uptake of 89Zr-imgatuzumab was observed, which decreased with dose 
increments in A431 bearing mice. In previous preclinical EGFR antibody-based imaging 
studies revealing mismatch between xenograft EGFR expression and tracer uptake, a 
large role was postulated for vascularity and vascular permeability for tracer delivery in 
the tumor (13, 18). Our results show that in addition to vascular differences between 
xenografts, circulating sEGFR can act as antigen sink and decrease tumor tracer uptake. 
Complexation of 89Zr-imgatuzumab and sEGFR, followed by liver sequestration as shown 
by ELISA, resulted in high 89Zr-imgatuzumab liver uptake, low blood pool availability and 
consequently relatively low uptake in A431 xenograft tumors at low tracer protein doses.
In contrast, in A549 and H441 xenografts low 89Zr-imgatuzumab liver uptake and 
sEGFR plasma levels were observed. In these models 89Zr-imgatuzumab tumor uptake 
was dose dependent, with highest uptake observed for low tracer protein doses, 
comparable to earlier findings for various antibody-based tracers targeting HER family 
members (8, 10,15). Higher 89Zr-imgatuzumab tumor uptake was found in H441 compared 
to A549 xenografts in our study, despite lower in vitro and ex vivo EGFR expression based 
upon ELISA. No difference in microvascular density was found between all models. 
Therefore, differences in 89Zr-imgatuzumab uptake in A549 and H441 are most likely 



























































Figure 5. A), Human EGFR extracellular domain concentration in plasma of A431, A549 and H441 xenograft 
bearing and non-tumor bearing control mice. B), Human EGFR extracellular domain level in liver tissue lysates 
of A431, A549 and H441 xenograft bearing and non-tumor bearing control mice. C), Human EGFR extracellular 
domain concentration in serum-free supernates of confluent cell cultures of A431, A549 and H441 cells. D, 
Human EGFR extracellular domain concentration in serum-containing supernates of confluent cell cultures of 
A431, A549 and H441 cells, only statistical significances against A431 are shown for clarity.
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lower tumor cell density on H&E in A549. Furthermore, vascular permeability in the H441 
is higher, as shown by the high accumulation of 111In-IgG control at higher doses, which was 
also seen in an earlier study (10). Specific spleen uptake of 89Zr-imgatuzumab was observed 
in all tumor models, which decreased with 89Zr-imgatuzumab dose increments. Spleen 
targeting of 89Zr-imgatuzumab can be explained by its affinity, through glycoengineering, 
for the murine analog of the FcyRIIIA receptor, FcγRIV, on macrophages and monocytes (5) 
and resembles our experience with similarly glycoengineered HER3 mAb 89Zr-RG7116 (10).
Several isoforms of circulating sEGFR have been found in ovarian, metastatic breast 
and non-small cell lung cancer patients and healthy volunteers (28–31). All sEGFR 
isoforms contain subdomain III of the EGFR extracellular domain, to which EGFR mAbs 
imgatuzumab, cetuximab and panitumumab bind (26, 32), but lack the transmembrane 
and cytoplasmic domains of the EGFR receptor (28, 29). While cetuximab is known to 
inhibit sEGFR shedding in vitro (26), it is currently unknown whether imgatuzumab has 
potential to inhibit sEGFR shedding. sEGFR is commonly shed by proteolytic cleavage 
from human carcinoma cells expressing over 7×105 EGFR receptors (33). Of the present 
cell panel, only A431 is known to shed a ~105 kDa sEGFR isoform, due to an aberrant 
transcript, as well as a 110 kDa sEGFR isoform (34–36). Because of its aberrant sEGFR 
shedding potential, the A431 cell line was used to reliable induce human sEGFR shedding 
in a murine system and served as a model for the interaction between the endogenous 
sEGFR isoforms and EGFR monoclonal antibody tracers. Besides proteolytic cleavage, 
alternate splicing events in normal tissues result in mRNA transcripts encoding for 
60-kDa, 80-kDa and 110-kDa sEGFR isoforms, that are the major source of sEGFR in 
patients and healthy volunteers (29).
sEGFR levels in A431 tumor-bearing mice were 837 ± 71 ng/mL plasma, corresponding to 
~2.5 sEGFR for each 89Zr-imgatuzumab molecule in circulation for the 10 μg tracer dose, 
reflecting a high degree of competition of sEGFR with tumor-bound EGFR. Increasing 
the 89Zr-imgatuzumab dose to 160 μg, mitigated sEGFR competition for tumor bound 
EGFR, resulting in higher tumor uptake. A limited number of preclinical imaging studies 
have included shed or circulating antigen measurements. c-MET tracer 89Zr-onartuzumab 
tracer kinetics were not influenced by 14.1 ± 5.2 ng/mL per gram tumor shed c-MET in 
MKN-45 xenografts at high tracer doses of 64 to 128 μg (25). However, similar to our 
results, high CA19.9 mAb 89Zr-5B1 liver uptake and decreasing tumor uptake over time 
was observed for in Colo205-Luc xenografts secreting large amounts CA19.9 (2500 ± 
1033 U/mL), but not in DMS79 and BcPC3 xenograft bearing mice with no detectable 
serum CA19.9 (37). Free prostate specific antigen (PSA) targeting 89Zr-5A10 showed a 
similar principle, liver uptake was 24.6 ± 4.9 %ID/g for 89Zr-5A10 in LNCaP-AR xenograft 
bearing mice in presence of 18.35 ± 2.7 ng/mL free PSA in serum. Liver uptake was 
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2.5-fold lower for both 89Zr-5A10 in PSA-negative PC3 tumor bearing mice and 89Zr-IgG 
control in LNCaP-AR tumor bearing mice (38), confirming the ability of circulating antigen 
to direct antibody tracers to the liver.
In transgenic mice developing mutant and KRAS mutated NSCLC, murine endogenous 
plasma sEGFR and EGFR liver expression decreased after carcinogenesis (39). Lower 
concentrations circulating sEGFR were also found in humans with NSCLC, when compared 
to healthy controls (28). However, reported clinical sEGFR serum concentrations vary 
greatly depending on detection method and between patients and matched control 
groups (30). sEGFR concentrations in cancer patients ranged between 25.5 ± 4.5 
(19.4-40.1) in NSCLC vs. 35.9 ± 5.2 (20.6-44.2) ng/mL in controls based upon a commercial 
ELISA kit (28), to 545 ± 503 (ND-2139) in metastatic breast cancer vs. 546 ± 706 
ng/mL (12-3461) in matched controls based upon an acridinium-linked immunosorbent 
assay (ALISA) assay (31). In healthy volunteers sEGFR serum concentrations ranged 
between 0.0125 and 5 μg/mL based upon ALISA (30), corresponding to a 140,000-fold 
or only 5-fold molar excess of cetuximab at peak and through concentrations compared 
to sEGFR (40). In one patient with ovarium cancer up to 9.1 μg/mL sEGFR was 
measured (21). It is therefore conceivable that EGFR targeting tracer kinetics could 
be influenced in a subset of patients with high sEGFR levels. This might be especially 
true when patient are treatment-naïve, considering many immunoPET agents use 
microdosing. If patients received multiple doses of EGFR antibody prior to tracer 
injection, sEGFR could already have been depleted and the sEGFR effect will most likely 
not be seen. 
Strikingly, high liver uptake and rapid blood clearance was shown for 89Zr-cetuximab PET 
in a recent clinical study (16, 17). 89Zr-cetuximab liver radiation burden in patients was up 
to two-fold higher (16) compared to antibody-based tracers anti-CD20 89Zr-ibritumumab 
tiuxetan (41) and anti-CD44v6 89Zr-cmAb U36 (42). Liver uptake of up to 40 mg was also 
seen for murine cetuximab analog 111In-mAb225 in patients, while dose escalation up to 
300 mg increased blood availability and tumor uptake of 111In-mAb225. (43). Both mouse 
and human liver tissues are known to express EGFR (44), although liver uptake in the 
present study cannot be explained by presence of murine EGFR in liver, as imgatuzumab 
is not cross-reactive (5). Our findings suggest that in addition to hepatic EGFR expression, 
part of the liver accumulation of EGFR antibody tracers in humans might be explained 
by sEGFR-tracer complexation and subsequent liver sequestration. This would suggest 
incorporating sEGFR analyses in preclinical and clinical EGFR imaging studies to assess 
the influence of sEGFR on EGFR tracer kinetics.
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Concluding, 89Zr-imgatuzumab accumulates in and visualizes EGFR-expressing tumors. 
High shed sEGFR levels in blood can reduce 89Zr-imgatuzumab blood pool availability 
and lower tumor uptake, due to redirection of tracer-sEGFR complex to the liver. Higher 
tracer protein dose increased 89Zr-imgatuzumab tumor uptake by saturating sEGFR-
mediated liver uptake. Combined, these findings could improve interpretation of (pre)
clinical EGFR imaging by taking sEGFR levels into account. Furthermore, this phenomenon 
could possibly also apply to imaging of other antigens with soluble isoforms or which are 
heavily shed.
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Supplementary Figure 1. A), Maximal attainable specific activity for zirconium-89 labeling of Df-imgatuzumab 
conjugate. B), Retained affinity of 89Zr-imgatuzumab compared to naked imgatuzumab by competition assay. 
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Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer 
with tyrosine kinase inhibitor lapatinib can induce a compensatory HER3 increase, 
which may attenuate antitumor efficacy. Therefore, we explored in vivo HER3 tumor 
status assessment after lapatinib treatment with zirconium-89 (89Zr)-labeled anti-HER3 
antibody mAb3481 positron emission tomography (PET). 
Lapatinib effects on HER3 cell surface expression and mAb3481 internalization were 
evaluated in human breast cancer cell lines SKBR3 and BT474 using flow cytometry. 
Next, effects of daily 25 and 50 mg/kg lapatinib doses on 89Zr-mAb3481 BT474 xenograft 
PET uptake in mice were assessed (n=8-9). PET-scans were made after daily lapatinib 
treatment for 9 days, starting 3 days prior to 89Zr-mAb3481 administration. Subsequently, 
ex vivo 89Zr-mAb3481 organ distribution analysis was performed and HER3 tumor levels 
were measured with Western blot and immunohistochemistry. 
In vitro, lapatinib increased membranous HER3, and consequently mAb3481 
internalization 1.4-fold and 1.7-fold in SKBR3 and BT474 respectively. 89Zr-mAb3481 BT474 
tumor uptake was remarkably high at SUVmean 5.6±0.6 (51.8±7.7 %ID/g) using a 10 µg 
89Zr-mAb3481 protein dose in vehicle treated mice. However, when compared to vehicle, 
both 25 and 50 mg/kg lapatinib did not affect 89Zr-mAb3481 ex vivo biodistribution and 
PET uptake in BT474 tumors, and ex vivo HER3 tumor expression remained unchanged. 
In conclusion, lapatinib increased in vitro HER3 tumor cell expression, but not when 
these cells were xenografted. 89Zr-mAb3481 PET accurately reflected HER3 tumor status. 
89Zr-mAb3481 PET showed high, HER3-specific tumor uptake and such an approach 
might sensitively assess HER3 tumor heterogeneity and treatment response in patients. 
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Introduction
Human epidermal growth factor receptor 3 (HER3, also ERBB3) is an important 
regulator of cell growth and differentiation (1,2). Upon ligand binding, HER3 interacts 
with other human epidermal growth factor receptor (HER) family members, such 
as epidermal growth factor receptor (EGFR) and HER2, to form heterodimers. In 
contrast, HER2:HER3 dimers are also formed in a ligand-independent manner (3). HER3 
heterodimerization leads to activation of downstream signaling such as the PI3K/Akt 
and RAS-MAPK pathways, thereby prompting biological processes involved in tumor 
growth and maintenance (1). The importance of HER3 in human cancers has long been 
underestimated, due to its impaired tyrosine kinase activity and relatively low tumor 
expression. However, EGFR:HER3 and HER2:HER3 heterodimers are the most potent 
among HER family signaling complexes (4,5). HER3 expression is associated with poor 
prognosis, and found overexpressed in human breast, colorectal, gastric, head and 
neck and ovarian cancer (1,6). In addition, HER3 is strongly implicated as key mediator 
of resistance to various treatments, including HER-targeting agents, chemotherapy, 
estrogen receptor antagonists and RAF/MEK inhibitors (1,7).
Targeting HER family proteins is an important treatment strategy for many solid tumors, 
with treatment options consisting of monoclonal antibodies (mAbs) and tyrosine 
kinase inhibitors (TKIs) (8). Among approved agents for clinical use is EGFR/HER2 TKI 
lapatinib for trastuzumab-refractory HER2-positive metastatic breast cancer patients. 
Unfortunately, intrinsic or acquired lapatinib resistance frequently occurs in these 
patients (8). Preclinical studies showed that lapatinib treatment of HER2-positive breast 
cancer xenograft models can lead to a rapid compensatory increase in HER3 expression, 
signaling activity and plasma membrane relocalization (9,10). Two weeks lapatinib 
treatment increased HER3 expression as measured immunohistochemically (IHC) in 
HER2-overexpressing breast cancers of newly diagnosed patients. This might attenuate 
the antitumor action of lapatinib (9). Additional HER3 blockade might overcome 
resistance to HER-targeting agents. Combining anti-HER3 mAbs with HER2 inhibitors 
enhanced tumor growth inhibition in HER2-positive breast cancer xenografts (11).
Hence, multiple HER3 targeted mAbs are in various phases of clinical development (1).
HER3 expression might be a potential biomarker to monitor and predict treatment 
efficacy of HER-targeting therapies, given its compensatory role in HER signaling and 
overexpression. 
Because HER3 expression is dynamic, an equally dynamic assessment of HER3 tumor 
status might be indicated, rather than invasive static techniques such as provided by 
IHC measurements of biopsies. Non-invasive three-dimensional whole body positron 
emission tomography (PET) imaging of HER3 over time could potentially address this.
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Molecular characteristic such as HER3 can be imaged with PET, using antibodies 
radiolabeled with zirconium-89 (89Zr, t½ = 78.4 h), for optimal lesion accumulation (12). 
Previous pre(clinical) studies have shown HER3 antibody PET imaging can safely provide 
information about anti-HER3 mAb distribution and tumor HER3 expression levels 
(13–16). However, to date no (pre)clinical studies have investigated treatment effects 
of HER2 targeting drugs on the dynamics of HER3 expression using molecular imaging.
The aim of this study was to investigate the feasibility of in vivo whole body HER3 status 
assessment during lapatinib treatment in human breast cancer xenografts using HER3 
mAb 89Zr-mAb3481 PET imaging. 
Materials and methods
Cells lines and materials
Human breast cancer cell lines BT474 and SKBR3 were obtained from the American Type 
Culture Collection. BT474 was cultured in Roswell Park Memorial Institute-1640 medium 
(RPMI-1640, Gibco) supplemented with 10% fetal calf serum (FCS, Bodinco BV) and SKBR3 
in Dulbecco's Modified Eagle Medium (DMEM, Gibco) high glucose + 10% FCS. Cells 
were incubated at 37 °C in a humidified atmosphere with 5% CO2. Both HER2 amplified 
breast cancer cell lines BT474 and SKBR3 are highly sensitive (half maximal inhibitory 
concentration < 0.1 µM) for lapatinib (17). Anti-human mouse HER3 IgG1 mAb mAb3481 
and corresponding isotype control mouse IgG1 mAb002 were purchased from R&D 
Systems. For mAb treatments and flow cytometric measurements, a total concentration 
of 20 µg/mL was used, unless otherwise indicated. Lapatinib-di-p-toluenesulfonate 
(LC Labs) was dissolved in dimethyl sulfoxide , stored at −20 °C and diluted in fresh 
medium for use. Final concentration of dimethyl sulfoxide in experiments never exceeded 
0.1% v/v. For animal experiments, lapatinib-di-p-toluenesulfonate was suspended fresh 
daily in 0.5% hydroxymethyl propyl cellulose 4000 mPa.s (Hospital Pharmacy, UCMG), 
0.1% Tween 80 (Sigma).
Flow cytometry
Analysis of HER3 expression was performed using flow cytometry. Cells were harvested 
in phosphate-buffered saline (PBS: 9.7 mM Na2HPO4, 1.6 mM KH2PO4, 150 mM NaCl, 
pH = 7.2) containing 2% FCS (FACS buffer) and kept on ice prior to use. mAb3481 in FACS 
medium served as HER3 primary antibody, while bound primary antibody was detected 
using a PE-conjugated goat anti-mouse secondary polyclonal antibody (1010-09,
SouthernBiotech) diluted 1:50 in FACS medium. To determine surface expression 
and internalization of mAb3481, tumor cells were incubated on ice with mAb3481. 
Subsequently, HER3 surface expression was measured in mAb3481 incubated cells, 
which were washed with ice-cold FACS buffer and incubated with secondary antibody for 
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1 hour on ice. To determine the non-internalized fraction, mAb3481 incubated cells were 
washed twice with ice-cold FACS buffer, incubated in original culture medium at 37˚C 
for 1, 2, or 4 hours respectively and subsequently incubated with secondary antibody 
for 1 hour on ice. The internalized fraction of mAb3481 was determined by subtracting 
the non-internalized fraction from the measured surface expression. Duplicate samples 
were measured for each condition, and corrected for background fluorescence and 
unspecific binding of secondary antibody. Measurements were performed on a BD 
Accuri C6 (BD Biosciences). Data analysis was performed with FlowJo v10 (Tree Star) and 
surface receptor expression was expressed as mean fluorescent intensity (MFI). 
Western Blots
After appropriate treatments, cells were washed twice with ice-cold PBS and lysed in 
Mammalian Protein Extraction Reagent (M-PER, Thermo Scientific), supplemented with 
phosphatase and protease inhibitors (Thermo Scientific), for 60 minutes, scraped and 
cellular contents transferred to micro centrifuge tubes for storage at -20 °C until analysis. 
For preparation of xenograft whole-cell lysates, tumor pieces were homogenized by 
mechanical disruption in M-PER lysis buffer. Protein concentrations of lysates were 
determined using the Bradford protein assay (18). Protein samples from total cell lysates 
(20 or 50 μg) were subjected to electrophoretic separation on 7.5 or 10% polyacrylamide 
gels and transblotted onto polyvinylidine fluoride membranes (Millipore). Blots were 
blocked at room temperature for 1 hour in Tris-buffered saline (TBS)/Tween 20 (TBS-T) 
(0.05%), containing 5% bovine serum albumin. Blocking was followed by incubation 
with 1:1000 rabbit anti-HER3 (Clone C17, Santa Cruz Biotechnology), 1:10000 mouse 
monoclonal anti-actin (clone C4, MP Biomedicals) or 1:10000 rabbit anti-human anti-
GAPDH (EPR6256, Abcam). Blots were subsequently washed and incubated with 1:1500 
HRP-anti-mouse or HRP-anti-rabbit antibodies (Dako). Detection was performed using 
Lumi-Light Western blotting substrate (Roche Diagnostics Nederland BV). Images 
were captured using a digital imaging system (Bio-Rad). Densitometric analysis on 
immunoreactive spots was performed with ImageJ v1.47, normalized using actin or 
GAPDH and expressed as fold increase versus control. 
89Zr-mA3481 HER3 tracer production
mAb3481 was incubated with a 1:10 molar ratio of antibody to tetrafluorphenol-N-
succinyldesferal (Df, ABX GmbH, Hamburg, Germany) as described earlier (12), yielding 
on average 2.96 Df bound per mAb3481 molecule. Df-mAb3481 conjugates were 
checked for aggregation and fragmentation by a Waters size exclusion high performance 
liquid chromatography) system, equipped with a dual wavelength absorbance detector, 
in-line radioactivity detector and TSK-GEL G3000SWXL column (JSB, Eindhoven, The 
Netherlands). PBS (140 mmol/L NaCl, 9 mmol/L Na2HPO4, 1.3 mmol/L NaH2PO4; pH = 7.4)
was used as mobile phase. 
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89Zr labeling was performed as described earlier (19), using clinical grade 89Zr (Perkin 
Elmer). Maximum attainable specific activity was determined by radiolabeling Df-
mAb3481 conjugate with specific activities between 50 and 1000 MBq 89Zr/mg 
conjugate. Radiochemical purity (RCP) of 89Zr-labeling was assessed by trichloroacetic 
acid precipitation test (20). 
Mouse IgG1 isotype control mAb002 (R&D Systems) was used as unspecific control 
tracer molecule in in vivo experiments. For indium-111 (111In) labeling, mAb002 was 
conjugated with p-SCN-Bn-DTPA (Macrocyclics) as described earlier (21). Radiolabeling 
was performed using 111In-chloride (Mallinckrodt). Radiochemical purity of 111In-mAb002 
labeling was checked by instant thin layer chromatography using 0.1 M citrate buffer 
pH 6.0 as eluent. 
Animal experiments
Nude mice (male BALB/cOlaHsd-Foxn1nu, Envigo), implanted subcutaneously (sc) with 
0.36 mg 17β-estradiol 90-day release pellets (Innovative Research of America), were 
used for all animal experiments. All inoculations were performed sc using 5*106 cells in 
300 µL of a 1:1 mix of PBS and high growth factor Matrigel (Corning), and xenografts were 
allowed to establish to volumes of at least 100-200 mm3 before start of experiments. 
Tumor size and animal weight were measured twice weekly.
BT474 xenografted mice were treated with vehicle or 25 mg/kg lapatinib (both conditions 
n=9) daily via oral gavage until sacrifice. Three days after start of treatment, mice received 
10 μg 89Zr-mAb3481 (3-4 MBq), combined with 10 μg 111In-mAb002 (1 MBq) unspecific 
control via the penile vein. Another cohort of BT474 xenografted mice received vehicle 
or 50 mg/kg lapatinib (both conditions n=8) daily via oral gavage until sacrifice. Three 
days after start of treatment mice received 25 µg 89Zr-mAb3481 (3-4 MBq) and 25 μg 
111In-mAb002 (1 MBq) via penile vein injection. MicroPET scans were made 6 days post 
tracer injection (pi) of both cohorts using a Focus 220 PET scanner (CTI Siemens). 
Scans were reconstructed and in vivo quantification performed using AMIDE v1.0.4 (22). 
MicroPET data are presented as mean standardized uptake value (SUVmean). After PET 
scans, mice were sacrificed and organs of interest collected for ex vivo biodistribution 
analysis. Organs and standards of the injected tracer were counted in a calibrated 
well type LKB-1282-Compu-gamma system (LKB WALLAC) and weighed. After decay 
correction, ex vivo tissue activity was expressed as the percentage of injected dose per 
gram tissue (%ID/g). Xenograft tumors were part formalin-fixed and paraffin-embedded 
for IHC and part frozen for subsequent analysis. All animal experiments were approved 
by the Institutional Animal Care and Use Committee of the University of Groningen.
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Ex vivo analyses
Formalin-fixed, paraffin-embedded tissue slices (3-4 µm) were deparaffinized and 
rehydrated. Heat-induced antigen retrieval was performed in 10 mM TRIS/EDTA (pH 
9.0) at 100°C for 15 minutes and endogenous peroxidase was blocked by 30-minute 
incubation with 0.3% H2O2 in PBS. Slides were stained for HER3 with a 1:50 dilution of 
rabbit polyclonal antibody (Clone SC-285, Santa Cruz Biotechnology). Incubation with 
secondary antibody (EnVision System, Dako HRP; Dako) was performed for 30 minutes, 
followed by application of diaminobenzidine chromogen for 10 minutes. Hematoxylin 
counterstaining was applied routinely, and hematoxylin & eosin (H&E) staining served 
to analyze tissue viability and morphology. Digital scans of slides were acquired by a 
NanoZoomer 2.0-HT multi slide scanner (Hamamatsu) and analyzed with NanoZoomer 
Digital Pathology viewer software.
Statistical analyses
Data were assessed using GraphPad Prism (GraphPad v5.0) for differences using the two-
sided Mann-Whitney test for non-parametric data and the two-sided unpaired Student’s 
T-test for parametric data. P-values < 0.05 were considered significant, with * indicating 
P<0.05 and ** denoting P<0.01.
Results
In vitro effects of lapatinib on HER3 levels and mAb3481 internalization in SKBR3 and 
BT474
Three day exposure to 250 nM lapatinib resulted in a 1.8 ± 0.1 and 1.8 ± 0.2 fold increase 
in membranous HER3 of BT474 (Fig. 1A) and SKBR3 (Fig. 1B) cells, respectively. Long 
term lapatinib treatment showed continued HER3 upregulation up to at least 6 days of 
treatment. Exposure of cells to 250 nM lapatinib for 72 hours resulted in a 74 ± 4% and 
43 ± 33% increase of absolute internalized mAb3481 in BT474 and SKBR3 cells 
respectively, when compared to controls (Fig. 1C).
In vivo effects of 25 mg/kg lapatinib on BT474 HER3 expression and 89Zr-mAb3481 
uptake 
Both 25 and 50 mg/kg lapatinib inhibited tumor growth in BT474 xenografted pilot mice 
(data not shown), therefore these doses were selected for evaluation of their effects on 
HER3 expression in vivo by 89Zr-mAb3481 PET. Lapatinib effects on HER3 expression and 
89Zr-mAb3481 tumor uptake were first evaluated using 25 mg/kg lapatinib and a 10 µg 
89Zr-mAb3481 tracer protein dose in BT474 xenografted mice. Tumor uptake 144 h pi for 
both treatments and vehicle were similar on 89Zr-mAb3481 PET scans, with a SUVmean 
of 5.6 ± 0.6 and 5.3 ± 1.3 for vehicle and 25 mg/kg lapatinib treated mice respectively 
(P = 0.73, Fig 2A, 2B). Ex vivo results were equal to in vivo findings, a similar high
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(P = 0.54, Fig 2C) and HER3-specific BT474 tumor uptake was found for both vehicle 
(51.8 ± 7.7 %ID/g) and 25 mg/kg lapatinib treated mice (53.3 ± 12.4 %ID/g), compared 
to 10.8 ± 3.1 and 10.8 ± 4.0 %ID/g for 111In-mAb002 controls respectively. Injected tracer 
protein doses for vehicle and lapatinib treated mice were comparable (Suppl. Fig. 1C). 
89Zr-mAb3481 in the blood pool, was low in both vehicle and 25 mg/kg lapatinib treated 
mice at 1.8 ± 2.2 and 2.2 ± 2.3 %ID/g respectively, compared to 13.1 ± 5.3 and 12.5 ± 4.0 
%ID/g for 111In-mAb002 control (Fig. 2D, Suppl. Fig. 2A, Suppl. Fig. 2B). No differential 
effect was observed for tumor growth in lapatinib versus vehicle treated mice (Fig 2E, 
Suppl. Fig. 1A). HER3 expression by BT474 tumors remained unchanged after lapatinib 
therapy, as measured by IHC and Western blot (Fig 2F, 2G). 
In vivo effects of 50 mg/kg lapatinib on BT474 HER3 expression and 89Zr-mAb3481 
uptake
Due to no observable tumor inhibition, low remaining 89Zr-mAb3481 blood pool levels 
at sacrifice, and a lack of lapatinib effects on HER3 expression and tumor tracer uptake 
in the 25 mg/kg lapatinib cohort, a second HER3 modulation was undertaken. This 
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Figure 1. Effects of long term (up to 6 days) lapatinib (lap) treatment on HER3 cell surface expression levels 
by A) for 50, 100 and 250 nM lapatinib in BT474, and B) for 100, 250 and 500 nM lapatinib in SKBR3 cells. C) 
2-hour HER3 mAb3481 internalization rate in BT474 and SKBR3 cells, after 72 h 250 nM lapatinib treatment, 
normalized to control.
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robust tumor inhibition and a tracer protein dose of 25 µg was used in an attempt to 
increase the residual 89Zr-mAb3481 blood pool. Increase in tracer protein dose to 25 µg
89Zr-mAb3481 led to a lower in vivo and ex vivo tumor uptake than observed for the 
10 µg tracer dose. Again, no difference for vehicle and 50 mg/kg lapatinib cohorts was 
observed, with SUVmeans of 4.0 ± 0.6 and 3.9 ± 0.8 respectively for BT474 tumors 144 h 
pi (P=0.79, Fig. 3A, 3B). Despite the tracer protein dose increase, ex vivo biodistribution 
showed a high HER3-specific BT474 tumor uptake of 46.9 ± 4.7% ID/g and 46.2 ± 7.7 
%ID/g for vehicle and lapatinib respectively, confirming PET data (Fig 3C). Blood levels 
for the 25 µg tracer protein dose were higher than observed for the 10 µg tracer dose at 
7.3 ± 2.3 %ID/g and 6.9 ± 1.5 %ID/g for 89Zr-mAb3481 with 17.0 ± 2.1 %ID/g and 
14.3 ± 3.2 %ID/g 111In-mAb002 observed for vehicle and lapatinib treated mice respectively 
(Fig 3D,suppl. Fig 2C,2D). Injected tracer protein doses for vehicle and lapatinib treated 
mice were comparable (Suppl. Fig. 1D). Tumor growth was affected, starting from day 7
after commencing 50 mg/kg lapatinib treatment, when compared to vehicle (Fig 3E, 
Suppl. Fig 1B). Ex vivo, HER3 expression in BT474 tumors remained unchanged after 50 
mg/kg lapatinib for 9 days, as measured by IHC and Western blot (Fig 3F, 3G). 
Discussion 
This study presents 89Zr-mAb3481, a HER3 antibody PET tracer, with remarkably high 
contrast and specific tumor uptake in human breast cancer xenografts. Lapatinib 
increased HER3 expression in vitro, but not in human breast cancer xenografts, while 
89Zr-mAb3481 accurately reflected in vivo HER3 tumor status post lapatinib treatment. 
In the preclinical setting, HER3 imaging has been extensively studied using affibodies 
and antibodies labeled with various radioisotopes for PET and single positron emission 




68Ga-HEHEHE-Z08698-NOTA showed tumor uptakes of 5.0 ± 0.6, 5 ± 1, 1.7 ± 0.6 and 
2.6 ± 0.4 %ID/g respectively in BT474 xenografts. Tumor-to-blood ratios of affibody 
tracers ranged between 7-25, while tumor uptake could be saturated by 70 µg cold 
affibody (23–25). Bispecific HER2/HER3 tracer 111In-DTPA-Fab-PEG24-HRG on the 
other hand, showed 7.0 ± 1.2, 4.4 ± 0.9 and 7.8 ± 2.1 %ID/g tumor uptake in SK-OV-3, 
MDA-MB-468 and BT474 xenografts (26). Among antibody-based tracers, glycoengineered 
human HER3 antibody 89Zr-lumretuzumab showed the highest uptake (27.5 %ID/g) in 
human head and neck cancer FaDu xenografts at the lowest (0.05 mg/kg) tracer protein 
dose tested (13). 64Cu-DTPA-patritumab showed uptake in BxPC3 human pancreatic 
cancer xenografts, which could be blocked by 800 µg cold patritumab (27). Anti-human 
HER3 rat IgG2a mAb 89Zr-Mab#58 showed 12.2 ± 4.5 %ID/g, respectively 17.8 %ID/g 
tumor uptake in stably human HER3 overexpressing rat hepatoma HER3/RH7777 and 
colorectal cancer tissue-originated spheroid C45 xenografts (14). 
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Compared to these preclinical HER3 tracers, 89Zr-mAb3481 had both the highest absolute 
tumor uptake observed and a tumor-to-blood contrast comparable or even superior to 
HER3 affibody-based tracers. High 89Zr-mAb3481 HER3-specific tumor uptake, when 
compared to other antibody-based tracers might be explained by its murine IgG1 
origin. Athymic nude mice, as used in the present study, have functional B-cells and 
thus antibody production, with circulating IgG1 levels reported at 1.25 ± 0.15 mg/mL 


























































































































Figure 2. Results for vehicle and 25 mg/kg lapatinib (lap) treated BT474 xenograft bearing mice. A) Representative 
coronal 89Zr-mAb3481 HER3 PET scans, 6 days post tracer injection. B) In vivo 89Zr-mAb3481 tumor and blood 
pool uptake, 6 days post tracer injection, expressed as SUVmean. C) Ex vivo 
89Zr-mAb3481 and 111In-mAb002 
tumor uptake data, presented as %ID/g. D) Ex vivo 89Zr-mAb3481 and 111In-mAb002 BT474 blood pool data, 
presented as %ID/g. E) Tumor volumes during treatment. F) Ex vivo tissue analysis. HER3 immunohistochemical 
staining for tumor tissues. G) HER3 Western blots of xenograft tumor lysates. Immunoreactive spots were 
quantified by densitometric analysis and normalized using anti-human GAPDH, normalized to vehicle..
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serum (28). Therefore, unspecific sink organs might already be saturated by circulating 
murine IgG1 from the host animal, resulting in higher 89Zr-mAb3481 tracer availability for 
tumor uptake, in contrast to non-murine IgG antibody tracers. 
A full 89Zr-mAb3481 protein dose escalation experiment was not performed in the 
present study. However, 10 µg 89Zr-mAb3481 in the 25 mg/kg lapatinib experiment 
























































































































Figure 3. Results for vehicle and 50 mg/kg lapatinib (lap) treated BT474 xenograft bearing mice. A) 
Representative coronal 89Zr-mAb3481 HER3 PET scans, 6 days post tracer injection. B) In vivo 89Zr-mAb3481 
tumor and blood pool uptake, 6 days post tracer injection, expressed as SUVmean. C) Ex vivo 
89Zr-mAb3481 and 
111In-mAb002 tumor uptake data, presented as %ID/g. D) Ex vivo 89Zr-mAb3481 and 111In-mAb002 blood pool 
data, presented as % ID/g. E) Tumor volumes during treatment, with * P<0.05 and ** P<0.01. F) Ex vivo tissue 
analysis. HER3 immunohistochemical staining of tumor tissues. G) HER3 Western blots of xenograft tumor 
lysates. Immunoreactive spots were quantified by densitometric analysis and normalized using anti-human 
GAPDH, normalized to vehicle.
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already showed excellent BT474 tumor uptake. Tracer blood levels in this experiment 
were depleted to 2.2 ± 2.3 %ID/g in lapatinib treated mice, after unexpectedly fast tumor 
growth, paired with the high specific BT474 tumor uptake. Tumor growth inhibition, 
increase in 89Zr-mAb3481 tumor uptake and ex vivo HER3 upregulation were not observed 
in the 25 mg/kg lapatinib 89Zr-mAb3481 PET experiment. Therefore, lapatinib dose was 
increased to 50 mg/kg for a second cohort to induce a more robust tumor inhibition 
and possibly HER3 induction. Because low 89Zr-mAb3481 blood levels could hamper 
visualization of the potential extra HER3 expression, tracer protein dose was increased 
to 25 µg. Indeed, increased tracer protein dose raised 89Zr-mAb3481 blood levels to
6.9 ± 1.5 %ID/g for lapatinib treated mice at sacrifice, and only marginally lowered BT474 
tumor tracer uptake. However, 89Zr-mAb3481 tumor uptake and HER3 tumor expression 
remained unaltered after 50 mg/kg lapatinib treatment. Observed differences in tumor 
uptake between 25 and 50 mg/kg lapatinib validation cohorts were approximately 10% 
based upon biodistribution data, while in vivo uptake data showed a differential of ~30% 
in SUVmean. This discrepancy between ex vivo biodistribution and in vivo PET uptake data 
might be attributed to the partial volume effect (29), as tumors of the 25 mg/kg lapatinib 
group were 2.2-fold larger at an average of 492 ± 218 mm3, compared to only 226 ± 49 
mm3 for the 50 mg/kg cohort.
Imaging of HER3 response to treatment has been performed before. Dual EGFR/HER3 
antibody 89Zr-MEHD7945A, revealed an increase in triple-negative breast cancer patient-
derived xenograft tumor uptake from 5.74 ± 2.40 % ID/g to 9.76 ± 1.51 % ID/g after 
pan-AKT inhibitor GDC-0068 treatment (30). Effects of GDC-0068 effects on HER3 alone, 
were imaged with 64Cu-anti-HER3-F(ab'), which showed MDA-MB-468 tumor uptake 
increased from SUVmean of 0.35±0.02 for vehicle to 0.73±0.05 (P<0.01), three days 
after treatment initiation (31). In vitro, 48 hours 5 µM GDC-0068 treatment resulted in 
74%, 102%, and 65% increased HER3 surface expression in MDA-MB-468, HCC-70 and 
MCF-7 human breast cancer cells respectively (31). Lapatinib treatment in vitro in the 
present study led to a similar 70% increase in HER3 membrane expression, albeit at a 
lower concentration of 250 nM, while 5 µM lapatinib potently inhibited BT474 cells in 
culture. In vivo, BT474 tumors remained sensitive to lapatinib treatment, as shown by 
continued tumor growth suppression in 50 mg/kg lapatinib treated animals. Therefore, 
it is conceivable that any lapatinib-induced increase in HER3 expression in BT474 tumors 
might have been offset by tumor cell inhibition. In contrast to cell cultures, drug plasma 
concentration cannot be not tightly controlled in mice, with preclinical data showing 
highly variable plasma concentrations for single 30 and 60 mg/kg oral lapatinib doses in 
mice, ranging from approximately 1-5 µM at 1 h, to approximately 50-500 nM at 16 h after 
administration (32). Therefore, the therapeutic window of lapatinib might have been 
too narrow to upregulate HER3 expression in vivo, without major effects on tumor 
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proliferation. 89Zr-mAb3481 PET did, however, accurately reflect the actual HER3 tumor 
status after lapatinib treatment, as both HER3 expression and 89Zr-mAb3481 tumor 
uptake remained unchanged. 
Similar to present results, gastric cancer patients showed unaltered HER3 mRNA 
levels after lapatinib plus capecitabine therapy, however, elevated HER3 mRNA levels 
at baseline did correlate with an increased response rate to the combination (33). In 
ovarian cancer, low HER3 mRNA levels represented a more sensitive phenotype for HER2 
dimerization blocking mAb pertuzumab and gemcitabine treatment (34). Identification 
of tumor HER3 levels and heterogeneity might therefore pose an attractive option for 
patient stratification. The highly specific tumor uptake in the present study, indicates 
that changes and variation in HER3 expression might be sensitively assessed using a 
humanized version of 89Zr-mAb3481 for HER3 PET. 
This measurement of HER3 tumor expression is likely also feasible in the clinic, as several 
clinical HER3 PET imaging studies already showed feasibility for HER3 heterogeneity 
assessment. Human HER3 antibody 64Cu-patritumab revealed tumor uptake in cancer 
patients, but also showed high liver uptake, which decreased after pre-administration of 
9 mg/kg cold unlabeled patritumab (15). Clinical application of glycoengineered human 
HER3 antibody 89Zr-lumretuzumab (NCT01482377) showed tumor specific uptake, which 
was partly saturated by therapeutically relevant doses of 400, 800 and 1600 mg unlabeled 
lumretuzumab (16). Furthermore, HER3 antibody 89Zr-GSK2849330 (NCT02345174) is 
currently evaluated in patients with advanced HER3 expressing solid tumors.
Concluding, 89Zr-mAb3481 HER3 PET imaging revealed a remarkably high specific tumor 
uptake, with superior contrast compared to other preclinical HER3 imaging agents. 
Lapatinib treatment induced HER3 upregulation in human breast cancer cell lines in 
vitro, but not in corresponding xenograft tissues. In vivo HER3 status was accurately 
reflected by 89Zr-mAb3481 PET. Sensitive 89Zr-HER3 antibody PET imaging of HER3 in 
response to various treatments or HER3 expression screening might pose an attractive 
option for the clinic. 
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Supplemental Figure 1. Ex vivo tumor weights of A) vehicle or 25 mg/kg lapatinib (lap), and B) 
vehicle or 50 mg/kg lapatinib treated BT474 xenografted mice. Effective injected 89Zr-mAb2381 
tracer protein dose of C) vehicle and 25 mg/kg lapatinib, and D) vehicle and 50 mg/kg lapatinib 

























































































































































































































































































Supplemental Figure 2. Ex vivo organ uptake of A) 89Zr-mAb2381 and B) 111In-mAb002 in vehicle and 25 mg/kg 
lapatinib (lap) treated BT474 xenografted mice. Ex vivo organ uptake of C) 89Zr-mAb2381, and D) 111In-mAb002 
of vehicle and 50 mg/kg lapatinib treated BT474 xenografted mice. Data are expressed as % ID/g ± SD.
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c-MET and ligand hepatocyte growth factor (HGF) are often dysregulated in human 
cancers. Dynamic changes in c-MET expression occur and might predict drug efficacy 
or emergence of resistance. Non-invasive visualisation of c-MET dynamics could 
therefore potentially guide c-MET-directed therapies. We investigated the feasibility of 
zirconium-89 (89Zr)-labelled one-armed c-MET antibody onartuzumab positron emission 
tomography (PET) to detect relevant c-MET level changes, induced by c-MET-mediated 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib resistance 
or heat shock protein-90 (HSP90) inhibitor NVP-AUY-922 treatment in human non-small 
cell lung cancer (NSCLC) xenografts. 
In vitro membranous c-MET levels were determined by flow cytometry. HCC827ErlRes, 
an erlotinib resistant clone with c-MET upregulation, was generated from the exon-19
EGFR-mutant human NSCLC cell line HCC827. 89Zr-onartuzumab PET scans were made 
of mice bearing HCC827 and HCC827ErlRes tumours in opposite flanks. HCC827 
xenografted mice underwent 89Zr-onartuzumab PET scans, before, and while on 
biweekly intraperitoneal 100 mg/kg NVP-AUY-922 or vehicle. Ex vivo, tumour c-MET 
immunohistochemistry was correlated with imaging results. 
In vitro, membranous c-MET was 213 ± 44% upregulated in HCC827ErlRes versus 
HCC827, while c-MET was 69 ± 9% downregulated by NVP-AUY-922 in HCC827 cells. 
In vivo 89Zr-onartuzumab tumour uptake was 26% higher (P<0.05) in erlotinib-resistant 
HCC827ErlRes than in HCC827 xenografts, while HCC827 tumour uptake was 33% lower 
(P<0.001) post NVP-AUY-922 treatment.
The results illustrate that 89Zr-onartuzumab PET effectively discriminates relevant c-MET 
level changes and can potentially be clinically applied to monitor c-MET status.
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Introduction
c-MET is a receptor tyrosine kinase (RTK) with roles in embryogenesis, tissue repair and 
regeneration in homeostasis. Dysregulation of c-MET is often found in solid cancers as a 
consequence of mutation, protein overexpression, gene amplification and auto/paracrine 
upregulation of its ligand hepatocyte growth factor (HGF). Aberrant activation of c-MET/
HGF signalling leads to increased tumour proliferation, invasiveness and angiogenesis, 
resulting in poor prognosis in various human cancers, including non-small cell lung 
cancer (NSCLC) and gastric cancer (1). NSCLC patients harbouring epidermal growth 
factor receptor (EGFR) activating mutations can be treated with the EGFR TKIs erlotinib 
and gefitinib. Resistance to EGFR TKIs in NSCLC invariably occurs in these patients, due to 
secondary mutations or activation of bypass signalling pathways, such as c-MET/HGF (2,3). 
Both c-MET and HGF have been implicated in resistance against EGFR-targeted therapies,
due to crosstalk via shared downstream signalling intermediaries (2,4). Concurrent
transient exposure to HGF can result in lasting resistance to EGFR targeting TKIs, by 
providing positive selection pressure for c-MET upregulated resistant sub clones (5,6). 
As such, c-MET mediated resistance in EGFR TKI resistant NSCLC patients was detected 
in around 5-15% of patients with quantitative polymerase chain reaction or fluorescence 
in situ hybridisation (2,7).
Several c-MET-directed treatment strategies have been reported. NVP-AUY-922, a non-
geldanamycin heat shock protein 90 (HSP90) inhibitor, can potently downregulate EGFR 
and c-MET, and can overcome c-MET mediated resistance in an EGFR TKI resistant clone 
of NSCLC cell line HCC827 (8). NVP-AUY-922 is currently in clinical trials in advanced 
EGFR mutant NSCLC refractory to EGFR TKIs (NCT01646125, NCT01124864), or with an 
EGFR exon 20 mutation (NCT01854034). Combination of NVP-AUY-922 with erlotinib in a 
phase I/II study of progressive erlotinib-treated NSCLC patients resulted in a 16% partial 
tumour response rate (9). 
Another form of c-MET directed therapy involves antibodies. Onartuzumab, is a 99 kDa 
one-armed antibody, reactive to human but not murine c-MET. Onartuzumab inhibits 
HGF binding, blocks c-MET receptor phosphorylation and downstream signalling and 
showed anti-tumour efficacy in preclinical models (10). Analysis of a randomised phase II
trial in advanced NSCLC revealed improved progression-free and overall survival in 
c-MET immunohistochemistry (IHC) positive patients when onartuzumab was added 
to erlotinib (11). However, the METLUNG randomised phase III clinical trial, combining 
erlotinib with onartuzumab or placebo in c-MET IHC positive advanced NSCLC patients, 
was terminated early because of futility (12). MET amplification and overexpression, 
on the other hand, are associated with increased response to c-MET inhibitors (13). 
Recently, splice alterations in exon 14 of the MET gene (METex14), found in ~3% of 
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human lung cancers, were associated with in vitro and clinical sensitivity for c-MET 
tyrosine kinase inhibitor (TKI) capmatinib and the ALK/ROS1/MET TKI crizotinib (14). 
METex14 leads to impaired c-MET downregulation and degradation, resulting in c-MET 
protein overexpression (15).
Selection of patients with c-MET amplification or overexpression could therefore 
potentially be beneficial for therapy decisions, due to their amenability for c-MET-
directed agents. IHC is generally performed on archival tissues and therefore reflects 
c-MET status of the retrieved tissues at that particular point in time. c-MET status, 
however, can vary over time and between lesions, indicating a need for biomarkers 
capable of capturing this plasticity for the body as a whole (13,16). Non-invasive PET 
could potentially provide for non-invasive whole-body c-MET status assessment 
capability to capture c-MET dynamics after emergence of a c-MET-mediated EGFR TKI 
resistance, or as response to HSP90 inhibition. 
For ease of clinical translation, we selected the therapeutic antibody-based PET tracer 89Zr-
onartuzumab, which was reported earlier to effectively discriminate c-MET expression in 
human gastric cancer xenografts (17). Several other antibodies and antibody fragments 
tracers have been reported for preclinical c-MET PET imaging (18). These studies used 
either an immunogenic full-length murine antibody DN30 (19) or antibody fragments 
and other protein scaffolds such as 89Zr-labeled H2 cys-diabody, H2 minibody (20) 
and anticalin 89Zr-PRS110 (21). In contrast to 89Zr-onartuzumab, these tracers are not 
readily translatable to the clinic, as none of these tracer protein backbones have been 
administered to patients before, and would therefore require extensive safety testing. 
Furthermore, tracers based upon the HGF ligand such as 64Cu-HGF, as well as bivalent 
antibody DN30 (19,22) might unwantedly stimulate tumour growth by activating c-MET. 
We therefore aimed to validate the ability of 89Zr-onartuzumab PET to assess c-MET 
upregulation-mediated erlotinib resistance, as well as c-MET downregulation after 
HSP90 inhibitor NVP-AUY-922 treatment in human NSCLC xenografts.
Material & Methods
Cell Lines & Chemicals 
Human NSCLC cell line HCC827 was obtained from the American Type Culture Collection. 
Cells were authenticated using STR profiling in April 2015 by BaseClear and quarantined 
until screening for microbial and mycoplasma contamination were proven negative. 
Cells were subcultured twice weekly, using Roswell Park Memorial Institute-1640 (RPMI-
1640) supplemented with 10% foetal calf serum (FCS, Bodinco BV) and incubated in a 
fully humidified atmosphere at 37 °C and 5% pCO2. HCC827ErlRes, a stable erlotinib-
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resistant sub clone, was generated by culturing parental cell line HCC827 in presence of 
1 μM erlotinib and 50 ng/mL recombinant human HGF (PeproTech) for 2 weeks, followed 
by 2 weeks in 1 μM erlotinib, analogous to Turke et al. (6). NVP-AUY-922 (Luminespib, 
LC-Labs) and erlotinib (LC-labs) were dissolved in dimethyl sulfoxide (DMSO), and 
aliquots stored at -80 °C. 
In vitro cell analyses
Surface expression of EGFR and c-MET was assessed using a BD Accuri™ C6 flow 
cytometer (BD Biosciences). Cetuximab (5 mg/mL, Merck) and onartuzumab (60 mg/mL, 
Genentech) served as primary antibodies for EGFR and c-MET respectively, mouse anti-
human Fc-specific FITC conjugated secondary antibody (clone HP-6017, Sigma-Aldrich) 
was used for read-out of both EGFR and c-MET expression with 10,000 events assessed 
per sample. Sensitivity of HCC827 and HCC827ErlRes cell lines to erlotinib and NVP-
AUY-922 after 4 days treatment was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay (23). 
89Zr-Onartuzumab tracer development and quality control
Onartuzumab was conjugated with five molar ratios (1:1, 1:2, 1:3, 1:5 and 1:10) antibody 
to tetrafluorphenol-N-succinyldesferal-Fe3+ (Df, ABX GmbH), in triplicates per ratio, as 
described earlier (24). Df-onartuzumab conjugates were checked for aggregation and 
fragmentation by a Waters size exclusion high performance liquid chromatography (SE-
HPLC) system, equipped with a dual wavelength absorbance detector, in-line radioactivity 
detector and TSK-GEL G3000SWXL column (JSB). Phosphate buffered saline (PBS; 140 
mmol/L NaCl, 9 mmol/L Na2HPO4, 1.3 mmol/L NaH2PO4; pH = 7.4) was used as mobile 
phase. The ratio of conjugated tetrafluorphenol-N-succinyldesferal-Fe3+ to antibody was 
determined by antibody-bound versus unbound 430 nm signal of Fe3+ on SE-HPLC. 
89Zr labelling was performed as described earlier (25), using clinical grade 89Zr-oxalate 
(Perkin Elmer). Maximum attainable specific activity was determined by radiolabelling 
Df-onartuzumab conjugates with specific activities between 50 and 1000 MBq 89Zr/mg 
conjugate. Radiochemical purity (RCP) of 89Zr-labelling was assessed by trichloroacetic 
acid precipitation test (26). Stability of 89Zr-onartuzumab was tested for seven days in 
0.9% NaCl at 4 °C, human serum at 37 °C and 0.5 M HEPES pH 7.2 buffer at 37 °C. 
Immunoreactivity of Df-onartuzumab conjugates was assessed by competition assay, as 
described earlier. In short, NUNC BreakApart 96-well plates were coated overnight at 4 °C 
with 100 μL 100 ng/mL c-MET extracellular domain (Genentech) in 0.1 M Na2CO3 buffer 
pH 9.6. 89Zr-onartuzumab was diluted to 5000 ng/mL in assay diluent which consisted 
out of PBS, 0.5% bovine serum albumin fraction V (Bio-Connect) and 0.05% Tween 20 
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(Sigma-Aldrich). Plates were washed with washing buffer (PBS with 0.05% Tween 20) 
and blocked by 200 μL assay diluent for 1 h at room temperature and washed again. 
Eight dilutions between 0.004 to 156.25-fold molar excess unmodified onartuzumab 
was pre-mixed 1:1 with diluted 89Zr-onartuzumab solution and 100 μL of the mixtures 
were incubated in wells for 1 hour at room temperature. After washing, wells were 
broken apart and counted using a calibrated well-type LKB-1282-Compu-gamma system 
(LKB WALLAC). Counts were plotted against concentration competing unmodified 
onartuzumab and the half maximal inhibitory concentration (IC50) was calculated using 
Graphpad 5.0 (Graphpad Software, Inc.). The IC50-value was divided by the final tracer 
concentration (2,500 ng/mL) to yield the immunoreactive fraction. 
111In-OA-NBC and 89Zr-OA-NBC control tracer 
To determine non-specific tracer distribution in organs, as well non-specific tumour 
uptake, a one-armed isotype control antibody OA-NBC (Genentech) was co-injected and 
used as control tracer in all experiments. For indium-111 (111In) labelling, OA-NBC was 
conjugated with p-SCN-Bn-DTPA (Macrocyclics) as described earlier (27). Radiolabelling 
was performed with 111In-chloride (Mallinckrodt). Radiochemical purity of 111In-OA-NBC 
labelling was checked by silica gel instant thin layer chromatography (ITLC) using 0.1 M 
citrate buffer pH 6.0 as eluent. Furthermore, OA-NBC was incubated with a 1:5 molar 
excess of OA-NBC to Df, similar as described for Df-onartuzumab, to yield Df-OA-NBC 
conjugate for 89Zr-OA-NBC experiments.
Animal experiments
Male nude mice (BALB/cOlaHsd-Foxn1nu, Envigo) were inoculated subcutaneously (sc) 
with xenograft tumours. Mice bearing only HCC827 xenograft tumours, received 5*106 
HCC827 cells sc in the right flank.
To determine optimal tracer protein dose and imaging time point, three groups (n = 4-6) 
inoculated with HCC827 xenografts received 10, 25 or 100 μg (effective injected protein 
doses: 9.7 ± 0.2, 24.0 ± 0.3 and 96.7 ± 0.9 μg at 4.24 ± 0.20, 4.57 ± 0.15 labelled with 4.76 
± 0.13 MBq respectively) 89Zr-onartuzumab, co-injected with an equal amount of 111In-
OA-NBC (1 MBq) isotype control via penile vein injection. Tumour sizes were 183 ± 63, 
234 ± 46 and 180 ± 92 mm3 for the 10, 25 and 100 µg dose groups respectively. All 
tracer injections contained 10 μg radiolabelled 89Zr-onartuzumab (specific activity: 
~400-500 MBq/mg) and 10 μg 111In-OA-NBC (specific activity: ~100 MBq/mg) with 
cold onartuzumab and OA-NBC added to reach the total stated protein doses. Another 
group (n = 3) received 10 μg 89Zr-OA-NBC (effective protein dose injected 9.7 ± 0.3 µg at 
4.47 ± 0.13 MBq), co-injected with 10 μg 111In-OA-NBC (1 MBq) to validate the use of 
111In-OA-NBC as proxy for an 89Zr-labelled control molecule. MicroPET scans were made 
1, 3 and 6 days post injection (pi), followed by ex vivo biodistribution after the final scan. 
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Upregulation of c-MET after erlotinib resistance of the HCC827 cell line was evaluated 
by inoculating mice (n=10) with 5*106 HCC827 cells on the right flank and 5*106 
HCC827ErlRes cells in the opposite flank. Tumour sizes were 457 ± 182 and 240 ± 74 mm3 
for HCC827 and HCC827ErlRes tumours (P<0.01) respectively at biodistribution (day 6). 
Mice received 10 μg 89Zr-onartuzumab (effective protein dose injected 9.7 ± 0.2 µg at 
4.42 ± 0.09 MBq), co-injected with 10 μg 111In-OA-NBC (1 MBq) via penile vein injection. 
MicroPET scans were made 6 days pi, followed by ex vivo biodistribution.
In vivo evaluation of HSP90 inhibition effects on c-MET expression was performed 
using HCC827 xenograft bearing mice. Mice bearing tumours sized 159 ± 65 mm3 
and 208 ± 112 mm3 received 10 μg 89Zr-onartuzumab (effective protein dose injected 
9.7 ± 0.1 and 9.8 ± 0.1 µg at 4.68 ± 0.15 and 4.44± 0.22 MBq respectively for NVP-AUY-922 
and vehicle), co-injected with 10 μg 111In-OA-NBC (1 MBq) via penile vein injection on
day 0. Scans were made on day 6, after which mice were treated via intraperitoneal 
injection with either 100 mg/kg NVP-AUY-922 in 5% glucose (n=7) or 5% glucose vehicle 
(n=6) on day 6, 10, 13, 16 and 19. Mice received a second identical tracer injection on 
day 13 (effective protein dose injected 9.7 ± 0.1 and 9.6 ± 0.2 µg at 4.45 ± 0.36 and 
4.41 ± 0.37 MBq respectively for NVP-AUY-922 and vehicle), followed by microPET 
scans on day 19 and ex vivo biodistribution. Tumours measured 205 ± 127 mm3 for NVP-
AUY-992 versus vehicle treated mice at 313 ± 198 mm3 at sacrifice.
All microPET scans were performed using a Focus 220 rodent scanner (CTI Siemens). 
MicroPET scans were reconstructed and in vivo quantification was performed using 
AMIDE v1.0.4 (28). Region of interests (ROI) were drawn for tumour based upon ex vivo 
weight assuming 1 g/cm3 tissue density, or measured tumour volume for longitudinal 
experiments. Scan data are presented as mean standardised uptake value (SUVmean), 
which was calculated from the mean activity in the region of interest, divided by the 
injected dose (corrected for decay) per gram body weight, as described earlier (29). 
For biodistribution studies, organs and standards of the injected tracer were counted 
using a calibrated well-type LKB-1282-Compu-gamma system (LKB WALLAC) and 
weighed. 111In and 89Zr were counted in a single measurement at 311-500 and 758-
1144 KeV respectively, with crosstalk in the 111In channel corrected for using a reference 
89Zr dilution series. After decay correction, ex vivo tissue activity was expressed as the 
percentage of injected dose per gram tissue (%ID/g). Xenograft tumours were formalin-
fixed and paraffin embedded for subsequent immunohistochemistry (IHC) analysis. All 
animal experiments were approved by the Institutional Animal Care and Use Committee 




Formalin fixed, paraffin-embedded 4 µm tissue slices were stained for c-MET using 
1:400 diluted monoclonal rabbit anti-human c-MET antibody (#ab51067, Abcam) (21). 
Hematoxylin & eosin (H&E) staining was performed regularly to assess tissue viability 
and morphology. Digital scans of slides were acquired using a NanoZoomer 2.0-HT multi 
slide scanner (Hamamatsu) and analysed with NanoZoomer Digital Pathology viewer 
software.
Statistical analysis
Data are presented as mean ± SD. Statistical analyses were performed with Graphpad 
Prism 5.0 using the two-sided Mann-Whitney test for non-parametric data and two-
sided paired Student’s T-test for paired data. P-values ≤ 0.05 were considered significant.




















































































Figure 1. A) In vitro flow cytometric analysis of EGFR and c-MET membrane expression in HCC827ErlRes cells, 
normalised to expression in parental cell line HCC827. B) In vitro MTT proliferation assay in HCC827 and 
HCC827ErlRes cells with increasing exposure to erlotinib for 4 days. C) In vitro flow cytometric analysis of EGFR 
and c-MET membrane expression in HCC827 and HCC827ErlRes cells after 24 hours treatment with 25, 50 and 
100 nM NVP-AUY-922, normalised to untreated controls. D) In vitro MTT proliferation assay in HCC827 and 
HCC827ErlRes cells with increasing exposure to NVP-AUY-922 for 4 days.
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Results
Effects of erlotinib resistance and NVP-AUY-922 treatment on c-MET expression 
An erlotinib-resistant clone, HCC827ErlRes, was generated from parental cell line HCC827, 
by culturing cells for two weeks with 50 ng/mL HGF and 1 µM erlotinib, followed by two 
weeks culture in presence of 1 µM erlotinib. Surface expression, as measured by flow 
cytometry, of c-MET in HCC827ErlRes was upregulated to 213 ± 44%, while EGFR surface 
levels were downregulated to 35± 17% of levels in parental HCC827 cells (Fig. 1A).
HCC827ErlRes cells were able to fully proliferate in presence of up to 1000 nM erlotinib as 
measured by MTT assay, while parental HCC827 remained highly sensitive for erlotinib, 
with an IC50 of 12 nM (Fig. 1B). NVP-AUY-922 treatment reduced surface expression of 
EGFR and c-MET (Fig. 1C). NVP-AUY-922 treatment was equally effective in reducing cell 
viability of both HCC827 and HCC827ErlRes (Fig. 1D). 
Figure 2. A) Representative microPET scans 24, 72 and 144 h pi for 10, 25 and 100 μg 89Zr-onartuzumab (n=6, 
n=5 and n=4 respectively) and 10 μg 89Zr-OA-NBC in HCC827 xenografts (n=3). B) Ex vivo tumour uptake data 
6 days pi for 10, 25 and 100 μg 89Zr-onartuzumab and 10 μg 89Zr-OA-NBC compared to 111In-OA-NBC control in 
HCC827 xenografts. C) MicroPET quantification for tumour uptake 24, 72 and 144 hours pi for 10, 25 and 100 
μg 89Zr-onartuzumab and 10 μg 89Zr-OA-NBC in HCC827 xenografts
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Figure 3. A) Representative microPET scans 144 hours pi of HCC827 (P, right flank) and HCC827ErlRes (ER, left 
flank) xenografted mice (n=10). B) MicroPET quantification for HCC827 and HCC827ErlRes tumour uptake 144 
hours pi in HCC827 and HCC827ErlRes xenografted mice. C) Ex vivo uptake data for HCC827 and HCC827ErlRes 
tumours, presented as % ID/g 89Zr-onartuzumab and 111In-OA-NBC control. D) Ex vivo tissue analysis. c-MET and 
hematoxylin and eosin immunohistochemical staining for HCC827 and HCC827ErlRes tumours
Figure 4. A) Representative microPET scans 144 hours pi, before (day 6) and during vehicle (n=6) or 100 mg/
kg NVP-AUY-922 (n=7) treatment (day 19) in HCC827 xenografted mice. B) MicroPET quantification for tumour 
uptake before (day 6) and during vehicle or 100 mg/kg NVP-AUY-922 treatment (day 19) in HCC827 xenografts. 
C) Ex vivo uptake data (day 19) for vehicle and NVP-AUY-922 treated HCC827 tumours, presented as % ID/g 89Zr-
onartuzumab and 111In-OA-NBC control. D) c-MET and hematoxylin and eosin immunohistochemical staining 
for vehicle and NVP-AUY-922 treated tumours
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89Zr-onartuzumab tracer development 
Conjugation of Df to onartuzumab yielded approximately 60% conjugation efficiency for 
all molar reaction ratios tested (Supplementary Fig. 1A). Df-onartuzumab conjugates 
were able to consistently bind 500 MBq 89Zr/mg Df-onartuzumab with RCP ≥ 95%, at 
ratios above 1:2 onartuzumab bound to Df (Supplementary Fig. 1B). Competition assay 
revealed a trend for lower immunoreactivity at higher conjugation ratios, signifying a 
need for balancing required specific activity with retained affinity of Df-onartuzumab 
conjugates (Supplementary Fig. 1C). Aggregation and fragmentation of Df-onartuzumab 
conjugates was not observed. An 1:5 conjugation reaction ratio, yielding 3.11 ± 0.33 Df 
bound to onartuzumab, was chosen as optimal for animal studies. 89Zr-onartuzumab was 
stable in vitro, with a maximum observed decrease in RCP from 99.0 ± 0.2% to 91.0 ± 
6.6% in human serum after 7 days at 37°C (Supplementary Fig. 1D). All 89Zr-onartuzumab 
tracer batches had a RCP ≥95% by TCA precipitation, while 111In-OA-NBC batches had a 
RCP ≥90% by instant thin layer chromatography (ITLC).
89Zr-onartuzumab protein dose escalation 
89Zr-onartuzumab tumour uptake increased over time for all tracer protein doses tested, 
with highest tumour and least background organ uptake observed at day 6 pi (Fig. 2A). 
89Zr-onartuzumab tumour uptake was higher compared to the co-injected 111In-OA-NBC 
control tracer in all tracer protein dose groups (Fig. 2B, S2A, S2B). 10 and 25 μg 89Zr-
onartuzumab dose groups showed similar tumour uptakes of 31.6±8.7 and 29.8±12.1 
%ID/g, while uptake in the 100 μg 89Zr-onartuzumab dose group trended lower (P=0.17 
vs. 10 μg) at 23.5±9.4 %ID/g. PET scans showed a SUVmean of 2.7±0.9, 2.9±0.7 and 2.2±0.8 
for tumours of the 10, 25 and 100 μg 89Zr-onartuzumab dose groups respectively (Fig. 
2B, 2C, Supplementary Fig 2A, 2B). 89Zr-OA-NBC control showed no accumulation 
in HCC827 tumours over time (Fig. 2A, 2C, Supplementary Fig. 2A, 2B), while ex vivo 
tumour uptake was similar to 111In-OA-NBC (Fig. 3B, Supplementary Fig. 2A, 2B), showing 
suitability of 111In-OA-NBC as proxy for 89Zr-OA-NBC. Based upon these results, a 10 μg 
89Zr-onartuzumab protein dose was used in the next mouse cohorts.
In vivo effects of erlotinib resistance on 89Zr-onartuzumab PET
PET scans showed 24% higher 89Zr-onartuzumab uptake (Fig. 3A, 3B, P<0.01), with 
a SUVmean 3.3 ± 0.5 for HCC827ErlRes, compared to a SUVmean 2.7 ± 0.3 for HCC827 
xenografts. Biodistribution revealed a 26% higher 89Zr-onartuzumab tumour uptake 
(Fig. 3C, Supplementary Fig. 3, 6, P<0.05) for erlotinib resistant HCC827ErlRes 
tumours at 38.1±8.4 %ID/g, compared to 30.2±3.5 % ID/g for HCC827 tumours. 
Similar Comparison of the tumour-to-muscle and tumour-to-blood ratios for 
the 2 groups showed similar trends, but did not reach significance. IHC revealed 
similar levels of necrosis, as well as higher c-MET expression for HCC827ErlRes 
than HCC827, in accordance with 89Zr-onartuzumab PET and biodistribution data 
(Fig. 3D, Suppl. Fig. 5A).
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In vivo effects HSP90 inhibition on 89Zr-onartuzumab PET
NVP-AUY-922 treatment effects on c-MET expression was evaluated in HCC827 xenograft 
bearing mice. Mice receiving NVP-AUY-922 treatment showed 33±10% (P<0.001) lower 
SUVmean for 
89Zr-onartuzumab tumour uptake post treatment compared to baseline scans, 
while uptake on scans for vehicle-treated mice before and during treatment were similar 
(Fig. 4A, 4B). Biodistribution studies confirmed PET results and revealed 27% lower 
89Zr-onartuzumab tumour uptake for NVP-AUY-922 versus vehicle (Fig. 4c, Supplementary 
Fig. 4A, 4B, 6, P<0.05). Similar comparison of the tumour-to-muscle and tumour-to-
blood ratios for the 2 groups showed similar trends, but did not reach significance. IHC 
showed a marked decrease in c-MET expression, with similar levels of necrosis, in the 
tumours for NVP-AUY-922 compared to vehicle treated animals (Fig. 4D, Suppl. Fig. 5B). 
Discussion 
This paper illustrates the feasibility of in vivo imaging of c-MET dynamics by detecting 
upregulation after c-MET mediated erlotinib-resistance, as well as downregulation of 
c-MET following HSP90-directed therapy using 89Zr-onartuzumab PET in human NSCLC 
xenograft bearing mice. Monitoring c-MET in vivo with 89Zr-onartuzumab PET might 
provide for an attractive tool to detect c-MET mediated emergence of resistance against 
EGFR TKIs, as well as assess downregulation of c-MET in response to HSP90 inhibition. 
Furthermore it could be beneficial for patient selection for c-MET directed therapy, as 
MET amplification and overexpression are associated with increased response to c-MET 
inhibitors (13). 
Due to the different Df-Suc-N-onartuzumab linker chemistry used for 89Zr radiolabelling 
in the present study, compared to 89Zr-Df-Bz-SCN-onartuzumab used by Jagoda et al. 
(17), we performed a tracer protein dose escalation study to optimise 89Zr-onartuzumab 
protein dose and imaging time point. HCC827 tumours in the present study showed 
high contrast and c-MET specific 89Zr-onartuzumab uptake at 10 µg tracer protein dose. 
Higher protein dose of 89Zr-onartuzumab doses showed a trend for lower tumour uptake. 
This blocking effect was also shown by Jagoda et al. using 1 mg cold onartuzumab, and 
is most likely caused by its non-reactivity to murine c-MET (10,17). 89Zr-onartuzumab is 
remarkable in that respect, in that specific binding could be proven with a coventional 
blocking study (17). In contrast, cross-reactive antibodies might need a higher protein 
dose for optimal tumour contrast (30). Similar protein doses of 89Zr-OA-NBC and 111In-
OA-NBC one-armed isotype controls for 89Zr-onartuzumab, did not accumulate in tumour 
tissues, confirming the c-MET specificity of the 89Zr-onartuzumab signal. 89Zr-Df-p-SCN-
onartuzumab uptake in MKN-45 gastric cancer xenografts 5 days post injection was lower 
at 22.5 % ID/g, than observed for 89Zr-Df-Suc-N-onartuzumab in HCC827 xenografts (17). 
A direct comparison, however, is difficult due to differences in tumour models, desferal 
linker chemistries, tracer protein doses and day of biodistribution analysis. 
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Upregulation of c-MET in EGFR TKI gefitinib resistant HCC827-GR6 xenografts was 
visualised with a 89Zr-labelled H2 cys-diabody and H2 minibody, with two-fold more 
uptake observed in resistant tumours (20). Reported biodistribution data of the 
resistant tumours, however, excluded cystic areas, which affected approximately half 
of the resistant c-MET upregulated HCC827-GR6 tumours. Exclusions of these cystic 
areas might have artificially increased apparent uptake of these tracers. Furthermore, a 
highly variable absolute tumour uptake was observed, differing up to two-fold between 
experiments, correlating with a similar variation in remaining blood pool activity (20). 
We observed robust tumour uptake of 89Zr-onartuzumab. As the affinity for c-MET of the 
H2 cys-diabody and H2 minibody are comparable to onartuzumab, this is likely due to 
the high molecular weight of 89Zr-onartuzumab, resulting in a slower blood clearance and 
prolonged tumour exposure (10,20). 89Zr-onartuzumab tumour-to-muscle and tumour-
to-blood ratios showed similar trends, but did not reach significance for HCC827 versus 
HCC827Erlres tumours. However, we included the 111In-OA-NBC paired control molecule 
in each experimental animal, as valid control to determine specific tumour uptake 
(31), as well as ex vivo analysis for c-MET expression and necrosis. This strengthens the 
conclusion that extra uptake in c-MET upregulated HCC827ErlRes xenografts is indeed 
mediated by c-MET expression, and not through possible variations in tumour size, 
blood pool tracer availability and permeability effects. 
Pharmacokinetic read-out of c-MET in response to c-MET TKI PHA665752 therapy 
showed reduced total MET protein in human gastric cancer MKN-45 xenografts 
due to more necrosis which coincided with a lower uptake of c-MET specific peptide 
99MTc-AH-113018 (32). The AH113804 peptide was also labelled with 18F for PET, and 
could detect recurrences of c-MET expression basal-like breast cancer xenografts after 
surgical resection (33). A fluorescent labelled version of the same peptide was used 
as ‘red flag technique’ to detect polyps using an fluorescent endoscope technique in 
patients at risk of developing colon cancer (34).
We and others showed potent downregulation of both EGFR and c-MET with HSP90 
inhibitors NVP-AUY-922 and 17-DMAG in human NSCLC cell lines (8,35). c-MET 
downregulation by NVP-AUY-922 was furthermore shown to overcome c-MET mediated 
gefitinib and erlotinib acquired resistance in HCC827 sub clones (8). We could visualise 
this downregulation of c-MET by NVP-AUY-922 in vivo using 89Zr-onartuzumab PET, 
with sequential scans showing 33% lower uptake post treatment. This correlated with 
downregulation of c-MET protein on ex vivo IHC, while tumour necrosis levels were 
similar for NVP-AUY-922 and vehicle treated animals. 
A limiting factor of the present study could be the relative small effect sizes observed 
for up and downregulation of tracer tumour accumulation. Earlier preclinical studies 
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visualised downregulation of other key oncogenic proteins after HSP90 inhibition and 
everolimus treatment, such as HER2, vascular endothelial growth factor A (VEGF-A), as 
well as insulin-like growth factor 1 receptor (IGF1R) using 89Zr-labeled antibody tracers. 
Effect sizes of antibody tracer uptake reduction after target protein downregulation 
through HSP90 inhibition and everolimus treatment are comparable to 89Zr-onartuzumab 
after c-MET downregulation in the present study (36–39), and part of these preclinical 
studies were successfully translated to the clinic (40,41). Furthermore, insight into 
whole body c-MET target distribution, via non-invasive 89Zr-onartuzumab scans, could 
potentially enrich the patient population which might benefit from c-MET/HGF–targeted 
drugs (18).
Based upon these promising preclinical results, we conclude 89Zr-onartuzumab c-MET 
PET provides for a robust non-invasive, powerful and easily clinical translatable tool 
to visualise c-MET dynamics as possible biomarker for c-MET mediated resistance to 
erlotinib and for treatment response to HSP90 inhibition. 
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Supplementary Figure. 1 A) Conjugation reaction efficiency of Df to onartuzumab at varying molar reaction 
ratios. B) Radiochemical purity for 89Zr labelling at various conjugation ratios for Df to onartuzumab, with 
specific activities between 50-1000 MBq/mg conjugate. C) Retained affinity of 89Zr-onartuzumab at varying 
molar conjugation ratios of Df to onartuzumab, compared to naked onartuzumab by competition assay. D) 
Stability of 89Zr-onartuzumab in 0.9% NaCl at 4°C, human serum at 37°C and HEPES pH 7.2 at 37°C up to 7 days
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Supplementary Figure 2. A) Ex vivo organ uptake of 10, 25 and 100 μg 89Zr-onartuzumab and 
10 μg 89Zr-OA-NBC tracer protein doses, 6 days pi and B) corresponding ex vivo organ uptake 

































































Supplementary Figure 3. Ex vivo organ uptake of 10 μg 89Zr-onartuzumab and 10 μg 111In-OA-NBC in HCC827 









































































































































Supplementary Figure 4. A) Ex vivo organ uptake of 10 μg 89Zr-onartuzumab in vehicle and 100 mg/kg NVP-
AUY-922 treated mice, 6 days pi and B) corresponding ex vivo organ uptake 111In-OA-NBC in HCC827 xenograft 































Histologic grading of necrosis 
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AUY-922 treated HCC827 
tumours, with 0+ being 0-5% 
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15-25% necrosis 2+,  25-35% 
necrosis 3+ and over 35% 
necrosis as 4+. 
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In this issue Arulappu et al. present results of c-MET specific peptide [18F]AH113804 PET 
screening for local regional recurrence after surgical excision of orthotopically implanted 
HCC1954 human basal-like breast cancer (BLBC) xenografts. [18F]AH113804 PET could 
visualize this loco-regional recurrence as early as 6 days postoperatively, whereas CT did 
so after day 20, and tumors were first palpable only by day 27. They were also able to 
differentiate between high and low c-MET expressing tumors. Based upon these results 
the authors conclude that [18F]AH113804 c-MET-PET has potential as a clinical screening 
tool for earlier detection of loco-regional BLBC recurrences (1).
c-MET is an interesting target for molecular imaging and treatment in solid tumors. 
It is a tyrosine growth factor receptor and together with ligand hepatocyte growth 
factor (HGF), c-MET is often dysregulated in cancers, including breast cancer. Increased 
activation of the c-MET/HGF pathway leads to invasion, angiogenesis, motility and cell 
proliferation (2). 
Breast cancers are subdivided in molecular subtypes. One of them is triple negative 
breast cancer (TNBC), which is characterized by lack of HER2, estrogen and progesterone 
receptor overexpression. BLBC, which served as model for Arulappu et al. (1), expresses 
genes characteristic for normal basal or myoepithelial breast cells. BLBCs comprise 
around 80% of TNBCs and 80% of BLBCs are classified as a TNBC. Although not completely 
overlapping, BLBC is often used interchangeable with the term TNBC (3,4). About 
15-20% of all breast cancer patients have TNBC (5). Loco-regional relapses develop in 
12-14 % of these patients and the overall recurrence rate is 35-40% within 5 years (6,7). 
After primary breast cancer treatment current guidelines advice regular physical exams 
approximately every 3-12 months and yearly mammography for the first 5 years. In 
absence of clinical signs and symptoms suggestive of recurrent disease, no laboratory 
or imaging studies for metastases screening are advised (8–10). Most loco-regional 
recurrences present themselves by clinical signs and symptoms such as lumps, swelling 
or inflamed skin, while mammography and physical examination detect most other loco-
regional recurrences (11). 
Although screening for loco-regional recurrences using PET seems enticing, this 
reasoning incurs potential pitfalls. In contrast to the preclinical model where local 
recurrences were already present 6 days after surgery, recurrences in TNBCs peak 
between 1-2 years after surgery (6). Therefore follow-up of these patients would likely 
encompass numerous, costly, PET scans during the first 5 years next to the advised yearly 
mammographies. Moreover, the inherent spatial resolution of whole body PET scans is 
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currently around 10-15 mm, whereas loco-regional recurrences this size are likely to be 
detected by palpation or conventional mammography. When whole body PET scanning 
is performed distant metastases may also be visualized. Modern PET-CT cameras and 
dedicated positron emission mammography could improve spatial resolution of PET 
tracers (12), with for the dedicated positron emission mammography at a loss of whole-
body detection capability for possible distant metastases. Risk associated with radiation 
exposure induced by PET scans would have to be justified by potential outcome benefits. 
For instance, a single 18F-FDG PET scan incurs around 3.99 (European Association of 
Nuclear Medicine Research Ltd guidelines) to 6.2-7.1 mSv (13). The 60-65% of TNBC 
patients which will not relapse, would receive additional radiation exposure if routinely 
screened by c-MET PET, next to the ~0.4 mSv dose per annual mammography (13). The 
patient population which might be considered for c-MET PET imaging, could possibly 
be initially enriched by selecting for known local recurrence risk factors such as primary 
tumor size, vascular invasion, and node-positivity (14). However, a follow-up protocol 
of patients using a one-target approach is likely to result in a significant number of 
false negative results. This is mainly due to lack of expression of the c-MET receptor in 
about half of the TNBC patients (5). However, a selection for c-MET imaging based on 
expression in primary tumors might underestimate the c-MET expression, as conversion 
from low expressing primary tumors to high c-MET levels in recurrent lesions has been 
observed (15). It will however be difficult for c-MET to compete with more general tumor 
characteristics such as elevated glucose consumption reflected by 18F-FDG PET imaging, 
as 18F-FDG performs relatively well in TNBC (16). Given the above arguments we do at 
this moment not foresee a routine place for the [18F]AH113804 PET tracer for broad local 
recurrence screening. However, there may well be other future reasons to target c-MET 
for imaging.
There are several other successfully tested preclinical c-MET PET tracers, including 
copper-64 labeled HGF (17), zirconium-89 (89Zr) labeled anticalin PRS-110 (18), iodine-124 
and 89Zr-labeled full-length murine antibody DN30 (19), one-armed antibody 89Zr-
onartuzumab (20), as well as a 89Zr-labeled H2 cys-diabody and H2 minibody (21). They 
have different properties, such as binding site, residualizing radiometals for improved 
contrast and varying tumor targeting kinetics as well as clearance rates. Some strategies 
involve labeling of existing drug candidates as proxy for drug tumor deposition, while 
others involve specially generated c-MET targeting proteins.
Next to c-MET imaging with a PET tracer, imaging with a fluorescent tracer might be 
of interest. Recently, GE-137, a fluorescent c-MET probe of which the targeting moiety 
is based upon the same peptide used by Arulappu et al., was successfully applied to 
detect polyps in individuals at risk for colorectal cancer. These individuals underwent 
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regular screening colonoscopies and GE-137 served as an add-on ‘’red-flag’’ fluorescent 
imaging technique (22). Benefits of this strategy compared to radionuclide-based 
imaging are a less costly infrastructure and availability of ‘off the shelf’ non-radioactive 
tracers. It is especially of interest when information of a limited body area is needed 
as no whole body information can be obtained. In the future potentially multiple 
fluorescent tracers with different distinct wavelengths targeting several targets 
could be used simultaneously in a multiplexed imaging setting in order to gain even 
more insight. Fluorescence imaging of growth factor receptors/ligands in the breast 
is currently actively pursued in the intraoperative setting with ultimate goal to obtain 
superior information concerning tumor free margins. Moreover, recent developments 
in multispectral optoacoustic imaging allows for non-invasive real-time imaging using 
a hand-held probe in the outpatient clinic. This strategy combines superior resolution 
with high signal penetration for visualization of tissues. It might therefore be a tool for 
local breast recurrence screening purposes without radiation burden (23), while a c-MET 
fluorescent tracer could be part of the multispectral optoacoustic imaging screening 
with a tracer cocktail against often-expressed breast cancer targets. 
TNBCs are characterized by a generally poor prognosis compared to other breast cancer 
subtypes as well as a lack of targeted treatment options (24). This has stimulated the 
search for drugable targets for this particular subgroup. It is of interest that several c-MET 
targeted therapeutics are currently evaluated in breast cancer trials, such as the small 
molecule tyrosine kinase inhibitors tivantinib, cabozantinib and foretinib, one-armed 
c-MET antibody onartuzumab and autologous cMET redirected T cells. Preliminary 
clinical efficacy of such compounds in TNBC is modest (5). Pretreatment c-MET-PET 
scans as a non-invasive accompanying biomarker could potentially enrich the patient 
population that might benefit of c-MET/HGF targeted drugs (25), by providing insight in 
whole body c-MET target distribution. When imaging c-MET obtains a role in the clinic, 
the answers required for patients will ultimately guide selection of the imaging modality 
and optimal tracer.
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AMG 110, a Bispecific T cell Engager (BiTE®) antibody construct, induces T cell mediated 
cancer cell death by cross-linking epithelial cell adhesion molecule (EpCAM) on tumor 
cells with cluster of differentiation 3 epsilon (CD3ε) on T cells. We labeled AMG 110 with 
zirconium-89 (89Zr) or near infrared fluorescent dye (IRDye) 800CW to study its tumor 
targeting and tissue distribution. 
Biodistribution and tumor uptake of 89Zr-AMG 110 was studied up to 6 days after 
intravenous injection in nude BALB/c mice bearing high EpCAM expressing HT-29 
colorectal cancer xenografts. Tumor uptake of 89Zr-AMG 110 was compared with uptake 
in head and neck squamous cell cancer FaDu (intermediate EpCAM) and promyelocytic 
leukemia HL60 (EpCAM negative) xenografts. Intratumoral distribution in HT-29 tumors 
was studied using 800CW-AMG 110. 
Tumor uptake of 89Zr-AMG 110 can be clearly visualized using microPET imaging up to 
72 h after injection. Highest tumor uptake of 89Zr-AMG 110 at a 40 µg dose level of was 
observed at 6 h and 24 h (respectively 5.35 ± 0.22 %ID/g and 5.30 ± 0.20 %ID/g; n = 3 and 
n = 4). Tumor uptake of 89Zr-AMG 110 was EpCAM specific and correlated with EpCAM 
expression. 800CW-AMG 110 accumulated at the tumor cell surface in viable EpCAM 
expressing tumor tissue. 
PET and fluorescent imaging provided real-time information about AMG 110 distribution 
and tumor uptake in vivo. Our data support using 89Zr and IRDye 800CW to evaluate 
tumor and tissue uptake kinetics of BITE® antibody constructs in preclinical and clinical 
settings.
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Introduction
Cancer remains a major cause of death worldwide and one of the key disease areas 
with the greatest unmet medical needs. Therefore new treatment strategies are eagerly 
awaited. The use of T cells, especially cytotoxic T cells, in the battle against cancer has 
shown promising results using several approaches. However, most of these strategies 
are sensitive to inhibitory or escape mechanisms, such as major histocompatibility 
complex class I down regulation or induction of T cell tolerance, which can limit anti-
tumor efficacy. 
BiTE® antibody constructs are created to circumvent such inhibitory or escape 
mechanisms. They are comprised of two single-chain variable antibody fragments 
(scFv) that are covalently linked by a peptide linker and bind CD3ε as well as a surface 
target antigen on cancer cells. The activation of T cells by BiTE® antibody constructs 
is independent of matching major histocompatibility complex class I or costimulatory 
molecules. Furthermore, BiTE® antibody constructs engage a polyclonal population of 
T cells, including CD4+ and mainly CD8+ T cells. Binding of tumor cells and T cells by BiTE® 
antibody constructs results in the formation of a cytolytic synapse between tumor and 
T cells, which is followed by a release of pore-forming and pro-apoptotic components of 
cytotoxic T cell granules, mediating cancer cell death. The activation of T cells occurs only 
in the presence of a target cell. To date four BiTE® antibody constructs, blinatumomab, 
BAY2010112/AMG 212, MT111/AMG 211 and MT110/AMG 110 are or have been 
tested in clinical trials. Blinatumomab has been approved by the U.S. Food and Drug 
Administration to treat patients with Philadelphia chromosome-negative precursor 
B-cell acute lymphoblastic leukemia.
EpCAM is expressed on many epithelial tumors and cancer stem cells and is therefore an 
attractive target for BiTE® antibody constructs. An EpCAM targeting BiTE® called solitomab 
(AMG 110, formerly known as MT110) has been developed. AMG 110 mediates lysis of 
cancer cells by the activation of T cells in vitro and showed pharmacological activity at 
doses administered of at least 24 µg/day in the clinic.
In order to support clinical development of AMG 110 and other BiTE® antibody 
constructs, molecular imaging can be used as a powerful non-invasive tool to obtain 
valuable information on tumor uptake, biodistribution and pharmacokinetics. In a clinical 
setting this information can potentially be used to support patient tailored drug dosing. 
Because of its long radioactivity decay half-life of 3.27 days, zirconium-89 (89Zr) is well 
suited for capturing the in vivo pharmacokinetics of large molecules, such as antibodies. 
In addition, labeling antibodies with the near infrared (NIR) fluorescent dye 800CW can 
be used to study their intratumural tumor distribution with near infrared fluorescence 
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imaging and to enable molecular characterization of tumor and tissue sections ex vivo. 
We therefore labeled AMG 110 with 89Zr or IRDye 800CW to study its tumor targeting 
and tissue distribution via non-invasive microPET and fluorescence imaging.
Material and methods
BiTE® antibody constructs and cell lines
AMG 110 is a BiTE® antibody construct targeting human EpCAM and human CD3ε. The 
non-specific control BiTE® Mec14, shares the same anti-CD3ε single-chain antibody arm, 
but targets a haptene (mecoprop) with the second arm. Both BiTE® antibody constructs, 
± 55 kDa in size, were provided by Amgen. Two human EpCAM positive tumor cell 
lines, the colorectal adenocarcinoma HT-29 cell line and the head and neck squamous 
cell cancer FaDu cell line, and a human EpCAM negative promyelocytic leukemia HL-
60 cell line were used. We used HT-29 xenografts to study dose and time dependent 
tumor uptake of 89Zr-AMG110 as this cell line highly expresses EpCAM. We additionally 
used this cell line to compare EpCAM dependent tumor uptake of 89Zr-AMG110 with 
89Zr-Mec14. All cell lines were obtained from American Type Culture Collection and 
screened for microbial contamination and tested negative. Cell lines were authenticated 
by Baseclear using short tandem repeat profiling. This was repeated once a cell line has 
been passaged for more than 6 months after previous short tandem repeat profiling. 
HT-29 and HL-60 were routinely cultured in RPMI-1640 medium (Invitrogen) containing 
10% fetal calf serum (FCS; Bodinco BV). FaDu cells were cultured in DMEM (Invitrogen) 
supplemented with 10% FCS and 2 mM L-glutamine (Invitrogen). All cells were cultured 
under humidified conditions (37°C, 5% CO2). 
Animal experiments 
All animal experiments were approved by the Institutional Animal Care and Use 
Committee of the University of Groningen and conducted in male nude BALB/c mice 
(BALB/cOlaHsd-Foxn1nu, Harlan). After 1 week of acclimatization, 6 to 8 weeks old mice 
were subcutaneously injected with 10 x 106 HT-29 cells in 0.1 mL PBS, 5 x 106 FaDu cells in 
0.1 mL PBS or 2 x 106 HL-60 cells in 0.1 mL PBS. Tumor growth was monitored by caliper 
measurements. Penile vein tracer injection was performed 3 weeks after inoculation 
of HT-29 cells, 4 weeks after inoculation of FaDu cells and 5 weeks after inoculation for 
HL-60 cells. All scans and invasive proceedings were performed with isoflurane/medical 
air inhalation anesthesia (5% induction, 2.5% maintenance) for a maximum of 90 
minutes.
PET acquisition
Two mice were placed above each other in a Focus 220 rodent scanner (CTI Siemens), 
with the tumor in field of view. Mice were kept warm on heating mats. Acquisition times 
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differed between 10 minutes (0.5 h time point) and 75 minutes (144 h time point). 
A transmission scan of 515 seconds was performed using a 57Co point source to correct 
for tissue attenuation.
In vivo PET imaging and ex vivo biodistribution
For determining the time point for optimal tumor visualization, microPET images were 
obtained 0.5, 3, 6, 24, 48 and 72 h after injection of 20 µg 89Zr-AMG 110 (5 MBq). Data up 
to 24 h was obtained from 6 mice and data at 48 h and 72 h were obtained from 2 mice. 
For ex vivo biodistribution, animals were sacrificed at designated time points. 
Subsequently, organs and tissues were excised and weighed. Samples and prime 
standards were counted for radioactivity in a calibrated well-type γ-counter. Ex vivo 
tissue activity was expressed as percentage of the injected dose per gram tissue (%ID/g). 
A dose escalation biodistribution study was performed with 20 µg (n = 5), 40 µg (n = 4) 
and 500 µg (n = 3) 89Zr-AMG 110 (1 MBq) at 24 h post injection. Tumor weights did not 
differ significantly between the dose groups, respectively 0.23 ± 0.09 g, 0.33 ± 0.27 g 
and 0.47 ± 0.62 g (Supplemental Fig. 1A). Doses higher than 20 µg were supplemented 
with non-radiolabeled AMG 110. For the 40 µg protein dose, 89Zr-AMG 110 (1 MBq) 
time dependent tumor uptake was also determined. Biodistribution studies were 
performed at 6 (n = 3), 24 (n = 4), 72 (n = 4) and 144 (n = 5) h post tracer injection. Tumor 
weights did not differ significantly between different groups, respectively 0.20 ± 0.01 g, 
0.33 ± 0.27 g, 0.33 ± 0.10 g and 0.35 ± 0.15 g (Supplemental Fig. 1B).
To determine non-specific tumor uptake, 40 µg (1 MBq) 89Zr-Mec14 (n= 6) or 89Zr-AMG 
110 (n = 4) was injected in mice harboring HT-29 tumors. Tumor weights did not differ 
significantly between the two groups, respectively 0.32 ± 0.11 g and 0.33 ± 0.27 g 
(Supplemental Fig. 1C). MicroPET scans and ex vivo biodistribution were performed 24 h 
after tracer injection; at the time when tumor uptake of 89Zr-AMG 110 would be high and 
blood levels relatively low. Biological half-life of 89Zr-AMG 110 in whole blood and tumor 
was calculated using either percentage injected dose per cubic centimeter (%ID/cm3) 
(20 µg tracer dose, as used for determining optimal time-point) based on microPET scans 
or %ID/g (40 µg protein dose) by non-linear regression (one phase exponential decay) 
using GraphPad Prism software.
EpCAM specific uptake in relation to EpCAM expression was assessed with microPET 
imaging 24 h after injection of 40 µg 89Zr-AMG 110 in xenografted mice (n = 4-6 per 
group) bearing HT-29, FaDu or HL-60 tumors. Thereafter, mice were sacrificed for ex 
vivo biodistribution analysis. Tumor weights did not differ significantly between the 




Figure 1. Biodistribution of 89Zr-AMG 110 at a 20 µg dose level. A) Representative serial microPET imaging at 
0.5, 3, 6, 24, 48, and 72 h after injection, in one HT-29 bearing mouse. Yellow arrows indicate the tumor. B) 
In vivo quantification of tumor and blood levels of 89Zr-AMG 110 in time as presented in %ID/cm3. Data up to 
24 h was obtained from 6 mice and data at 48 h and 72 h were obtained from 2 mice. Data are presented as 
mean ± SD.
Figure 2. Dose dependent 89Zr-AMG 110 biodistribution in HT-29 tumor bearing mice, at 24 h after tracer 
injection. Mice were injected with 20 µg (n = 5), 40 µg (n = 4) or 500 µg (n = 3) protein doses. No significant 
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PET reconstruction
PET data was reconstructed by using an Ordered Subset Expectation Maximization 
(OSEM2D) reconstruction algorithm with Fourier rebinning, 4 iterations and 16 subsets. 
After reconstruction, images were quantified using AMIDE Medical Image Data Examiner 
software (version 1.0.4, Stanford University). Regions of interest were drawn for tumor 
and blood (heart). The level of 89Zr-AMG 110 or 89Zr-Mec14 is calculate as %ID/cm3. 
Ex vivo fluorescent imaging
For NIR fluorescence imaging, mice bearing HT-29 xenografts (n = 4) were co-injected 
with 40 μg 800CW-AMG 110 and 40 μg 680RD-Mec14. At 24 h after injection mice were 
sacrificed, tumor tissue was excised, formalin-fixed and paraffin embedded. Tumor 
slices were stained immunohistochemically for EpCAM (D9S3P, Cell Signaling) and 
with hematoxylin and eosin (H&E). Overview images of intratumoral 680RD-Mec14 
and 800CW-AMG 110 distribution were obtained with the Odyssey infrared imaging 
system (LI-COR Biosciences). For fluorescence microscopy, an inverted Leica DMI600B 
fluorescence microscope equipped with a Lumen Dynamics X-Cite 200DC light source 
was used. Nuclei were stained with 4',6-diamidino-2-phenylindole (DAPI, Sigma-Aldrich).
 
Statistical analysis. 
Data are presented as mean ± standard deviation (SD). Statistical analysis between 
two groups was performed using Mann-Whitney U-test (GraphPad, Prism 5). To test 
if differences between multiple groups were significant, we used a Kruskal-Wallis test 
(GraphPad, Prism 5). A bonferroni corrected Mann-Whitney U-test was subsequently 
used to compare differences between two groups. P values ≤ 0.05 were considered 
significant.
Results
In vivo evaluation of 89Zr-AMG 110 and 800CW-AMG 110. 
MicroPET images of the 20 µg 89Zr-AMG 110 dose showed time dependent tumor 
accumulation with a maximum of 3.25 ± 0.24 %ID/cm3 at 6 h post injection (Figs. 1A 
and 1B) and decreasing subsequently. Following the same pattern, kidneys showed 
the highest tissue uptake across time points, reaching a maximum of 60.26 ± 4.01 
%ID/cm3 at 6 h, indicating renal clearance. Blood levels of 89Zr-AMG 110 dropped rapidly 
(biological T
1/2
 = 1.51 h, Supplemental Fig. 4A). The washout of the tumor was relatively 
slow (biological T
1/2
 = 99.9 h, Supplemental Fig. 4B), starting at 6 h after injection. This 
resulted in increasing tumor-to-blood ratios over time, reaching 1.13 ± 0.29, 3.67 ± 0.29, 
4.10 ± 0.42 and 3.53 ± 1.03, respectively, at 6, 24, 48 and 72 h. 
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Figure 3. Time dependent 89Zr-AMG 110 (40 µg) biodistribution in HT-29 bearing mice. (A) Ex vivo biodistribution 
of 89Zr-AMG 110 was performed at 6 (n = 3), 24 (n = 4), 72 (n = 4) and 144 h (n = 5) after injection. Corresponding 
tumor-to-blood ratios increased  significantly (B). Data is presented as mean ± SD. Significance has been 
calculated for differences in tumor uptake and tumor-to-blood ratios. *P ≤ 0.05
Figure 4. Ex vivo biodsitribution 24 h after injection of 89Zr-AMG 110 (40 µg, n = 4) or 89Zr-Mec14 (40 µg,
n = 6) in HT-29 tumor bearing mice (A). Corresponding tumor-to-blood ratios were significantly higher for 
89Zr-AMG 110 than for 89Zr-Mec14 (B). Representative coronal microPET images of 89Zr-AMG 110 and 89Zr-Mec14 
visualizes the difference in tumor uptake. Yellow arrow indicates the tumor (C). Data is presented as mean ± SD. 
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A 40 µg and 500 µg protein dose resulted in a higher (not statistically significant) and 
more reproducible tumor uptake of 89Zr-AMG 110 compared to 20 µg (5.30 ± 0.21 and 
4.9 ± 0.21 versus 3.6 ± 1.2 %ID/g; P = 0.57 and 0.75 respectively, Fig. 2A). No statistical 
significant differences were found in tumor-to-blood or tumor-to-muscle ratio between 
the different protein doses tested (Supplemental Figs. 5A and 5B). All organs showed 
similar 89Zr-AMG 110 levels at all protein doses. Highest 89Zr-AMG 110 levels were found 
in the kidneys followed by liver and tumor. Due to a more reproducible tumor uptake, 
the remainder of the study was performed with a 40 µg instead of 20 µg dose level. 
The duration and level of 89Zr-AMG 110 tumor exposure was protein dose dependent 
and differed from blood. Biodistribution of 40 µg 89Zr-AMG 110 in time resulted in a 
Figure 5. Correlation between 89Zr-AMG 110 tumor uptake and EpCAM expression on tumor cells. (A) Ex vivo 
biodistribution of 89Zr-AMG 110 (40 µg), 24 h after tracer injection in HT-29 (n = 4; high EpCAM), FaDu (n = 5; 
intermediate EpCAM) or HL-60 (n = 6; EpCAM negative) bearing mice. (B) Representative coronal microPET 
images. Yellow arrows indicate the tumor. (C) Differences in EpCAM expression on HT-29 (n = 5), FaDu (n = 5) 









































































maximum tumor uptake at 6 and 24 h after injection of respectively 5.4 ± 0.2 %ID/g 
and 5.3 ± 0.3 %ID/g (Fig. 3A), declining subsequently. In contrast, tumor uptake after 
injection of 20 µg 89Zr-AMG 110 already peaked at 6 h and declined steadily thereafter 
(Fig. 1B). Biological half-life of 89Zr-AMG 110 after injection of a protein dose of 40 µg in 
blood was 4.1 h compared to 1.5 h for the 20 µg protein dose (Supplemental Fig. 4C). 
Washout of signal from the tumor was relatively slow compared to blood (T
1/2
 = 40.2 h, 
Supplemental Fig. 4D). The prolonged tumor retention of 40 µg 89Zr-AMG 110 resulted 
in increasing tumor-to-blood ratios over time, reaching 65.1 ± 15.5 at 144 h (Fig. 3B). 
Maximal tumor-to-muscle ratio was reached at 24 h (18.6 ± 3.6).
Figure 6. Intratumoral distribution of co-injected 800CW-AMG 110 (40 µg) and 680RD-Mec14 (40 µg) in HT-29 
tumors. (A) EpCAM was predominantly expressed on healthy tumor tissue as visualized with H&E and EpCAM 
IHC staining. (B) Corresponding macroscopic fluorescent imaging of 800CW-AMG 110 (green) and 680RD-
Mec14 (red) distribution, with minor overlapping signal (yellow). (C) Fluorescence microscopy images (630x), 
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HT-29 xenografts specifically retained 89Zr-AMG 110, but not the non-EpCAM binding 89Zr-
Mec14 BiTE®. Biodistribution of 89Zr-Mec14 showed low tumor uptake of 0.7 ± 0.1 %ID/g 
compared to 5.3 ± 0.3 %ID/g for 89Zr-AMG 110 at 24 h (Fig. 4A; P < 0.01). Accumulation of 
89Zr-Mec14 in blood and all organs except the kidneys was lower (≤ 2.4 %ID/g) compared 
to 89Zr-AMG 110 (≤ 5.6 %ID/g). 89Zr-Mec14 tumor uptake was comparable to non-specific 
uptake in other organs. As a result, a higher tumor-to-blood (33.4 ± 3.1 vs. 7.3 ± 1.2; 
P < 0.01; Fig. 4B) and a higher tumor-to-muscle ratio (18.6 ± 3.6 vs. 6.7 ± 0.8; P < 0.01) 
were observed for 89Zr-AMG 110. In line with these results, microPET images showed 
lower tumor uptake of 89Zr-Mec14 compared to 89Zr-AMG 110 (Fig. 4C). 
Tumor uptake of 89Zr-AMG 110 was correlated with the level of cell surface EpCAM 
expression (Fig. 5). It was highest in HT-29 tumors (5.3 ± 0.3 %ID/g) followed by FaDu 
(2.7 ± 0.6 %ID/g) and HL-60 (0.8 ± 0.2 %ID/g), while no differences were observed 
in uptake of normal organs in mice bearing the different tumor xenografts (Fig. 5A). 
Difference in tumor uptake could be clearly visualized by microPET (Fig. 5B). 
In vivo and ex vivo fluorescence imaging confirmed AMG 110 specific cell surface binding 
of HT-29 xenografts. Similar to 89Zr-AMG 110, in vivo imaging showed HT-29 retention of 
800CW-AMG 110, but not 680RD-Mec14 (Supplemental Fig. 6A). In accordance with low 
tumor levels found for 89Zr-Mec14 at biodistribution 24 h after tracer injection, 680RD-
Mec14 was cleared rapidly, with level detectable only ex vivo by 24 h (Supplemental 
Fig. 6B). Ex vivo macroscopic fluorescence imaging of HT-29 tumor slices showed 800CW-
AMG 110 colocalizing with viable EpCAM expressing tumor tissue, as shown by H&E and 
EpCAM staining (Figs. 6A and 6B). Fluorescence microscopy also showed presence of 
800CW-AMG 110 on the tumor cell surface (Fig. 6C). In contrast, non-EpCAM binding 
680RD-Mec14 mostly localized in necrotic tumor tissue. 
Discussion
We present the first non-invasive preclinical imaging study in which a bispecific T cell 
engaging antibody construct targeting EpCAM is labeled with a radionuclide, or a 
fluorophore, to visualize and quantify tumor uptake, tissue accumulation and clearance 
kinetics in vivo. In this study, 89Zr-AMG 110 showed consistent tumor uptake in xenografts, 
that is correlated with EpCAM expression. It also showed prolong tumor retention that is 
unusual for a reversible extracellular binder exhibiting rapid renal clearance. 
Remarkably, HT-29 tumor uptake of 89Zr-AMG 110 remained visible up to 72 h after 
injection, despite minimal cellular internalization. Both tumor uptake and organ uptake 
of 89Zr-AMG 110 was higher than of 89Zr-Mec14. This is likely the result of faster clearance 
of 89Zr-Mec14, as blood levels of 89Zr-Mec14 were also lower. NIR fluorescent imaging 
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with 800CW-AMG 110 confirmed AMG 110 localization at the tumor cell membrane 
in viable HT-29 tumor tissue. Minor accumulation of 680RD-Mec14 was observed in 
necrotic tumor tissue, which is likely due to non-specific binding. Together, these findings 
clearly demonstrated the advantage of using ImmunoPET to determine the dose level 
of BITE® antibody constructs necessary for tumor targeting, to assess the presence of 
target, and to study in vivo tissue exposure in real-time.
AMG 110 showed favorable tumor uptake and retention compared to a similar EpCAM 
binding agent. The EpCAM targeting radiopharmaceutical 68Ga-scFv429 also comprise 
two scFv fragments and has a similar molecular weight (51.2 kDa) as 89Zr-AMG 110. 
Furthermore, it exhibits monospecific bivalent binding and higher EpCAM affinity than 
AMG 110 (dissociation constant = 0.24 nM vs. 170 - 230 nM, respectively, as determined 
by plasmon resonance analysis). Despite bivalent binding and higher affinity, the 
highest tumor uptake (in %ID/g) of 68Ga-scFv429 in HT-29 tumors was 2.8 fold lower than 
89Zr-AMG110. Maximum tumor uptake of 68Ga-scFv429 was reached at 1 h, while maximum 
tumor uptake of 89Zr-AMG110 was reached at 6 h after injection. At these time points, 
the observed tumor-to-blood ratios were comparable (~1 and 1.1 ± 0.30, respectively). 
The higher tumor uptake of 89Zr-AMG 110 is most likely due to its longer circulating half-
life (1.4-4.1 h) compared to that of 68Ga-scFv429 (0.97 h). 
In addition to differences in tumor uptake kinetics and circulating half-life, preclinical 
imaging studies also showed that different tracers also differ in the ability to saturate 
tumor uptake. In contrast to membrane tumor targets c-MET and human epidermal 
growth factor receptor 3, saturation of EpCAM binding on HT-29 was not observed 
even when the 89Zr-AMG 110 total protein dose was increased to 500 µg. Thurber et al.
also observed no saturation of EpCAM binding in HT-29 xenografts after injection of 
an EpCAM antibody labeled with a NIR dye (VivoTag 680) at a total protein dose of 
180 µg. One possible explanation might be related to the abundance of cell surface 
EpCAM on HT-29 cells (2.3 x 106 receptors/cell). Another example supporting this 
hypothesis was illustrated by the lack of tumor saturation observed for 89Zr-trastuzumab, 
up to 500 µg in SKOV3 xenografted mice. Similar to the high level of EpCAM expression on 
HT-29 cells, expression of the human epidermal growth factor receptor 2 on SKOV3 cells 
is also high (6.6 x 106 receptors/cell). The inability to saturate human epidermal growth 
factor receptor 2 and EpCAM suggest that it may be difficult to saturate receptors when 
their cell surface expression exceeds ~2 x 106 receptors/cell at the dose levels evaluated. 
Alternatively, saturation of tumor targets may also depend on other in vivo properties of 
the antibodies including binding on/off kinetics, degree of tumor penetration and access 
to target at different protein dose levels. Additional radioactive- and optical-labeled 
antibody imaging studies, particularly those in the clinical setting, will help further 
elucidate mechanisms for driving uptake in tumors and tissues of interest. 
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Although the current preclinical study examined only the tumor antigen binding 
component of AMG 110, preclinical and clinical imaging studies showed that it’s feasible 
to image tumor uptake of tumor targeting CD3 bispecific antibodies in the presence 
of circulating T cells. A T cell mediated increase in tumor uptake has been observed 
with a tetravalent bispecific tandem antibody (TandAb), directed at mouse CD3ε and 
fibronectin extra domain B, in immunocompetent mice. 125I labeled TandAb with CD3ε 
affinity similar to that of AMG 110, showed that potential T cell binding outside of the 
tumor did not block tumor uptake or change its biodistribution. The mice in our study 
were immunodeficient, so tumor uptake of 89Zr-AMG 110 was not affected by T cells. 
As AMG110 does not bind mouse CD3ε, the effect of T cell binding on 89Zr-AMG 110 
distribution and tumor uptake could not be studied in immune competent mice. In a 
clinical setting, the presence of T cells might influence biodistribution and lead to a 
higher tumor uptake. Furthermore, 123I-OC/TR F(ab’)2, targeting folate receptor and CD3, 
has been used successfully to image malignant tumor lesions in ovarian cancer patients.
Given its overexpression by many tumor types, EpCAM is an interesting drug target. 
Different EpCAM-targeted drugs have been developed, including monoclonal antibodies, 
antibody fragments, bispecific antibodies and antibody-drug conjugates. Similar to these 
other experimental drugs, EpCAM expression on tumor cells is a prerequisite for effective 
treatment with AMG 110. Since EpCAM dependent 89Zr-AMG 110 tumor uptake has been 
demonstrated preclinically, this tracer, applied clinically, can potentially facilitate patient 
selection for AMG 110 treatment by providing information on drug access across all 
lesions. Moreover, 89Zr-AMG 110 or other radiolabeled BiTE® antibody constructs could 
potentially support clinical BiTE® development, as they could give additional information 
about tissue pharmacokinetics and uptake in tumors to support optimal dosing, and 
about uptake in critical organs to anticipate toxicity.
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Supplemental Figure 1. Differences in ex vivo tumor weights between the experiments, as measured after mice 
were sacrificed. A) Difference in tumor weights after resection from mice injected with 89Zr-AMG 110 at 20 µg 
(n = 5), 40 µg (n = 4) or 500 µg (n = 3) dose levels. B) Difference in tumor weights at 6 (n = 3), 24 (n = 4), 
72 (n = 4) and 144 h (n = 5) after injection of 40 µg 89Zr-AMG 110. C) Difference in tumor weights at 24 h after 
injection of 40 µg 89Zr-AMG 110 (n = 4) or 40 µg 89Zr-Mec 14 (n = 6). D) Difference in tumor weights between 
HT-29 (n = 4), FaDu (n = 5) and HL-60 (n = 6) tumors at 24 h after injection of 40 µg 89Zr-AMG 110. 
Supplemental Figure 2. Quality control of 89Zr-AMG 110 and 89Zr-Mec 14. A) Typical SE-HPLC chromatogram 
of 89Zr-AMG 110 (upper panel) or 89Zr-Mec 14 (lower panel), which is an overlay of 280 nm and radiochemical 
signal. B) binding of 89Zr-AMG 110 to an increasing number of HT-29 cells. C) Reciprocal plot to infinite antigen 






























































Supplemental Figure 3. Membrane binding and internalization of 89Zr-AMG 110 after binding EpCAM on 
HT-29 cells. Membrane bound and internalized fraction is expressed as percentage of initial cell associated 
radioactivity. Data is presented as mean ± SD. At several time points in the graphs of membrane bound 
89Zr-AMG 110, SD is not visible due its small size. 
Supplemental Figure 4. Biological half-life of 89Zr-AMG 110 in blood and tumor. Biological half-life of 20 µg 
89Zr-AMG 110 in A) blood and B) tumor, based on %ID/cm3. Biological half-life of 40 µg 89Zr-AMG 110 in C) blood 
and D) tumor, based on %ID/g. Data is presented as mean ± SD.
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Supplementary material & methods
Conjugation and labeling of AMG 110 and Mec14
 AMG 110 and Mec14 were first purified with water for injections using a Vivaspin-2 10 kDa 
filter (GE Healthcare). Conjugation was performed by allowing BiTE® antibody constructs 
to react with a 6.7-fold molar excess of N-succinyldesferrioxamine-B-tetrafluorphenol 
(N-sucDf-TFP, ABX), as described earlier. Conjugated BiTE® was radiolabeled on the same 
day with 89Zr-oxalate (PerkinElmer). Free 89Zr was removed by using a Vivaspin-2 10 kDa 
filter.
Supplemental Figure 5. Dose dependent A) tumor-to-blood and B) tumor-to-muscle ratios. Mice were injected 
with 20 µg (n = 5), 40 µg (n = 4) or 500 µg (n = 3) protein doses. No significant differences were observed in 
blood or tissue levels between the dose groups. Data is presented as mean ± SD.
Supplemental Figure 6. A) Representative sagittal two-dimensional in vivo fluorescence images at indicated 
time points, after coinjection of 40 μg 800CW-AMG 110 and 40 μg 680RD-Mec14. White arrow indicates location 
of the tumor. B) Fluorescent tracer uptake in HT-29 tumors over time, normalized to absolute fluorescence 







































For labeling with respectively IRDye 800CW and 680RD, purified AMG 110 and Mec14 
reacted with a 3-fold molar excess of IRDye as described earlier. Unreacted dye was 
removed using PD10 desalting columns (Fisher Scientific).
Quality control of 89Zr-AMG 110 and 89Zr-Mec14
Aggregation, fragmentation and concentration of 89Zr-AMG 110, 800CW-AMG 110, 89Zr-
Mec14 and 680RD-Mec14 were assessed using size exclusion high performance liquid 
chromatography (SE-HPLC). The Waters SE-HPLC system was equipped with a dual 
wavelength absorbance detector, an in line radioactivity detector and a size exclusion 
column (Superdex 75 10/300 GL column; GE Healthcare). PBS was used as mobile phase 
at a flow of 0.7 ml/min. Radiochemical purity (RCP) of 89Zr-AMG 110 and 89Zr-Mec14 was 
determined using trichloroacetic acid precipitation. 
The in vitro binding characteristics (immunoreactive fraction; IRF) of the radiolabeled 
BiTE® antibody constructs were determined in a cell binding assay as described by Lindmo 
et al. In short, two series of HT-29 cell dilutions were incubated in duplicate with 15 
ng/mL 89Zr-AMG 110 for 2 h at 4°C while shaking. To one of the cell series a 1000-fold 
excess of cold AMG 110 was added to block EpCAM specific binding and set the reference 
used to correct for non-specific binding. After 2 h incubation, cells were washed twice 
with PBS containing 1% human serum albumin (HSA). Radioactivity of standards and cell 
pellets were measured with a calibrated well-type γ-counter (LKB 1282; CompuGamma). 
The IRF was determined for each separate experiment by extrapolating to conditions 
representing infinite antigen excess, corrected for non-specific binding.
In vitro evaluation of 89Zr-AMG 110 
Internalization of 89Zr-AMG 110 was determined by incubating 106 HT-29 cells with 50 ng
89Zr-AMG 110 for 1 h at 4°C. Subsequently, unbound 89Zr-AMG 110 was removed by 
rinsing with PBS containing 1% HSA. Remaining activity, defined as initial cell associated 
radioactivity, was measured in a calibrated well-type γ-counter and set to 100%. Next 
cells were resuspended in culture medium (RPMI + 10% FCS, including T = 0) and
incubated 1, 2 or 4 h at 4°C or 37°C. Thereafter, medium was removed and cell pellet 
activity, defined as membrane bound + internalized, was measured in a calibrated well-
type γ-counter. Finally, cells were stripped using urea buffer (4 M urea, 2 M glycine, 
pH 2.0) (5) and washed twice with urea buffer. Radioactivity in the stripped pellet, 
representing the internalized radioactivity, was measured in a calibrated well-type 
γ-counter. Internalization was determined by the following formula: (internalized 
radioactivity/initial cell associated radioactivity) x 100%.
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Flow cytometry. 
To determine EpCAM expression by the cell lines, flow cytometry was performed with 
a BD Accuri™ C6 flow cytometer (BD Biosciences). HT-29, FaDu or HL-60 cells were 
incubated for 1 h at 4 °C, with 20 µg/mL mouse anti-human EpCAM antibody (Abcam, 
ab20160) and washed twice using phosphate buffered saline (PBS; 140 mmol/L NaCl, 
9 mmol/L Na2HPO4, 1.3 mmol/L NaH2PO4; pH = 7.4, UMCG) containing 0.5% FCS and 
2 mM ethylenediaminetetraacetic acid. Subsequently, cells were incubated for 1 h at 
4°C with (0.01 mg/mL) goat anti-mouse phycoerythrin secondary antibody (Southern 
Biotech). Cells were finally washed twice and EpCAM expression was assessed. 
Membrane expression was calculated as mean fluorescent intensity and expressed as 
percentage of HT-29 signal. 
In vivo fluorescent imaging 
For NIR fluorescence imaging, mice bearing HT-29 xenografts (n = 4) were co-injected 
with 40 μg 800CW-AMG 110 and 40 μg 680RD-Mec14. Mice undergoing fluorescent 
imaging were kept on an alfalfa-free diet to minimize autofluorescence. Imaging was 
performed at 0.5, 1, 3, 6 and 24 h after tracer injection, using the IVIS Spectrum (Caliper 
Life Sciences) imaging system. Excitation wavelengths were set at 640 nm for 680RD-
Mec14 and 745 nm for 800CW-AMG 110. Data were analyzed using Living Image 3.2 
software (Caliper Life Sciences). Tumor signal was determined by drawing regions of 
interest around tumor boundaries for both 680RD-Mec14 and 800CW-AMG 110.
Supplementary Results
Labeling and quality control of 89Zr-AMG 110 and 89Zr-Mec14 
AMG 110 and Mec14 were successfully conjugated with N-sucDf-TFP (ratio 1:3) and 
labeled with 89Zr. The retention time for AMG 110 and Mec14 was approximately 17 min. 
89Zr-N-sucDf-TFP, low-molecular-weight impurities and buffer additives eluted around 
25 min on the SE-HPLC (Supplemental Fig 2A). Upon N-sucDf-TFP conjugation and 89Zr 
labeling of AMG 110 and Mec14, SE-HPLC did not show aggregation or fragmentation 
and radiochemical purity was confirmed using trichloroacetic acid precipitation tests 
(respectively 96.8 ± 1.1% and 96.2%; n = 10 and n = 1). 
Conjugation of N-sucDf-TFP to AMG 110 and subsequent labeling with 89Zr resulted in a 
mean IRF of 0.60 ± 0.03 for EpCAM (Supplemental Figs. 2B and 2C; n = 6). Subsequent 
to EpCAM binding, 89Zr-AMG 110 showed minimal internalization by HT-29 cells at 37°C 
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Fluorescent labels are well suited as tracers for cancer drug monitoring. Identifying 
cellular target regions of these drugs with a high resolution is important to assess the 
working principle of a drug. In this study, we investigate the applications of label-free non-
resonant four-wave mixing (NR-FWM) microscopy in biological imaging in combination 
with fluorescence imaging of fluorescently-labeled cancer drugs. Results from human 
A431 tumor cells with stained nuclei and incubated with IRdye 800CW labeled cancer 
drug cetuximab targeting EGFR at the cell membrane show that NR-FWM is well suited 
for cellular imaging. A comparison between vibrationally nonresonant FWM imaging 
with vibrational resonant coherent anti-Stokes Raman scattering (CARS) signals revealed 
nearly identical qualitative information in cellular imaging. NR-FWM is also suitable 
for tumor tissue imaging in combination with fluorescence imaging of IRdye 800CW 
labeled, HER2 targeting cancer drug pertuzumab and provides additional information 
over transmission microscopy.
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Introduction
An important step in the development and testing of new targeted cancer drug candidates 
is the acquisition of information about their pharmacological and pharmacodynamic 
action. Targeted cancer drugs are designed to bind to specific biomolecules, involved 
in carcinogenesis and tumor growth, such as membrane proteins or ligands, for their 
effectiveness. To assess their effectiveness, the identification of target regions within a 
tumor with a high, subcellular resolution is a key aspect. 
Monoclonal antibodies (mAb), such as cetuximab and trastuzumab, are currently used 
as targeted cancer drugs (1). Cetuximab and trastuzumab are targeted to, respectively, 
the extracellular domain of human epidermal growth factor receptor (EGFR) and the 
human epidermal growth factor 2 (HER2) receptor at the cell membrane. Both EGFR 
and HER2 are implicated in regulating cell growth and proliferation and are frequently 
overexpressed, mutated or dysregulated in certain cancer types. mAbs with their high 
affinity, are suitable candidates for treatment, or when radioactively or fluorescently 
labeled, as tracer for tumors expressing these targets (2-4). 
One of the strategies to use a mAb as an imaging tracer for tumors is the labeling of 
the antibody with a fluorescent dye. Studies involving the above mentioned mAbs use 
IRdye 800CW for antibody labeling (4). The use of a dye with absorption and emission 
spectra in the 800 nm wavelength region circumvents the influence of autofluorescent 
molecules such as NADH and FAD and other native proteins, since these emit no red-
shifted autofluorescence in this wavelength region (5). Also, because IRdye 800CW 
absorbs and emits in the optical window of tissue, the loss of excitation light and 
fluorescence emission due to absorption and scattering by tissue is minimal (6). IRDye 
800CW has been tested for toxicity and approved by the FDA for human use (7). This 
combination of properties makes this particular dye optimal for fluorescence imaging 
in vivo (8).
Detection of drugs has been investigated extensively both in vivo and in model systems 
to assess the distribution of the drug in both healthy organs and malignant tumor tissue 
and to localize the binding targets of the cancer drugs. The microscopic localization and 
distribution of cancer drugs is currently mostly investigated using immunohistochemistry 
in combination with Hematoxylin and Eosin (H&E) staining (4,9,10). Simultaneously, 
information about the location of the different cellular components is obtained 
mostly using fluorescent probes targeted to specific cellular components (11). 
Immunohistochemistry has a limited resolution, and the addition of stains to visualize 
for example nuclei or blood vessels enables only selective imaging of the targets of the 
stains but does not provide information about other structures. The effects of addition 
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of stains to a biological system are not always known and could influence the biological 
process under investigation. Although the location of other cell components can be 
determined with a high 3D resolution using multi-photon excitation of stains (12), this 
technique is still limited in the sense that it is only sensitive to cellular structures that can 
be stained. Conventional (linear) microscopy techniques such as bright field and phase 
contrast microscopy are able to provide morphological information about the sample, 
but only with a low resolution in 3D. In contrast, nonlinear optical imaging techniques, 
such as coherent anti-Stokes Raman scattering (CARS), provide a label-free, inherently 
confocal method to image cellular morphology with a high resolution. 
CARS-microscopy is a nonlinear optical technique that is widely applied in biological 
imaging of cells and tissue (13), imaging of pharmaceutical compounds (14) and imaging 
of drug distribution in cells and tissue (15, 16). While most microscopy techniques require 
the addition of contrast agents such as fluorophores, CARS microscopy techniques are 
label-free since they exploit differences in vibrational energy levels between different 
chemicals. When the energy difference between the two input beams, pump 
       
  and 
Stokes,         , is equal to the energy of a molecular vibration, an additional amplitude 
in the anti-Stokes field is generated at frequency                       . Due to the quadratic 
dependence of the CARS signal on the incident pump laser power, the anti-Stokes field 
Figure 1. Energy level diagram of linear fluorescence  A) two-photon excited fluorescence. B) electronic resonant 
FWM. C), electronic nonresonant FWM. D) and vibrational resonant FWM (or CARS). E) The frequency used for 
one- and two-photon excitation is ωex (in red), with corresponding emission frequency ωem (dark red and blue 
in the linear and TPEF energy level diagram respectively). ωp (in purple) and ωs (in orange) are the applied 
pump and Stokes fields in non-resonant four-wave mixing or a CARS experiment and ωas (in green) indicates 
the generated anti-Stokes field.
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is generated mostly in focus. CARS-microscopy thus enables mapping of molecular 
information with a high resolution in x, y and z. A common contribution to the total 
anti-Stokes signal in CARS imaging, however, is the presence of a non-resonant four-
wave mixing (NR-FWM) signal, also referred to as the nonresonant background (17). 
This contribution is dependent on the electronic polarizability only. We will show that 
the vibrationally non-resonant four-wave mixing process is useful for morphological 
imaging and can be combined with molecule specific linear fluorescence imaging of 
IRdye 800CW labeled mAbs cetuximab and pertuzumab. Cetuximab and pertuzumab 
are used to target EGFR and HER2 respectively. We also combine NR-FWM microscopy 
with two-photon excitation fluorescence imaging of Hoechst 33342 or 4',6-diamidino-2-
phenylindole (DAPI) stained nuclei respectively. For this, both cell and xenograft tumor 
tissue samples are used. Figure 1 shows an energy level diagram of the mentioned 
optical processes. Morphological NR-FWM imaging here is based on spatial variations 
in the molecular and electronic density in the sample, and therefore spatial variations 
of the amplitude of the generated anti-Stokes signal. The generated NR-FWM intensity 
is compared with vibrational resonant CARS signals in order to extract insights on the 
advantages and drawbacks of the CARS and NR-FWM imaging modalities. 
Theoretical Background
This section describes the theoretical background of CARS, NR-FWM and the relation 
between the total anti-Stokes signal and the third order nonlinear susceptibility   . 
The total anti-Stokes signal (     ) is related to the third-order susceptibility (    ). The 
susceptibility  is generally described by a vibrational resonant (    ) and a vibrationally 
nonresonant or electronic part (       ) (17): 
                                                                       [Equation 1]
Here the resonant part describes the interaction of the pump and Stokes field with a 
molecule through a coupling with two vibrational energy levels in the electronic ground 
state of a molecule, whereas the non-resonant contribution describes interactions of 
the pump and Stokes field with a molecule through a, often non-resonant, coupling to 
excited electronic states to generate an anti-Stokes photon. In the latter process, no 
vibrational energy level is probed. An anti-Stokes signal is also generated when the 
difference frequency between the pump and probe beams is far from any vibrational 
resonance in the electronic ground state. This off-resonance contribution contributes 
also non-resonant signal to IAS (eq. 1). The spectrum of the interferometric mixing
term                 in equation 1 rapidly changes when 
           
       , i.e. in the
 neighborhood of a vibrational resonance. This spectral response arises from the rapidly 
changing vibrational phase that is associated with the vibrational resonant transition, 
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with respect to the phase of   
     
. Although the processes described by         are usually 
assumed to have a flat phase, resulting in a purely real        , electronic resonant FWM 
may also contribute a phase change to the anti-Stokes signal. Far away from excited state 
electronic resonances, this phase change is mostly small and contributes a constant 
phase, a flat phase, to the total phase in a CARS spectrum.
 
The total generated anti-Stokes intensity depends not only on the material property 
     
, 
but also on the cubic product of intensities of the pump and Stokes beams (18): 
 
                                         
 [Equation 2]
The aim of CARS experiments is commonly to acquire material-specific information by 
probing vibrational resonances. The signal-to-noise ratio of this signal is reduced due 
to the non-resonant contributions to IAS. Therefore, reduction of the NR-FWM signals 
while generating vibrational resonant signals is a major goal in CARS research. Methods 
implemented in CARS microscopy to reduce the non-resonant background are based on 
well-known techniques in CARS spectroscopy and include polarization CARS (19, 20), 
frequency modulated CARS (FM-CARS) (21) or heterodyne CARS (17). These techniques 
improve the signal-to-noise ratio of the CARS signal. Although the removal of the NR-
FWM signals increases the chemical specificity of resonant CARS techniques, the 
vibrationally non-resonant FWM signals could be used to generate contrast in samples. 
Because the vibrationally nonresonant FWM signal contributions are generated by all 
sample components, unlike the resonant contributions, these nonresonant contributions 
can be used to image cellular and tissue structures. 
Some work on NR-FWM-imaging of biological samples has been performed. Mahou 
et al. (22) applied non-resonant four-wave mixing microscopy to image C. Elegans 
worms and zebra fish embryos and showed that spatial variations in        can be used to 
image cells and cell substructures. Comparisons between NR-FWM microscopy, third 
harmonic generation (THG), second harmonic generation (SHG) and two-photon excited 
fluorescence by Mahou et al. (22) showed that each of these techniques has a specific 
advantage: NR-FWM microscopy provides label-free contrast in the sample based on 
spatial variations in      . THG enables label-free imaging of interfaces in the sample due to 
large differences in        at interfaces, but requires higher power than NR-FWM for a 250 fs 
pulse duration. SHG and TPEF can be used for (label-free) molecule-specific imaging.
Min et al. (23) applied NR-FWM microscopy with a small difference in wavelength 
between pump and Stokes beams (near-degenerate NR-FWM) to image live A549 human 
non-small cell lung cancer cells and muscle and brain tissue morphology. Min et al. (23) 
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use near-degenerate electronic resonant FWM microscopy to image absorbing but non-
fluorescent molecules by tuning the pump wavelength to match the absorption band of 
the molecule. Potma et al. (17) showed that the non-resonant FWM intensity produced 
at different locations in a single NIH-3T3 mouse fibroblast cell can be used to generate 
contrast in the cell. The recorded NR-FWM image of a single NIH-3T3 cell shows the cell 
membrane and the nucleus and the overall morphology.
Materials and Methods
Sample Preparation
Cetuximab (Erbitux®, Merck KgaA) and pertuzumab (Perjeta®, Roche) are buffer 
exchanged into 0.9% NaCl using Vivaspin 2 ultracentrifuge concentrators (GE Healthcare). 
After pH is set to 9.0 with 0.2 M sodium carbonate, IRDye 800CW-NHS ester in DMSO 
at 5 mg/mL (Licor Biosciences) is added in a 1:3 (cetuximab) and 1:2 (pertuzumab) 
molar ratio of antibody to IRDye 800CW-NHS and incubated during 1 hour at 20°C. 
Purification of antibody-dye conjugates from unreacted dye is performed using PD10 
desalting columns (GE Healthcare). Final concentration, purity and labeling efficacy are 
analyzed using Size-Exclusion High Performance Liquid Chromatography (SE-HPLC) with 
absorbance detection wavelengths at 220, 280 and 780nm. Cetuximab-IRDye 800CW 
yielded 2.6 dye-molecules/mAb, whereas pertuzumab-IRDye 800CW yielded 1.7 dye-
molecules/mAb, both products were over 95% pure. Cetuximab-IRdye 800CW is used 
for single cell imaging and pertuzumab-IRdye 800CW is used for the breast cancer 
model (vide infra). Because the mass ratio between a single antibody and a single IRdye 
800cw molecule is roughly 150 kDa to 1 kDa, the obtained labeling ratio for Cetuximab 
and Pertuzumab antibodies has only a small effect on the total weight of the original 
antibody. Also, as the antigen binding site of the antibodies is very small compared to 
the total antibody, it is unlikely that the antigen binding site is occupied by one or more 
IRdye 800cw molecules at the mentioned labeling ratios.
Cellular imaging is performed using the EGFR-overexpressing human squamous cell 
carcinoma cell line A431. A431 cells are cultured in Dulbecco’s Modified Eagles Medium 
(DMEM) with high glucose supplemented with 10% fetal bovine serum (FBS). Cetuximab-
IRdye 800CW is added to the cells at a concentration of 20 μg/mL, which amounts to 10 
μg for a 2 cm2 monolayer of cells. This results in 4.1 * 1013 antibody molecules per 
120,000 cells. The incubation time is 30 minutes at 37 °C. The cells are fixed in a 4% 
paraformaldehyde solution in PBS for 15 minutes. Nuclei are stained by a 0.1 μg/mL 
Hoechst H33342 solution during 20 minutes incubation. 
All animal experiments are approved by the Institutional Animal Care and Use Committee 
of the University of Groningen. For tissue imaging, male Balb/C nude mice (BALB/
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cOlaHsd-Foxn1nu, Harlan) were used. Xenografts are inoculated subcutaneously using 
HER2 overexpressing SK-BR-3 breast cancer in a 1:1 mixture of PBS and matrigel. When 
tumors measured 100-200 mm3, mice are injected with 100 μg pertuzumab-IRdye 
800CW via the penile vein and sacrificed 6 days post injection. Xenografts are excised 
and fixed in 4% neutral buffered formaldehyde solution, paraffin embedded and slices 
with a thickness of 4 μm are cut. Slices are placed on a cover glass using a warm water 
bath and dried overnight at 60 °C. Subsequently, slices are de-paraffinized and the nuclei 
were stained with DAPI. 
Optical Microscopy
Linear fluorescence, nonlinear fluorescence and CARS microscopy are performed on an 
Olympus IX71 inverted microscope, equipped with a FluoView300 scan unit. A set of 
Galvo mirrors scans the beams over the sample to generate a 2-dimensional image. The 
excitation light is produced by an optical parametric oscillator (OPO, APE Berlin GmbH, 
Germany) pumped by a 22 ps pulsed, frequency doubled Nd:YVO4 1064 nm wavelength 
laser (Coherent Paladin). The narrowband signal output of the OPO is tunable from 
710 nm to 980 nm by changing the crystal temperature and a Lyot filter installed in the 
OPO cavity (24). The idler output of the OPO is not used. 
A part of the laser fundamental at 1064 nm beam is directed to the microscope. Before 
it enters the microscope, it is spatially overlapped with the OPO signal beam using a 
dichroic mirror, and temporally overlapped using a delay stage in the 1064 nm beam path. 
The signal beam and fundamental beam are used as pump and Stokes beam respectively 
for the generation of CARS and NR-FWM signals. For vibrational resonant CARS images 
the frequency difference between the signal and 1064 nm beam is set to match the CH2-
stretch vibrations at 2845 cm-1. For NR-FWM imaging, the frequency difference is set to 
2698 cm-1, within the silent region for Raman spectroscopy (25). At this frequency, the 
anti-Stokes signal contains no vibrational resonant contributions from biomolecules. The 
wavelength of the anti-Stokes signal was 676 nm for a difference of 2698 cm-1 between 
the pump and Stokes beam. The frequency of 2698 cm-1 was selected to optimize for 
the wavelength-dependent transmission efficiency of the setup in combination with the 
available optical filters as well as the wavelength-dependent detection efficiency of the 
photodetector. For SHG, only the 1064 nm beam is used.
For clarification, an overview of the different modalities with corresponding excitation 
wavelengths is shown in Fig. 2. Figure 2 also shows a measured averaged background-free 
spontaneous Stokes Raman spectrum of an A431 cell. The spontaneous Raman spectrum 
was measured on a different microscope described elsewhere (26), using a 647.1 nm 
continuous wave laser and a home built spectrometer. This spectrum was measured at 
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the Stokes side, but plotted at the anti-Stokes side of the pump beam (indicated by the 
magenta arrow labeled ωp) used in the CARS modality at 2845 cm
-1. In this figure, the 
spectral locations of the imaging modalities NR-FWM, CARS, TPEF and linear fluorescence 
explained in Fig. 1 are shown using corresponding color coding. The IRdye 800CW 
excitation beam is shown in red at 770 nm (ω
ex
), with corresponding emission at 800 nm 
in dark red (ωem). The two-photon excitation modality used to excite Hoechst 33342 and 
DAPI is indicated by the two red arrows at 385 nm wavelength, representing the two 770 
nm photons involved. The corresponding Hoechst 33342 emission is represented by the 
blue arrow at 400 nm (ωem). From the spontaneous Raman spectrum it can be seen that 
CARS at 2845 cm-1 (green solid, ωas) is measured at resonance in the CH-stretch region 
and that the NR-FWM at 2698 cm-1 (green dashed, ωas) is measured off-resonance. Note 
that the 2845 cm-1 peak is relatively small compared to the total intensity in the CH-
stretch region. This could be different in CARS experiments, since the signals in CARS 
experiments are generated coherently. The NR-FWM anti-Stokes signal at 2698 cm-1 is 
represented by a dashed line. In our experiments, the wavelength of the pump beam is 
tuned, such that only the wavenumber axis represents the NR-FWM modality correctly. 
The Stokes beam, at 1064 nm, is shown at the Stokes side of the pump beam in orange 
(ωs). For excitation of the IRdye 800CW fluorophore the signal beam is tuned to 770 nm. 
A power of 40 µW was used. For two-photon excited fluorescence of Hoechst 33342 
and DAPI, the power of the signal beam at 770 nm was increased to 50 mW. Resonant 
CARS and FWM images were recorded at excitation powers of 50 mW and 95 mW for the 
signal beam and 1064 nm Stokes beam respectively. 
Figure 2. Spontaneous Stokes 
Raman spectrum plotted at the 
anti-Stokes side of the pump 
beam at 0 cm-1. The Raman 
spectrum is divided in the CH-
stretch region (-3200 to -2500 
cm-1) and the fingerprint region 
(-1800 to 0 cm-1). The imaging 
modalities are also indicated in 
this figure at the corresponding 
wavelength with respect to the 
Raman spectrum. The location of 
the different excitation beams and 
the detected signals as shown in 
Fig. 1 are overlaid on the Raman 
spectrum. The detected signals 
are the vibrational nonresonant 
FWM signal at 2698 cm-1 (dashed 
green, ωas), vibrational resonant 
CARS (solid green, ωas), Hoechst 
TPEF emission (blue, ωem) and 
IRdye 800CW fluorescence 
emission (dark red, ωem).
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Both beams are focused on the sample using a 60 x 1.2 NA Olympus water immersion 
objective (UPLANSAPO IR, Olympus). IRdye 800cw, Hoechst 33342 and DAPI fluorescence 
are collected using the 1.2 NA objective and detected with a photomultiplier tube (PMT, 
Hamamatsu, R3896) in backward detection mode. Vibrational resonant CARS and the 
NR-FWM signals are detected in the forward direction using a 0.55 NA condenser. 
Appropriate filters were placed in front of the PMT (Hamamatsu, R3896) to reject the 
pump and Stokes beams. Images are recorded with a pixel dwell time of 10 microseconds 
and typically 3 averages. Nyquist sampling criteria are satisfied for the one-photon and 
multi-photon imaging modalities. Transmission images were recorded by detecting the 
transmitted intensity of the pump beam at 770 nm while the beam scans over the cell, 
using a fiber coupled to a photomultiplier tube. All images were corrected for the spatial 
variations in collection efficiency of the generated signals. This was done by measuring 
the CARS signal of a droplet of DMSO, which is expected to generate a homogeneous 
CARS intensity in the field of view. Any non-homogeneous intensities in the image 
correspond to spatial variations in collection efficiencies. This signal has been used for 
correction of the images.
Results and Discussion
Cellular Imaging
In Fig. 3C a laser light transmission image is shown of a single, DAPI-stained, A431 
cell incubated with cetuximab-IRdye 800CW. Figure 3A shows the corresponding 
fluorescence emission image of cetuximab-IRdye 800CW. Figure 3B shows a two-photon 
excited fluorescence image of Hoechst 33342, indicating the location of the cell nucleus 
with an inherently confocal resolution. The image size is 78 x 78 μm consisting of 
1024 x 1024 pixels. All images are recorded at the same z-position of the objective and 
the same field of view.
The transmission and Hoechst 33342 images provide information about cellular 
morphology, whereas the fluorescence image provides information about the location 
of the cancer drug cetuximab with high selectivity. The combination of images suggests 
that the fluorescently-labeled cetuximab is present mainly at the cell membrane, as 
expected; the shape of the fluorescence emission completely surrounds the nucleus in 
the 2-dimensional image plane. Some fluorescence intensity can be seen from the distal 
ends of the cell or from intracellular regions. By comparing the fluorescence emission 
image (Fig. 3A) with the transmission image (Fig. 3C), the fluorescence emission appears 
to co-localize with the cell membrane. Because the signals recorded in the transmission 
and linear fluorescence image also contain contributions from out of focus regions in the 
cell, it is difficult to determine the exact location of the fluorescence emission image with 
respect to the cell membrane and other cellular components. Both discussed methods, 
Hoechst staining and transmission microscopy, have their limitations in the sense that 
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only information is obtained about the location of a certain cellular compound (nucleus 
stained with Hoechst 33342) or that the depth resolution is relatively low (transmission 
image).
In Fig. 3, the one- and two-photon fluorescence modalities are combined with the 
nonlinear label-free optical imaging modalities CARS- and NR-FWM-microscopy in 
Fig. 3D and 3E respectively. Figure 3D shows a CARS image at 2845 cm-1, probing the 
CH2 stretching vibrations, predominantly present in lipids (27). This image shows the 
Figure 3. Multimodal images of fixed A431 cells, incubated with cetuximab-IRdye 800CW and stained with 
Hoechst 33342. The images show the IRdye 800CW fluorescence emission image: A) Hoechst 33342 TPEF 
image B), laser transmission image C), CARS image at 2845 cm-1 D) and NR-FWM image at 2698 cm-1 E). The 
size of the scale bar shown in C is 5 μm (relevant for all panels A-E). The intensity profile plot of the white line 
in A, D and E is shown in F. The black line shows the average background intensity. The arrows in D indicate the 
lipid droplets (LD) that were used for quantitative analysis in Table 1.
Table 1. Signal to noise ratio calculated for several lipid droplets (shown in 
Fig. 3) and cytoplasm regions (not shown in Fig. 3)
Signal to noise ratio in CARS image 
(mean ± standard deviation)
Signal to noise ratio in NR-FWM image 
(mean ± standard deviation)
Lipid droplet 1 19.89 ± 2.45 13.25 ± 2.30
Lipid droplet 2 28.20 ± 5.80 16.30 ± 2.28
Lipid droplet 3 14.74 ± 2.73 9.40 ± 2.20
Cell cytoplasm region 1 10.01 ± 1.43 8.00 ± 1.13
Cell cytoplasm region 2 15.73 ± 2.07 12.65 ± 1.62
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vibrationally resonant anti-Stokes signals arising from lipid structures in the A431 cells 
on top of the vibrationally non-resonant four-wave mixing signals that are also present at 
this vibrational frequency. An image of the same cell far from vibrational resonances was 
recorded at 2698 cm-1 (Fig. 3E), to compare qualitatively the differences and similarities 
between the image at resonance 2845 cm-1 (Fig. 3D) and an off-resonance image. It 
can be observed from a comparison between Fig. 3D and E that the vibrationally non-
resonant four-wave mixing contribution dominates the response in the image recorded 
at resonance. A large part of the signal could also arise from the interferometric mixing 
term as stated in equation 1. The interferometric mixing term dominates over the purely 
vibrational resonant term when the non-resonant contributions are large compared to 
the vibrational resonant contributions.
The image in Fig. 3D shows the morphology of the cell. The cell membrane, cell nucleus 
and 2 nucleoli can be identified. The nucleoli are specialized areas in the nucleus, which 
correlate with the dark spots in the Hoechst TPEF emission image in Fig. 3B, as indicated 
by the purple arrows. Lipid droplets produce a large anti-Stokes intensity at 2845 cm-1. 
A large amount of lipid droplets is located in the upper left corner of the cell in Fig. 3D. 
Also in other regions of the cell lipid-rich structures can be identified. The lipid droplets, 
nucleoli and the nucleus can also be identified in the NR-FWM image in Fig. 3E.
Intensity profiles are shown in Fig. 3F. The profiles show the intensity of the IRdye 
800CW fluorescence emission, the CARS and the NR-FWM signals as measured along 
the white line in Fig. 3A, D and E. The colors of the curves in Fig. 3F correspond with the 
lines in the figures marked with identical colors. These profiles are shown to compare 
the signal measured in the off-resonance image with the signal measured in the image 
on resonance. In both the CARS and NR-FWM intensity line profiles, large variations in 
intensity are observed as a function of position in the cell. This can be compared with 
a region outside the cell, where a homogeneous body of PBS generates a uniform anti-
Stokes signal. From this it can be concluded that water inside the cell has a significant 
contribution to the total anti-Stokes signal. Other molecules, such as organic molecules 
inside the cell soma could also contribute to the total CARS signal.
In Fig. 3F two features, a nucleolus and a lipid droplet, are indicated with a star at 11 and 
20 µm respectively in the 2845 cm-1 intensity profile plot. In the 2845 cm-1 profile, the 
lipid droplet signal is higher compared to the (non-resonant) signal generated by water 
than in the 2698 cm-1 profile plot. This indicates the presence of additional mixing term 
or vibrational resonant contributions to the total lipid droplet signal at 2845 cm-1. 
Although the NR-FWM image at 2698 cm-1 is far from any vibrational resonance (Fig. 
2) a high contrast can be observed (Fig. 3E). The contrast in the NR-FWM image arises 
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from a combination of molecular density differences and third-order refractive index 
differences. From the small difference in lipid droplet signal and the almost identical 
intensity profile in the CARS and NR-FWM images we can conclude that the non-
resonant background has significant contributions to the overall anti-Stokes signals at 
2845 cm-1. The vibrational resonant contributions to the signal increase the intensity 
and contrast, but is not necessary for imaging the cellular morphology (see Fig. 3D and 
Fig. 3E). It should be noted that, in general, the ratio between vibrational resonant and 
NR-FWM signals depends on the Raman scattering cross sections, feature sizes and the 
electronic properties of the material. It is apparent that an excellent contrast can be 
obtained with NR-FWM imaging of cells, i.e. without the need to stimulate vibrational 
resonant contributions contained in 
     
. 
Figure 4A shows a combination of the NR-FWM with TPEF and linear fluorescence. This 
figure shows that the fluorescence emission from cetuximab-IRdye 800CW (false color-
coded as red) co-localizes with the cell membrane. Out of focus fluorescence emission 
however limits the axial resolution of the fluorescence image. The axial resolution of 
linear fluorescence is on the order of 2 µm, which is comparable to the average cell 
thickness. The lateral resolution of TPEF is on the order of 500 nm, which enables a 
better localization of the probe volume in the cell. The local minima in the Hoechst 
33342 stained region co-localize with the nucleoli that are also clearly distinguishable 
in the NR-FWM image. Figure 4B shows an image obtained by subtracting the NR-FWM 
image at 2698 cm-1 from the CARS image at 2845 cm-1. In this difference figure, the cell 
shape and lipid droplets can be identified. It can be seen here that the advantage of CARS 
imaging over NR-FWM imaging is mainly its suitability for molecule-specific imaging in 
this particular example. 
Figure 5 shows a CARS (5A) and NR-FWM (5B) mixing image of a single A431 cell. The 
cellular morphology can be identified in both images. In the line profile plot in Fig 5C it 
can be seen that the lipid droplets generate more signal in the CARS image, as is also 
shown in Fig. 4B. 
Figure 4. Overlay image of 
cetuximab-IRdye 800CW 
fluorescence emission, Hoechst 
33342 TPEF fluorescence emission 
and non-resonant four-wave 
mixing image at 2698 cm-1 (A) and 
difference figure NR-FWM at 2698 
cm-1 subtracted from CARS image 
at 2845 cm-1 (B).
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For a quantitative comparison between the CARS and NR-FWM signals, the signal-to-
noise ratio (SNR) is calculated for several regions in the cell shown in Fig. 3 and Fig. 5. The 
SNR is calculated according to Eq. 3:
                                                          [Equation 3]
Table 1 shows the SNR for three lipid droplets indicated in Fig. 3 and for two different 
regions of the cell cytoplasm in both the CARS and NR-FWM image. Table 2 shows 
the SNR for three lipid droplets indicated in Fig. 5 and also for two different regions 
of the cell cytoplasm. In these two tables it is shown that the SNR of the lipid droplets 
is approximately twice as large in the CARS image compared to the NR-FWM image. 
The SNR of the cell cytoplasm is only slightly larger in the CARS image compared to 
the NR-FWM image. Here the SNR in the CARS image only increases by a factor 1.2 
approximately compared to the NR-FWM image.
The molecular properties of IRdye 800CW and the chosen excitation field frequencies 




Figure 5. CARS (A) and NR-FWM (B) image of a single A431 cell, recorded at 2845 cm-1 and 2698 cm-1 
respectively. The field of view is 23 x 23 µm2. The line profile plots (C) for the CARS and NR-FWM image is shown 
including the black line, indicating the average background intensity. Distance line starts at 0 μm at the left side 
of the image. The arrows in A indicate the lipid droplets (LD) that were used for quantitative analysis in Table 2.
Table 2. Signal to noise ratio calculated for several lipid droplets (shown in 
Fig. 5) and cytoplasm regions (not shown in Fig. 5)
Signal to noise ratio in CARS image 
(mean ± standard deviation)
Signal to noise ratio in NR-FWM image 
(mean ± standard deviation)
Lipid droplet 1 14.72 ± 4.14 6.48 ± 0.61
Lipid droplet 2 12.65 ± 3.05 6.40 ± 1.21
Lipid droplet 3 14.30 ± 3.87 6.58 ± 0.83
Cell cytoplasm region 1 5.67 ± 1.17 4.88 ± 0.85
Cell cytoplasm region 2 5.73 ± 0.91 5.11 ± 0.72
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Figure 6. Multimodal images of tumor slices obtained from a mouse bearing human breast cancer SK-BR-3 
xenograft tumor, injected with pertuzumab-IRdye 800CW. The images show: distribution of pertuzumab-IRdye 
800CW (A), DAPI stained cell nuclei (B), tumor morphology using CARS (C) at 2845 cm-1, tumor morphology 
using NR-FWM at 2698 cm-1 (D), transmission image of tumor section (E), collagen distribution using second 
harmonic generation (F), overlay of pertuzumab and DAPI image, showing the distribution of pertuzumab with 
respect to the cell nuclei (G) and overlay of collagen SHG and NR-FWM image (H). The size of the scale bar in 
panel 6E is 10 μm and is relevant for all panels 6A – 6H. The image size is 78 x 78 μm and consists of 1024 x  
1024 pixels. The lines in 6C and 6D indicate the region used for the profile plot in Fig 7.
images. This photodamage is a result of the relatively high excitation power required for 
the latter three modalities. Consequentially, first the image of the linear fluorescence of 
IRdye 800CW was acquired and only then the non-linear imaging modes were carried 
out.
Tumor Tissue Imaging
Non-linear imaging in combination with imaging of fluorescence-labeled cancer drugs 
was also applied to tumor tissue. Tumor tissue was imaged by collecting the single-
photon excited fluorescence from pertuzumab-IRdye 800CW, TPEF of Hoechst, CARS at 
2845 cm-1 and NR-FWM at 2698 cm-1. The tumor tissue was derived from an inoculated 
human breast cancer cell line SK-BR-3, which overexpresses HER2, xenografted in a 
mouse that was injected with the anti-HER2 antibody pertuzumab-IRdye 800CW.
Figure 6 shows the result of multimodal imaging of slices of tissue from the tumor 
xenograft, recorded at the same position in the sample. The distribution of pertuzumab-
IRdye 800CW in the SK-BR-3 tumor is visualized in Fig. 6A. Clearly, pertuzumab-IRdye 
800CW is non-uniformly distributed in this tumor section and in individual cells. The 
location of the cell nuclei is subsequently visualized in the DAPI TPEF image in Fig. 6B. 
The CARS image and the NR-FWM image in Fig. 6C and 6D show the morphology of the 
tumor tissue based on spatial variations in    . In both these figures, cell nuclei can be 
identified. Also in tissue sections, the nucleoli can be discriminated from surrounding 
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nuclear components. Contrast between lipid-rich regions and tumor cells in the tumor 
section is clearly visible in both CARS and NR-FWM images. In the IRdye 800CW and 
DAPI overlay image in Fig. 6G, the fluorescence emission shows the location of the 
cytoplasmic membrane of cells within the tumor. The fluorescence emission co-localizes 
with the boundary of some tumor cells that can be identified in the NR-FWM and CARS 
images (indicated with the green arrows in Fig 6). This implies that the membrane has 
been stained, which is expected, because pertuzumab binds to receptor molecules on 
the cell membrane. Some nuclei can be identified in Fig. 6G that are not surrounded by 
a IRdye 800CW stained cytoplasmic membrane. These nuclei are smaller and differently 
shaped compared to the nuclei surrounded by an IRdye 800cw stained membrane. 
These cells could be native mouse cells present in the tumor. Also, the fact that the 
IRdye 800CW positive cells are grouped together and that the cells without a membrane 
stain are located outside of this region suggests that non-stained cells are native mouse 
cells. However, washing steps in the de-paraffinization step could also result in loss of 
fluorescent tracer from parts of the tumor tissue slice. Furthermore, lack of fluorescence 
could be due to necrosis in parts of the xenograft or represent residual pockets of 
Matrigel used in the xenografting of SK-BR-3 cells.
NR-FWM and CARS microscopy both provide significantly better contrast in this tumor 
sample than transmission microscopy, as can be seen from a comparison of the laser 
light transmission Fig. 6E with the NR-FWM and CARS images (6C and D). Especially 
due to the thickness (4 µm) of this tumor slice, NR-FWM and CARS are more suitable 
techniques for morphological imaging of this sample than transmission imaging. This 
is because the detected signal in CARS or NR-FWM is generated in a small confocal-like 
spot, whereas the transmission beam is affected by out of focus regions in the sample. 
Comparing the CARS and NR-FWM images and the corresponding line profile plots in 
Fig. 7, differences in relative intensities are observed. Both techniques provide label-free 
contrast in cellular and tissue imaging, where the vibrational resonant part in the CARS 
Figure 7. Intensity profile plot of the blue 
(CARS image) and green (NR-FWM image) 
line in figure 6. Distance line starts at 0 μm at 
the left side of the image.
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images provides additional chemical specific contrast. The distribution of collagen in the 
tumor is shown in Fig. 6F, using second harmonic generation (SHG) and overlaid with the 
NR-FWM image (6H). 
The suitability of NR-FWM imaging was demonstrated both in cells incubated with 
cetuximab-IRdye 800CW as well as in tumor xenograft tissue from animals injected with 
pertuzumab-IRdye800CW respectively. Both cancer drugs show a membrane staining, 
as expected. In tumor tissue, where also other components beside cells are present, NR-
FWM imaging is very suitable for morphological imaging.
Conclusion
We have demonstrated the potential of a multimodal microscopy combination of 
linear NIR fluorescence imaging with NR-FWM imaging to investigate the distribution 
of tumor-targeting drugs such as cetuximab and pertuzumab in cells and tissues. We 
have compared CARS imaging with non-resonant four-wave mixing (NR-FWM) imaging 
and have found that NR-FWM is an excellent approach to label-free cellular and tissue 
morphological imaging. The contrast in NR-FWM is based on spatial differences in 
    
, 
which is of the similar quality as vibrational resonant CARS. It can be concluded that 
the vibrational resonant contribution to the total anti-Stokes signal is not essential to 
provide high contrast images based on general total 
     
.
From comparing CARS and NR-FWM quantitatively, it can be concluded that small lipid 
droplets inside cells provide approximately a twofold signal-to-noise ratio compared to 
NR-FWM. The contrast in regions of the cell that contains mostly cytoplasm and without 
clearly visible organelles shows minor differences between CARS and NR-FWM images.
By creating a hybrid microscope system that integrates linear fluorescence, two-photon 
excited fluorescence, second harmonic generation, laser light transmission imaging 
and coherent anti-Stokes Raman scattering and non-resonant four wave mixing, it is 
possible to selectively image fluorescently labeled cancer drugs and obtain morphology 
information about target location of the drugs in the cell or tumor tissue. 
For future work, a combination of NR-FWM with confocal linear fluorescence will 
provide a better resolution for fluorescence imaging and could be used for numerous 
applications in biological imaging, including resolving the sub-cellular distribution of 
fluorescently labeled drugs in axial and lateral direction.
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Curative solid cancer treatment often consists of surgery to remove the tumor, combined 
with radiation therapy and systemic therapy. When systemic treatment fails this is often 
due to development of resistance of the tumor to treatment. Currently, treatment 
approaches are expanding. Insight into characteristics on which cancers rely for growth 
and metastasis have resulted in identification of multiple ‘hallmarks of cancer’ and 
distinct molecular subtypes of many cancers. This has led to a plethora of tumor therapies 
targeting specific tumor characteristics (1,2). Immunotherapeutics belong to another 
emerging drug class, which exerts its action through modulation of the immune system, 
engineered T-cells or by inhibiting tumor-mediated immune suppression. Promising, 
durable responses to immunotherapeutics have been observed in a number of tumor 
types (3).
The human epidermal growth factor receptor (HER) family belongs among the growth 
factor receptors found aberrant in human cancers, and consists of epidermal growth 
factor receptor (EGFR), HER2, HER3 and HER4. Furthermore, abnormal activation of the 
tyrosine kinase receptor c-MET and its ligand hepatocyte growth factor (HGF) are found 
causative for many solid cancers. Dysregulation of these growth factor receptors lead to 
cancer hallmarks such as increased cell survival, proliferation, angiogenesis, metastasis 
and invasion (4,5). HER proteins and c-MET form intricate interlinked pathways, 
through shared downstream proteins. Targeted treatment directed against one of these 
receptors can therefore result in treatment resistance via compensatory upregulation, 
amplification or mutation of another receptor or downstream proteins to take over the 
proliferative drive. Another cancer characteristic commonly found overexpressed in 
many forms of human cancers is transmembrane glycoprotein epithelial cell adhesion 
molecule (EpCAM), which was shown to have a functional role in tumor proliferation, 
invasion and migration (6). 
Molecular imaging is an attractive tool to non-invasively assess whole-body target 
expression, biodistribution, tumor delivery and accessibility of targeted therapies and 
immunotherapeutics. Molecular imaging allows for non-invasive in vivo measurement 
of molecular characteristics, either through radionuclide-based single photon emission 
computed tomography (SPECT) and positron emission tomography (PET), nuclear 
magnetic resonance for magnetic resonance imaging (MRI), or by employing endogenous 
molecules and dyes for optical imaging. Therapeutic biomolecules such as antibodies and 
antibody fragments can be used as tracers after modification with a dye or radioactive 
isotope, allowing study of organ distribution, pharmacokinetics, pharmacodynamics 
and tumor targeting. PET provides inherent three-dimensional whole body uptake data 
of lesions over time. Longitudinal studies involving multiple PET scans can therefore 
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provide information regarding tumor marker plasticity in response to therapy (7). In 
order to label highly marker-specific antibodies for use as PET tracer, radioisotopes such 
as zirconium-89 (89Zr) can be employed (8). 89Zr is particularly well suited for imaging 
large biomolecules as its physical half-life of 3.27 days matches the biological half-life 
of antibodies. IRDye 800CW fluorescently labeled antibodies on the other hand, can be 
employed for optical techniques such as fluorescence imaging. Advantages of fluorescent 
tracers comprise of the possibility to study drug intra-organ distribution in high resolution 
from the macroscopic, down to microscopic scale, without radiation burden. Drawbacks 
of conventional fluorescence imaging are limited signal penetration, lack of whole body 
imaging capabilities and three-dimensional information. Novel optoacoustic imaging 
techniques negate part of these drawbacks, as signal contains spatial information and 
signal penetration is greatly enhanced compared to standard fluorescence techniques, 
allowing to study fluorescent tracer biodistribution in more detail. 
The research described in this thesis was performed to develop new 89Zr and IRDye 
800CW-labeled antibodies and antibody fragments for PET and optical imaging 
techniques to evaluate drug tumor targeting, organ distribution as well as treatment-
induced changes in target dynamics. 
Chapter 1 provides a brief description of the background and outline of this thesis. 
Chapter 2 comprises a literature search, following which we reviewed how molecular 
imaging techniques can potentially facilitate optimal implementation of molecular 
targeted agents in cancer, using the human epidermal growth factor receptor family 
as a model. Among topics discussed were how molecular imaging strategies can be 
employed to characterize target expression in lesion, monitor drug effectiveness and 
detect emergence of treatment resistance. Furthermore, an integrative omics discovery 
platform was described to unveil ‘effect sensors’, new molecular imaging targets, which 
are critical and informative markers for treatment effectiveness or resistance. Currently, 
a great arsenal of molecular probes is available to image human epidermal growth factor 
receptor family members and related proteins, but these are not always indicative for 
treatment response. Therefore, we argued that a rational and unbiased omics-based 
discovery platform approach should be employed to discover effect sensors, indicating 
treatment efficacy and resistance.
The preclinical studies presented in this thesis were performed using 89Zr and IRDye 
800CW labeled antibodies and antibody-based fragments for PET and near-infrared 
fluorescence imaging respectively. 89Zr-labeled antibodies were used to assess target 
expression, influence of circulating antigen, tissue distribution, as well as response and 
156
CHAPTER 8
resistance to targeted therapies in vivo in chapters 3, 4, 5 and 6. A near-infrared dye 
IRDye 800CW labeled antibody fragment was furthermore employed to study in vivo 
fluorescence imaging for in vivo tumor targeting and ex vivo macro- and microscopic 
intratumoral drug distribution in chapter 6, while in chapter 7, an IRDye 800CW-labeled 
fluorescent antibody probe was used in a novel microscopic method. 
Preclinical EGFR imaging using radiolabeled monoclonal antibodies (mAbs) have revealed 
a mismatch between in vivo EGFR expression and tumor tracer uptake. Shedding of 
extracellular domain can influence the biodistribution of antibody-based tracers. 
Soluble EGFR extracellular domain (sEGFR) is found in the blood of cancer patients and 
healthy volunteers and could potentially influence kinetics of an EGFR antibody tracer. In 
chapter 3 we explored whether sEGFR could influence the kinetics and tumor targeting 
of EGFR antibody-based PET tracer 89Zr-imgatuzumab. To investigate the effects of 
circulating sEGFR on tracer kinetics, protein dose of 89Zr-imgatuzumab was escalated 
in mice bearing three different EGFR-expressing human tumor xenografts, A431 (EGFR 
overexpressing, epidermoid), A549 and H441 (both EGFR medium expressing, non-
small cell lung cancer (NSCLC)). 89Zr-imgatuzumab uptake in A431 tumors was highest at 
29.8 ± 5.4 percentage injected dose per gram tissue (%ID/g) in the 160 μg dose group. 
Contrary, highest uptake in A549 and H441 tumors was found at the lowest (10 μg) 
89Zr-imgatuzumab dose. High 89Zr-imgatuzumab liver accumulation was found in A431 
xenografted mice, which decreased with antibody dose increments. 89Zr-imgatuzumab 
liver uptake in A549 and H441 xenografted mice was low at all doses. sEGFR levels in 
liver and plasma of A431 bearing mice were up to 1000-fold higher than levels found 
in A549, H441 and non-tumor xenografted mice. 89Zr-imgatuzumab could effectively 
visualizes EGFR-expressing tumors. High sEGFR levels redirected 89Zr-imgatuzumab to the 
liver, in which case tumor visualization could be improved by increasing tracer antibody 
dose.  
Treating HER2-driven breast cancer with the EGFR/HER2-targeting tyrosine kinase 
inhibitor (TKI) lapatinib can lead to a rapid compensatory increase in expression, signaling 
activity and relocalization of HER3 to the plasma membrane. Immunohistochemistry 
showed increased HER3 expression in newly diagnosed HER2-overexpressing breast 
cancer patients, 2 weeks after lapatinib treatment initiation, which might attenuate 
antitumor action. In chapter 4, we therefore investigated the potential of dynamic 
assessment of HER3 tumor status using PET, instead of using invasive techniques such 
as repeated biopsies. Treatment effects of lapatinib on in vivo HER3 expression were 
studied using HER3 PET tracer 89Zr-mAb3481. In vitro, lapatinib increased membranous 
HER3, and consequently mAb3481 internalization 1.4-fold and 1.7-fold in SKBR3 
and BT474 respectively. 89Zr-mAb3481 BT474 tumor uptake was remarkably high at a 
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mean standardized uptake value (SUVmean) of 5.6 ± 0.6 (51.8 ± 7.7 %ID/g) using a 10 µg 
89Zr-mAb3481 protein dose in vehicle treated mice. However, when compared to vehicle, 
both 25 and 50 mg/kg lapatinib did not affect 89Zr-mAb3481 ex vivo biodistribution and 
PET uptake in BT474 tumors, and ex vivo HER3 tumor expression remained unchanged. 
In conclusion, lapatinib increased in vitro HER3 tumor cell expression, but not when 
these cells were xenografted. 89Zr-mAb3481 PET accurately reflected HER3 tumor status. 
89Zr-mAb3481 PET showed high, HER3-specific tumor uptake and such an approach 
might be of interest to sensitively assess HER3 tumor heterogeneity and treatment 
response in patients. 
Dynamic changes in c-MET expression of tumors occur and could indicate drug efficacy 
of inhibitors or emergence of resistance towards EGFR tyrosine kinase inhibitors (9). 
Non-invasive visualization of c-MET expression dynamics could therefore potentially 
guide the use of c-MET directed therapies. In Chapter 5a we investigated the suitability 
of c-MET antibody PET tracer 89Zr-onartuzumab to detect c-MET dynamics in response to 
EGFR TKI resistance and to HSP90 inhibition in human EGFR mutant NSCLC xenografts. In 
vitro, membranous c-MET was 69 ± 9% downregulated by NVP-AUY-922, while c-MET was 
213 ± 44% upregulated in HCC827ErlRes compared to HCC827. c-MET PET revealed 33% 
(P<0.001) lower tumor uptake post NVP-AUY-922 treatment, while erlotinib-resistant 
HCC827ErlRes 89Zr-onartuzumab uptake was 26% higher than in HCC827 xenografts. 
89Zr-onartuzumab PET effectively discriminates relevant c-MET level changes, illustrated 
by HSP90 inhibition leading to downregulation and erlotinib resistance-mediated 
upregulation in NSCLC xenografts, and can potentially be clinically applied to monitor 
c-MET status.
In Chapter 5b the potential clinical applications of and developments in c-MET-targeted 
PET and optical imaging tracers in breast cancer and other malignancies is discussed. We 
suggested that pretreatment c-MET PET scans as a noninvasive accompanying biomarker 
might enrich the patient population that might benefit from c-MET/HGF–targeted drugs, 
by providing insight in whole-body c-MET target distribution. c-MET fluorescent tracers 
on the other hand could be part of a multispectral optoacoustic imaging screening with 
a tracer cocktail against often-expressed breast cancer targets. 
Recently, understanding of the mechanisms used by cancers to escape immune 
responses has led to multiple new immune-based cancer treatment strategies. One of 
such strategies is the bispecific T cell engager (BiTE) antibody construct platform. BiTe 
constructs consist of a variable arm recognizing a tumor-specific marker, and another 
binding cluster of differentiation 3 (CD3) on cytotoxic T-cells, to elicit polyclonal T-cell 
responses to target-expressing tumor cells (6). Chapter 6 details our study towards the 
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tumor targeting and tissue distribution of 89Zr and IRDye 800CW labeled BiTe AMG 110, 
directed against EpCAM on tumor cells, and CD3 on T-cells. Tumor uptake of 89Zr-AMG 110 
could be clearly visualized using small-animal PET imaging up to 72 h after injection. 
Highest tumor 89Zr-AMG 110 uptake was observed at 6 and 24 h for the 40 μg protein 
dose level, at respectively 5.35 ± 0.22 and 5.30 ± 0.20 % ID/g. 89Zr-AMG 110 tumor uptake 
was EpCAM-specific and correlated with EpCAM expression. IRDye 800CW-AMG 110 
accumulated at the tumor cell surface in viable EpCAM-expressing tumor tissue. PET and 
fluorescent imaging provided real-time information about AMG 110 distribution and 
tumor uptake in vivo. These data support using 89Zr and IRDye 800CW labeled bispecific 
T cell engager antibody constructs to evaluate tumor and tissue uptake kinetics in 
preclinical and clinical settings.
In chapter 7 we reported the applications of label-free non-resonant four-wave mixing 
(NR-FWM) microscopy in combination with fluorescence imaging of IRDye 800CW 
labeled cetuximab and pertuzumab targeting EGFR and HER2 respectively. Microscopy 
analysis was performed in vitro on human cancer cells and on ex vivo xenograft tumor 
tissues. In this chapter a comparison was made between vibrational NR-FWM imaging 
and vibrational resonant coherent anti-Stokes Raman scattering signal. Furthermore, 
suitability of NR-FWM tumor tissue imaging in combination with fluorescence imaging 
of IRDye 800CW-labed tracers was explored. A comparison of vibrational non-resonant 
FWM imaging with vibrational resonant coherent anti-Stokes Raman scattering signals 
revealed nearly identical qualitative information in cellular imaging. NR-FWM is also 
suitable for tumor tissue imaging in combination with fluorescence imaging of IRDye 
800CW-pertuzumab and provides additional information over transmission microscopy.
In conclusion this thesis describes the development of new fluorescent and PET imaging 
tracers to assess tumor targeting and tracer distribution, as well as the application of PET 
tracers to monitor tumor status following targeted therapies.
Discussion and future perspectives
Most commonly used molecular imaging probes used in oncology practice target general 
tumor processes such as tracking glucose metabolism with 18F-fluorodeoxyglucose 
(18F-FDG) and 18F-3’-fluoro-3’-deoxy-L-thymidine (18F-FLT) incorporation in DNA 
synthesis. Molecular imaging capabilities have vastly expanded with the introduction 
of immunoPET, which allows highly specific antibodies and other protein scaffolds to 
be employed as tracers for cancer markers. Many new cancer therapies and candidates 
are largely protein or antibody-based. Furthermore, tailor-made antibodies or other 
protein scaffolds with high target-specificity can be raised against antigens of interest 
with relative ease. These drugs and tailor-made molecules can thus form the basis of 
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tracer molecules for molecular imaging of their respective antigens. Tracers based upon 
clinical candidate molecules have the further advantage of ease of clinical translation 
and can aid drug development.
Molecular imaging has the potential of expanding our knowledge of whole-body target 
expression, biodistribution, tumor delivery and accessibility for large protein-based 
targeted cancer therapies. Small scale clinical studies can yield precious information on 
tumor targeting, target heterogeneity and antibody kinetics. Molecular imaging might 
additionally be used to predict marker-dependent deposition of marker-directed toxic 
payloads, such as ADCs. Imaging strategies might furthermore be employed to rationally 
design combination therapy strategies for improved deposition of such toxic payloads 
to lesions. Among recently published trials employing immunoPET are 89Zr-trastuzumab 
and 89Zr-MMOT0530A scouting target availability and tumor deposition of their 
respective antibody-drug conjugate counterparts ado-trastuzumab emtansine (T-DM1) 
and DMOT4039A targeting HER2 and mesothelin respectively in cancer patients (10,11). 
However, most clinical trials using immunoPET agents have only been performed in 
relative small clinical trials. Larger clinical trials are required to provide insight in the 
value of various targeted immunoPET tracers for clinical practice. One of such trials, 
the ongoing multicenter Dutch breast IMPACT trial, is aimed at assessing the clinical 
value of PET using 89Zr-trastuzumab and fluorine-18 16α-fluoroestradiol (18F-FES) tracers 
for HER2 and the estrogen receptor in metastatic breast cancer patients (IMPACT-MBC, 
NCT01957332). 
Antibodies possess non-linear and variable kinetics, due to their interactions with 
various immune components, soluble forms of receptors, the enhanced permeability 
and retention effect of large molecules, tumor load and receptor density (12,13). One of 
the key strengths of molecular imaging is the possibility of acquiring whole-body drug 
biodistribution and kinetics over time using labeled versions of a drug. In chapter 3, we 
showed that shedding of the EGFR extracellular domain could redirect antibody-based 
EGFR tracer 89Zr-imgatuzumab towards the liver, and therefore influence tumor targeting 
of this antibody to great extent. Recent clinical trials using 89Zr-cetuximab showed 
relatively high liver uptake, when compared to other 89Zr-labeled antibody tracers 
(14,15). This finding may warrant studies into what extent sEGFR levels can influence 
the kinetics, liver targeting and interpretation of EGFR-targeted tracers and possibly 
therapeutic dosing of EGFR antibodies in the clinical setting.
Tumor rewiring and acquired mutations pose a large problem by causing resistance or 
limiting anti-tumor efficacy of targeted cancer treatments. Key mediators of resistance 
against HER-family targeted treatments are HER3 and c-MET. In chapters 4 and 5a, we 
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described the preclinical application of immunoPET tracers to detect relevant changes 
in protein levels and receptor dynamics of these growth factor receptors following 
treatments or emergence of resistance. As discussed in chapter 2, established oncogenic 
growth factor receptor imaging, however, may not suffice to assess treatment efficacy 
and resistance for HER-family driven cancers. Levels or dynamics of HERs do not 
necessarily change after therapy efficacy or resistance, and HER expression levels do 
not necessarily equate to treatment effectiveness. Integrative omics in large patients 
cohorts, with its unbiased approach, may support the search for new effect sensors, 
reporting the activation status of relevant biological pathways, and thereby better 
reflect the treatment status of the patient. Rational and unbiased omics-based discovery 
platforms can be employed to increase and refine this arsenal with tracers for effect 
sensor indicating treatment efficacy and resistance. Furthermore, in order to unveil 
the many relevant process that happen intracellular, technical advances should be 
aimed at bringing high affinity, large molecular weight probes such as antibodies and 
analogues past the relevant cellular membranes, to allow for high contrast visualization 
of intracellular processes in tumor cells.
An emerging field in cancer therapeutics is modulating immune checkpoints to elicit 
antitumor action by the hosts immune system, which have shown encouraging clinical 
results in various tumor types, with many candidate molecules in development and 
several immune checkpoint inhibitors are already registered for treatment of cancer 
patients. These potent drugs often elicit higher toxicity patterns and possess smaller 
therapeutic indices than targeted therapies against non-immune antigens. A further 
complicating factor for decision-making during treatment with immunotherapeutics is 
apparent pseudo-progression, which can mask disease response in patient subsets (16). 
Therefore, molecular imaging is an increasingly interesting option to study optimal dose, 
lesion and immune effector cell marker expression, as well assessing therapy response of 
this drug class. ImmunoPET and fluorescently labeled drug analogues can furthermore 
be used to provide understanding of the biodistribution of novel immunotherapeutic 
protein scaffolds. To support clinical drug development, 89Zr and IRDye 800CW-labeled 
BiTEs can elucidate the optimal dose and distribution of the immunotherapeutic 
BiTEs. Because of its abundant tumor expression, EpCAM can be utilized as docking 
station, to home antibody constructs like BiTEs towards cancer cells. In chapter 6, we 
investigated the preclinical biodistribution and intratumoral distribution of EpCAM-
targeted BiTE AMG110 in human xenografts. Currently, another BiTE clinical candidate, 
targeting human carcinoembryonic antigen (CEA), 89Zr-AMG211 is studied in patients 
with advanced gastrointestinal cancers (NCT02760199) to assess tumor tracer uptake 
and normal organ distribution. 
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Nuclear-based molecular imaging has high specificity of signal, ease of quantitation and 
penetration, but radiation burden limits its use. Besides radionuclide-based imaging 
strategies, optical imaging might be used for organ-level visualization of multiple 
markers simultaneously without radiation burden and at lower cost. To widen the scope 
of molecular imaging, novel in vivo fluorescent techniques such as optoacoustics, as well 
as intraoperative and endoscopic fluorescence imaging techniques and ex vivo analysis 
methods can be applied to broaden the horizon of fluorescent probes in molecular 
imaging of cancers (17).
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Curatieve behandeling van solide tumoren bestaat veelal uit een chirurgische ingreep om 
de tumor te verwijderen, al dan niet gecombineerd met radiotherapie en systemische 
behandeling. De patiënten die overlijden aan kanker doen dat meestal doordat de tumor 
resistent wordt voor systeembehandeling. Tegenwoordig nemen de medicamenteuze 
behandelingsmogelijkheden steeds verder toe. Nieuwe inzichten in belangrijke 
biologische eigenschappen die tumoren gebruiken voor groei en uitzaaiing, hebben geleid 
tot de identificatie van verschillende moleculaire subtypen binnen vele kankersoorten. 
Deze inzichten hebben daarnaast geleid tot een overvloed aan kankertherapieën gericht 
tegen deze specifieke tumorkenmerken. Immunotherapie betreft een nieuwe klasse van 
geneesmiddelen, waarvan het werkingsmechanisme berust op het gericht beïnvloeden 
van immuunsysteemkenmerken, modificatie van T-cellen, of door remming van de 
tumor-gemedieerde onderdrukking van het immuunsysteem. Veelbelovende, duurzame 
tumorresponsen zijn gerapporteerd voor meerdere tumortypen na toepassing van de 
groep van immuuncheckpointremmers binnen de immunotherapeutische middelen. 
De humane epidermale groeifactorreceptor (HER) familie behoort tot de groep van 
groeifactorreceptoren die vaak afwijkend signaleringsgedrag vertonen in humane 
kankers. De HER-familie bestaat uit de epidermale groeifactorreceptor (EGFR), HER2, 
HER3 en HER4. Abnormale activiteit van de tyrosinekinasereceptor c-MET en haar 
ligand hepatocytengroeifactor (HGF), wordt ook vaak als causale factor gevonden 
voor diverse solide tumortypen. Ontregeling van deze groeifactorreceptoren leidt tot 
verschillende algemene tumoreigenschappen zoals verhoogde celoverleving, celdeling, 
vaatnieuwvorming, metastasering en invasering. HER-eiwitten en c-MET hebben een 
complexe onderling verbonden signaleringsroute via diverse gedeelde eiwitten in hun 
signaaltransductieroute. Gerichte therapie tegen één van deze receptoren kan daarom 
resulteren in therapieresistentie via compenserende toename, amplificatie of mutatie 
van de andere receptor, om zodoende de celgroei in stand te houden. Naast deze 
eiwitten wordt ook de glycoproteïne epithelial cell adhesion molecule (EpCAM) veelvuldig 
verhoogd aangetroffen in vele vormen van kanker, welke daarbij een functionele rol 
speelt in verhoogde celdeling, invasering en migratie. 
Moleculaire beeldvorming is een aantrekkelijke techniek om niet-invasief de 
doeleiwitexpressie, biodistributie, opname in en toegankelijkheid van de tumor voor 
immuno- en gerichte therapieën te kunnen bepalen in het gehele lichaam. Moleculaire 
beeldvorming maakt het daarnaast mogelijk om niet-invasief moleculaire kenmerken 
in vivo uit te lezen, door gebruik te maken van radio-isotopen voor zowel single photon 
emission computed tomography (SPECT) als positron emission tomography (PET), 




het gebruik van fluorescent-gelabelde en lichaamseigen moleculen voor optische 
beeldvormingstechnieken. Therapeutische biomoleculen zoals antilichamen en 
antilichaamfragmenten kunnen worden gebruikt in een speurdosis als specifieke tracer 
voor doeleiwitten, na modificatie met een kleurstof of radio-isotoop, hetgeen onderzoek 
van orgaanbiodistributie, farmacokinetiek, farmacodynamiek en tumoropname mogelijk 
maakt. PET-beeldvorming maakt het daarnaast mogelijk om inherent driedimensionale 
informatie te verkrijgen over laesies in het gehele lichaam in de tijd. Longitudinale 
studies met meerdere PET-scans in de tijd kunnen daarom informatie verschaffen over de 
verandering van een tumorkenmerk of doeleiwit als respons op de therapie. Het radio-
isotoop zirkonium-89 (89Zr) is een van de opties om doeleiwit-specifieke antilichamen 
te labelen voor gebruik als PET-tracer. 89Zr is bijzonder geschikt voor het labelen van 
grote biomoleculen voor gebruik als PET-tracer, waaronder antilichamen, aangezien 
de fysische halfwaardetijd van 3.27 dagen goed overeenkomt met de biologische 
halfwaardetijd van antilichamen. Anderzijds kunnen antilichamen, gelabeld met het 
fluorescente label IRDye 800CW worden gebruikt voor optische technieken, zoals nabij-
infrarode fluorescente beeldvorming. Voordelen van fluorescente tracers bestaan onder 
meer uit de mogelijkheid om de intra-orgaanverdeling op micro- en macro niveau te 
kunnen bestuderen met een hoge resolutie, zonder stralingsbelasting. Nadelen zijn een 
beperkt doordringend vermogen in weefsels, het niet mogelijk zijn om beeldvorming van 
het gehele lichaam te doen en het ontbreken van driedimensionaliteit van de verkregen 
beelden. Nieuwe opto-akoestische beeldvormingstechnieken kunnen deze nadelen deels 
wegnemen, aangezien het signaal daarbij wel driedimensionale informatie bevat en het 
doordringend vermogen sterk is verbeterd ten opzichte van conventionele fluorescentie 
beeldvorming, waardoor fluorescente tracers tot in groter detail in beeld zouden kunnen 
worden gebracht. 
Het onderzoek in dit proefschrift was gericht op het ontwikkelen van nieuwe 89Zr en 
IRDye 800CW-gelabelde antilichamen en antilichaamfragmenten voor PET en optische 
beeldvormingstechnieken om zowel de tumoropname en orgaandistributie van 
deze geneesmiddelen, alsmede therapie-geïnduceerde effecten op de dynamiek van 
doeleiwitexpressie te kunnen bestuderen. 
Hoofdstuk 1 betreft een korte beschrijving van de achtergrond van het onderzoek 
en een introductie van de verschillende hoofdstukken. Hoofdstuk 2 omvat een 
literatuuronderzoek, waarbij een overzicht wordt gegeven over hoe moleculaire 
beeldvormingstechnieken zouden kunnen worden toegepast voor optimale 
implementatie van moleculair gerichte kankertherapieën, waarbij de HER-familie als 
voorbeeld wordt gebruikt. Onderwerpen die besproken worden betreffen onder meer 
hoe moleculaire beeldvorming de doeleiwitexpressie in tumorlaesies kan karakteriseren 
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en de effectiviteit van een geneesmiddel of het ontstaan van therapieresistentie zou 
kunnen uitlezen. Daarnaast wordt een integratief omics-gebaseerd ontdekkingsplatform 
beschreven voor zogenoemde ‘effectsensoren’, nieuwe doeleiwitten voor moleculaire 
beeldvorming die kritisch en informatief zijn voor effectiviteit van of resistentie tegen 
een geneesmiddel. Een groot arsenaal aan tracers tegen de HER-familie en gerelateerde 
eiwitten staat daarbij reeds ter beschikking. Echter, deze tracers zijn niet altijd informatief 
voor het voorspellen van geneesmiddeleffectiviteit. Daarom pleiten wij in dit hoofdstuk 
voor een rationele en onbevooroordeelde onderzoeksstrategie door gebruik van een 
integratief omics-gebaseerd ontdekkingsplatform voor nieuwe effectsensoren, welke 
geneesmiddeleffectiviteit of resistentie zouden kunnen voorspellen.
De preklinische studies in deze thesis zijn uitgevoerd met 89Zr en IRDye 800CW-gelabelde 
antilichamen en antilichaamfragmenten voor respectievelijk PET en nabij-infrarode 
fluorescente beeldvorming. 89Zr-gelabelde antilichamen zijn toegepast voor het bepalen 
van de doeleiwitexpressie, weefseldistributie, invloed van circulerend antigeen en voor 
uitlezen van respons op en resistentie tegen moleculair gerichte therapieën in vivo in 
hoofdstukken 3, 4, 5 en 6. Een IRDye 800CW fluorescent gelabeld antilichaamfragment 
is daarnaast toegepast in hoofdstuk 6 voor studie van tumoropname in vivo en voor 
macro en microscopische analyse van de geneesmiddeldistributie in de tumor ex vivo. 
In hoofdstuk 7 is een IRDye 800CW-gelabelde antilichaamtracers gebruikt voor nieuwe 
microscopische technieken. 
Preklinische EGFR beeldvormingsstudies met radioactief gelabelde monoklonale 
antilichamen lieten geen verband zien tussen de EGFR-expressie in vivo en tumoropname 
van de EGFR-gerichte tracer. Afscheiding van extracellulair domein van een doeleiwit 
door cellen kan de biodistributie van antilichaam-gebaseerde tracers beïnvloeden. 
Vrij EGFR extracellulair domein (sEGFR) wordt aangetroffen in het bloed van zowel 
kankerpatiënten als gezonde vrijwilligers en zou mogelijk de kinetiek van een EGFR-
gerichte antilichaamtracers kunnen beïnvloeden. In hoofdstuk 3 hebben wij de invloed 
van sEGFR op de kinetiek en tumoropname van EGFR-antilichaam-gebaseerde PET-tracer 
89Zr-imgatuzumab onderzocht. De invloed van circulerend sEGFR op de tracerkinetiek 
werd onderzocht door een 89Zr-imgatuzumab eiwitdosisescalatiestudie in muizen met 
drie verschillende gexenotransplanteerde EGFR-expresserende humane tumormodellen, 
te weten A431 (epidermoïd carcinoom, EGFR-overexpresserend), A549 en H441 (beiden 
niet-kleincellige longcarcinomen met gemiddelde EGFR expressie). 89Zr-imgatuzumab 
opname in de A431 tumoren was het hoogst voor de 160 μg dosisgroep met 29,8 ± 5,4 
procent geïnjecteerde dosis per gram weefsel (%ID/g). Opname in A549 en H441 tumoren 
daarentegen, was het hoogst voor de laagst geteste 89Zr-imgatuzumab eiwitdosis (10 μg). 




bij toediening van een hogere antilichaamdoses. 89Zr-imgatuzumab leveropname in A549 
en H441 tumordragende muizen was laag voor alle geteste eiwitdoses. sEGFR-spiegels 
in lever en plasma van A431 tumordragende muizen waren tot het 1000-voudige van 
de spiegels gemeten in A549, H441 en niet-tumordragende muizen. 89Zr-imgatuzumab 
kon effectief EGFR-expresserende tumoren visualiseren. Hoge sEGFR-spiegels leidden 
tot een verhoogde 89Zr-imgatuzumab leveropname, in welk geval tumorvisualisatie 
verbeterd kon worden door een verhoging van de antilichaamdosis. 
Behandeling van HER2-afhankelijke borstkanker met de EGFR/HER2-gerichte 
tyrosinekinaseremmer (TKI) lapatinib kan leiden tot een snelle compenserende toename 
in HER3 expressie, signaleringsactiviteit en relocatie naar het plasmamembraan. 
Toename van HER3 expressie is aangetoond met immuunhistochemie, 2 weken na start 
van behandeling met lapatinib in nieuw-gediagnosticeerde HER2-overexpresserende 
borstkankerpatiënten, hetgeen mogelijk de antitumorwerking van dit middel kan 
tegenwerken. In hoofdstuk 4 hebben wij de toepasbaarheid van dynamische PET-
bepalingen voor de HER3 tumorstatus onderzocht, als alternatief voor invasieve 
methoden zoals herhaald biopteren. Behandelingseffecten van lapatinib op HER3-
expressie werd in vivo onderzocht met HER3 PET-tracer 89Zr-mAb3481. Lapatinib 
veroorzaakte in vitro een sterke toename in HER3 membraanexpressie en in een 1,4 
en 1,7-voudige toename in mAb3481 internalisatie in respectievelijk SKBR3 en BT474 
tumorcellen. Opname van 89Zr-mAb3481 in BT474 tumoren was opmerkelijk hoog met 
een gestandaardiseerde gemiddelde opname (SUVmean) van 5,6 ± 0,6 (51,8 ± 7,7 %ID/g) 
voor de 10 µg 89Zr-mAb3481 eiwitdosis in placebo-behandelde muizen. Echter, lapatinib 
behandeling zorgde niet voor significante verschillen in 89Zr-mAb3481 biodistributie 
ex vivo en PET-tumoropname in BT474 tumoren, en ook de HER3 tumor-expressie 
bleef ongewijzigd ten opzichte van placebo. Concluderend, lapatinib verhoogd de 
HER3-expressie in vitro, maar niet wanneer deze cellen worden gexenotransplanteerd. 
89Zr-mAb3481 PET liet hoge HER3-specifieke tumoropname zien, en een soortgelijke 
aanpak zou interessant kunnen zijn om HER3 tumorheterogeniteit en de HER3 
tumorstatus in respons op behandeling uit te lezen in patiënten. 
Dynamische veranderingen in de c-MET-expressie van tumoren komen voor en kunnen 
indicatief zijn voor de effectiviteit van gerichte remmers, of voor ontstaan van resistentie 
tegen EGFR-gerichte TKI. Niet-invasieve beeldvorming van de c-MET-dynamiek kan 
daarbij mogelijk de toepassing van c-MET-gerichte therapieën ondersteunen. In 
hoofdstuk 5a hebben wij de toepasbaarheid van de c-MET-gerichte antilichaamtracer 
89Zr-onartuzumab voor detectie van de c-MET-dynamiek in respons op EGFR TKI 
resistentie en HSP90-remming onderzocht in een gexenotransplanteerd humaan 
EGFR-mutant niet-kleincellig longkankermodel. Membraanexpressie van c-MET werd 
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met 69 ± 9% verlaagd door NVP-AUY-922 behandeling in vitro, terwijl een 213 ± 44% 
hogere c-MET membraanexpressie werd aangetroffen in erlotinib-resistente subkloon 
HCC827ErlRes, vergeleken met de niet-resistente moedercellijn HCC827. c-MET PET liet 
een 33% (P<0.001) lagere tumoropname zien na behandeling met NVP-AUY-922, terwijl 
de tumoropname in erlotinib-resistente HCC827ErlRes tumoren 26% hoger was dan in 
HCC827 tumoren. 89Zr-onartuzumab PET kan effectief relevante veranderingen in c-MET-
expressie onderscheidden, hetgeen wordt geïllustreerd door HSP90-remming leidende 
tot een verlaging en erlotinib-resistentie leidende tot een verhoging van c-MET. 89Zr-
onartuzumab PET zou daarom mogelijk klinische toepassing kunnen vinden voor c-MET-
status bepaling. 
In hoofdstuk 5b worden de potentiële klinische toepassing en ontwikkeling van 
c-MET-gerichte PET en fluorescente tracers besproken voor zowel borstkanker als 
andere maligniteiten. c-MET PET-scans zouden voorafgaand aan behandeling, als 
een niet-invasieve begeleidende biomarker, potentieel de patiëntenpopulatie die 
zou kunnen profiteren van c-MET/HGF-gerichte therapieën kunnen verrijken. c-MET-
gerichte fluorescente tracers zouden anderzijds onderdeel kunnen zijn van een 
multispectrale opto-akoestische screening met een tracercocktail gericht tegen de 
meest veelvoorkomende doeleiwitten in borstkanker. 
Nieuwe inzichten in de mechanismen die tumoren gebruiken om immuunresponsen 
te ontwijken, hebben geleid tot vele immuun-gebaseerde gerichte kankertherapieën. 
Een van deze immuun-gebaseerde strategieën betreffen de bispecific t-cell engaging 
(BiTE) antilichaamconstructen. BiTE-constructen bestaan uit een variabele arm gericht 
tegen een tumor-specifiek doeleiwit, en een tweede arm gericht tegen cluster of 
differentiation 3 (CD3) op cytotoxische T-cellen. Cytoxische T-cellen zijn witte bloedcellen 
die na direct cel-celcontact celdood van kankercellen kunnen induceren door vorming van 
een cytolytische synaps, gevolgd door vrijkomen van pro-apoptotische en poriënvormende 
factoren uit granules. BiTE-constructen kunnen zodoende een polyklonale T-celrespons 
uitlokken tegen doeleiwitexpresserende tumorcellen. Hoofdstuk 6 beschrijft onze studie 
naar de tumoropname en weefseldistributie van de 89Zr en IRDye 800CW-gelabelde BiTE 
AMG 110, gericht tegen EpCAM op tumorcellen en CD3 op T-cellen. Tumoropname 
van 89Zr-AMG 110 kon worden gevisualiseerd tot zeker 72 uur na injectie met een 
microPET-scanner. Tumoropname van 89Zr-AMG 110 was het hoogst op 6 en 24 uur na 
injectie voor de 40 µg eiwitdosis, met respectievelijk 5,35 ± 0,22 en 5,30 ± 0,20 %ID/g. 
89Zr-AMG 110 tumoropname was EpCAM-specifiek en correleerde bovendien met de 
EpCAM-expressie. IRDye 800CW-AMG 110 accumuleerde op het celmembraan in vitale, 
EpCAM-expresserende tumorweefsels. PET en fluorescente beeldvorming waren in 




en tumoropname. Deze data ondersteunen het gebruik van 89Zr en IRDye 800CW-
gelabelde BiTE-constructen voor evaluatie van de kinetiek, tumor- en weefselopname in 
de preklinische en klinische setting. 
In hoofdstuk 7 rapporteren wij de toepassing van labelvrije non-resonant four-wave 
mixing (NR-FWM) microscopie, in combinatie met fluorescente beeldvorming van 
IRDye 800CW-gelabelde tracers cetuximab en pertuzumab, welke zijn gericht tegen 
respectievelijk EGFR en HER2. Microscopische analyse werd uitgevoerd op humane 
kankercellijnen in vitro en op gexenotransplanteerde tumorweefsels ex vivo. In dit 
hoofdstuk werd vibrationele NR-FWM beeldvorming vergeleken met het vibrationeel 
coherente anti-Stokes Raman verstrooiingssignaal. Voorts werd de toepasbaarheid van 
NR-FWM beeldvorming van tumorweefsel in combinatie met fluorescente beeldvorming 
van IRDye 800CW-gelabelde tracers onderzocht. Een vergelijking tussen vibrationeel 
niet-resonante FWM beeldvorming met het vibrationeel resonant coherente anti-Stokes 
Raman verstrooiingssignaal resulteerde in vrijwel identieke kwalitatieve informatie 
bij beeldvorming in cellen. NR-FWM is daarnaast ook toepasbaar voor beeldvorming 
in tumorweefsels in combinatie met fluorescente beeldvorming van IRDye 800CW-
pertuzumab en biedt additionele informatie ten opzichte van transmissiemicroscopie. 
Concluderend, deze thesis beschrijft de ontwikkeling van nieuwe tracers voor PET en 
fluorescente beeldvorming om de tumoropname en weefseldistributie van tracers te 
kunnen bestuderen, alsmede de toepassing van PET-tracers om de tumorstatus van 









Een PhD-project doe je uiteraard nooit alleen, graag wil ik daarom bij dezen van de 
gelegenheid gebruik maken om diverse mensen te bedanken die dit proefschrift mede 
mogelijk hebben gemaakt. 
Mijn grootste dank gaat uit naar mijn promotor prof. dr. E.G.E. de Vries en mijn 
copromotores dr. M.N. Lub-de Hooge en dr. A.G.T. Terwisscha van Scheltinga.
Prof. dr. E.G.E. de Vries, beste Liesbeth. Mijn eerste kennismaking met jou was in 
2010 voor de mogelijkheid voor een masteronderzoek in Amerika. Dit leidde tot 
een fantastische stage bij Genentech in San Francisco. Toen je vroeg of ik bij je wilde 
promoveren heb ik niet lang hoeven twijfelen. Door de vrijheid die jij biedt en jouw 
voorbeeld als onderzoeker heb ik in de afgelopen jaren heb ik enorm veel geleerd. Met 
je immer optimistische en kritische blik werd elk stuk sneller dan het licht in verbeterde 
vorm teruggestuurd en van commentaar voorzien. Ik had mij geen betere mentor 
kunnen wensen, dank voor alles!
Dr. M.N. Lub-de Hooge, beste Marjolijn. Onze wekelijkse overlegmomenten op de 
dinsdagochtend heb ik altijd als erg prettig ervaren. Ook als het onderzoek tegen zat 
kon ik altijd bij jou terecht. Ik heb veel aan jouw (praktische) inzichten gehad voor 
mijn experimenten en artikelen. Dit heeft ertoe geleid dat een groot deel van het werk 
inmiddels is gepubliceerd. Dank voor jouw begeleiding de afgelopen jaren. Ik hoop dat 
de komende tijd net zo succesvol wordt!
Dr. A.G.T. Terwisscha van Scheltinga, beste Anton. Het was fijn om jou in mijn promotieteam 
te hebben. Door jouw ervaring werden de vele (in vivo) experimenten en manuscripten 
naar een hoger plan gebracht. Daarnaast heb ik met genoegen de nodige uurtjes met 
je gepraat over zaken als carrière en jouw onderzoek in San Francisco. Helaas ben je 
vertrokken uit Groningen, maar daar staat een mooie uitdaging in het LUMC tegenover. 
Ik wens je erg veel succes toe in Leiden!
De leden van de leescommissie, prof. dr. O.C. Boerman, prof. dr. A.D.R. Huitema en prof. 
dr. P.H. Elsinga wil ik graag hartelijk bedanken voor hun beoordeling van dit proefschrift.
Daarnaast zou ik graag alle coauteurs willen bedanken voor hun essentiële bijdrage aan 
de hoofdstukken van dit proefschrift. 
In het bijzonder wil ik ook de OnQview projectleden van de Universiteit Twente, drs. Rick 
Krabbendam, dr. Altaf Hussain, dr. Khalid Daoudi, dr. Herman Offerhaus, prof. dr. Jennifer 
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Herek, dr. Cees Otto en prof dr. Wiendelt Steenbergen noemen. Het was een aangename 
en leerzame ervaring om de twee bloedgroepen van biomedisch en natuurkundig 
onderzoek samen te zien komen. Het heeft inmiddels al geleid tot een mooie publicatie, 
hopelijk volgen er meer!
 
I’d also like to extend my gratitude towards the members Biomedical Imaging Group 
of Genentech, in particular dr. Simon Williams, dr. Jan Marik, dr. Andreas Baudy, Annie 
Ogasawara, Judith Flores, Alex Vanderbilt, Jeff Tinianow and Herman Gill, for the 
interesting research internship, an experience which helped me kickstart my PhD project. 
Beste dr. Hetty Timmer-Bosscha en dr. Coby Meijer, dank voor alle hulp, input en 
ondersteuning en voor het feit dat voor elke vraag of probleem de deur altijd open 
stond. Dank ook voor jullie begeleiding tijdens de (imaging) meetings.
Prof dr. Steven de Jong, prof. dr. Marcel van Vugt en prof. dr. Frank Kruyt, dank voor alle 
begeleiding, input voor papers, meetings en constructieve opmerkingen. 
Prof dr. Jos Kosterink en alle medewerkers van de afdeling Klinische Farmacie en 
Farmacologie zou ik graag willen bedanken voor de samenwerking in de onderzoekslijn 
voor moleculaire beeldvorming en voor de feedback gedurende de diverse 
maandagmorgenpraatjes.
 
Prof dr. Rudi Dierckx en de medewerkers van de afdeling Nucleaire Geneeskunde en 
Moleculaire Beeldvorming (NGMB) wil ik danken voor de gastvrijheid. Daarnaast wil 
ik Jürgen Sijbesma in het bijzonder bedanken voor alle ondersteuning bij de microPET 
studies.
Prof. dr. Go van Dam, dank voor de bijdrage aan hoofdstuk 5B over de klinische 
mogelijkheden voor c-MET-gerichte PET en fluorescente tracers.
Zonder de professionele ondersteuning van de medewerkers van het CDP was dit 
proefschrift er niet geweest, waarbij ik met name veelvuldig een beroep heb mogen 
doen op Michel Weij, Ar Jansen, Magda Kwanten en drs. Miriam van der Meulen-Frank, 
waarvoor dank!
De secretariaten van zowel de afdeling Medische Oncologie, als Klinische Farmacie en 




Onmisbaar waren dr. Anouk Funke en dr. Esther van Straten, zonder wie het overzicht 
over alle projecten, budgetten, subsidies, meetings en samenwerkingsverbanden allang 
zoek zou zijn geweest, dank voor jullie inzet!
De deelnemers, voormalige deelnemers en begeleiders van de imaging meeting van 
de afgelopen jaren zou ik willen bedanken voor alle discussies, besprekingen en sociale 
activiteiten: drs. Elly van der Veen, drs. Stijn Waaijer, drs. Arjan Kol, drs. Frank-Jan 
Warnders, drs. Eva ter Weele, drs. Jolien Tjalma, drs. Elmire Hartmans, drs. Frederike 
Bensch, Linda Pot, Silke Vedelaar, drs. Clarieke Venema, drs. Kirsten Moek, drs. Kees 
Bisschop, drs. Suzanne van Es, Wytske Boersma-van Ek, drs. Frans Suurs, drs. Danique 
Giesen, drs. Siqi Qiu, drs. Thijs Wind, drs. Linda Broer, drs. Steven de Jongh, dr. Titia 
Lamberts, dr. Sietske Gaykema, dr. Michel van Kruchten, dr. Marlous Arjaans, drs. Matthijs 
Linssen, dr. Annelies Jorritsma-Smit, dr. Wouter Nagengast en dr. Carolien Schröder.
Een deel van mijn in vivo proeven vond plaats op de meest onmogelijke tijdstippen. 
Lijdend voorwerp waren daarbij onder meer mijn studenten drs. Joost van Raaij en drs. 
Danique Giesen. Het was leuk en leerzaam jullie te mogen begeleiden en te zien groeien 
in het onderzoek, dank voor het vele werk dat jullie verzet. Joost, ik wens je heel veel 
succes met je carrière in de ziekenhuisfarmacie! Danique, veel succes gewenst met jouw 
eigen promotietraject binnen onze groep!  
Deze lijst is natuurlijk nooit volledig en ik zou daarom graag eenieder willen bedanken 
die hier niet met naam genoemd is, maar wel op enigerlei wijze betrokken is geweest 
bij mijn promotietraject. De collega’s en oud-collega’s van Multidisciplinair Oncologisch 
Laboratorium (MOL) de Vitrine en van Nucleaire Geneeskunde en Moleculaire 
Beeldvorming mogen daarom niet ongenoemd blijven, dank voor alle gezelligheid op 
het lab. 
Daarnaast gaat mijn dank in het bijzonder uit naar het MOL biergenootschap (drs. Arjan 
Kol, drs. Frans Suurs, drs. Hylke Wieringa, drs. Joost Caumanns, drs. Pepijn Schoonen, 
drs. Rolf de Boer en drs. Sergi Guerrero-Llobet, Stijn Waaijer) voor alle ontspanning, 
speciaal bier-gerelateerde evenementen, dikke hompen vlees, pubquizen en natuurlijk 
de epische roadtrips in wisselende bezetting, The Hangover I ‘Portland - San Luis Obispo 
- San Diego’ en The Hangover II ‘New York - Boston’. Binnenkort tijd voor nummer III?
Uiteraard kan ook het belang van gezellige kamergenoten in een ruime kamer met 
goede koffie niet worden onderschat. De G-unit, G-010, heeft geen gebrek aan al deze 
kwaliteiten. Huidige G-unit bewoners en alumni, dr. Marlous Arjaans, drs. Marloes 
Peters, drs. Linda Broer, drs. Gerda de Vries, drs. Arjan Kol, drs. Margot de Looff en 
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drs. Denise van Marion zou ik daarom van harte willen bedanken voor alle geklets, 
morele steun, roomie-diners met de +1-en, Oprah-printjes, en Reddit-momentjes.
Mijn paranimfen, mr. Joost Vogel, dank dat je helemaal vanuit Londen bent overgekomen 
voor deze dag, we maken er wat moois van! Drs. Arjan Kol, het grootst aantal keer 
genoemd worden in dit dankwoord zegt genoeg. Ik zie uit naar jouw promotie! 
Beste drs. Hylke Wieringa, fantastisch dat wij beiden op deze dag onze verdediging 
mogen houden en vieren, veel succes gewenst zometeen!
Verder zou ik dr. Wim Velema, dr. Jasper Lodder, drs. Arnout Janse, drs. Rosalie Moorlag, 
drs. Maarten Mensink, dr. Carian Boorsma, dr. Niels Martens, drs. Maaike Wouda, drs. 
Janneke Geerlinks, drs. Liza Mennega, drs. Leonora de Raad, drs. Marleen Hennemann, 
drs. Robin Weber, drs. Jochem Hoekstra, drs. Dorine Welberg, Govert Nieuwhof, Sybren 
Eldering, dr. Marleen van Oosten, drs. Hans Waalkens, drs. Anouk Kool, drs. Hans ten 
Kate en drs. Maarten van der Meer willen bedanken voor alle activiteiten buiten het 
onderzoek om.
Mijn familie en schoonfamilie, Pa, Ma, Marleen, Ezio, Bart, Sanne, Geert, Elise, Aimée, 
Maxim, Silas, Samir, Nida, Ruben, Iba, Elias, Esmee en Luna, dank dat jullie er altijd 
waren, zowel in de mooie als de moeilijke tijden die we hebben meegemaakt. 
Nour, dankjewel voor jouw onvoorwaardelijke steun en liefde. !                           



